Gene profiling of lung toxicity by Balharry, Dominique
G ene Profiling  of Lung  
T oxic ity
Dominique Balharry
CARDIFF
UNIVERSITY 
PRIFYSGOL
CaeRDY|§>
A thesis presented for the degree of Doctor of Philosophy
at
Cardiff University 
May 2005
Cardiff School of Biosciences 
Cardiff University 
Museum Avenue 
CARDIFF 
CF10 3US
UMI Number: U584715
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U584715
Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
Contents-
C o n t e n t s
C o n ten ts  i
A c kn o w ledg em en ts  vii
D eclaration  viii
Publications  and  C o m m u n ic a tio n s  ix
A bbreviations  x
A bstract xiii
1.0 In tro d u c tio n  1
1.1 T he R espira to ry  Sy ste m  2
1.1.1 Ov er vie w  2
1.1.2 Stru c tu r e  an d  Func tio n  o f  the  Re spirato ry  Bro nch io les  5
1.1.3 Str u c tu r e  a n d  Func tio n  o f the  A lveoli 7
1.1.3.1 Ty pe  I (m em b rano us ) Pn eum o cyte  9
1.1.3.2 Type II (g ra n u la r )  Pneum ocyte 10
1.1.3.3 Po res  of Kohn  (Interalveo lar  Po r e s ) 11
1.1.3.4 A lveolar  Macr o pha g e  12
1.1.3.5 Pulm onary  S urfactant  1 3
1.1.4 The Pathw ays o f  Lung in ju ry  1 4
1 1.4.1 O edem a  1 5
1.1.4.2 Inflammation  17
1.1.4.3 A lveolar  Pro teino sis  18
1.1.4.4 P ulm onary  F ibrosis 19
1.2 Bleo m ycin  20
1.2.1 St r u c tu r e  a nd  M echanism s  of T o xic ity  20
1.2.2 T he Ev o lu tio n  o f  Bleo m ycin  Indu ced  Lung  Injury 23
1.2.3 A nimal M o dels  of Bleo m ycin -Indu ced  Lung Injury  26
1.3 T o x ic o g e n o m ic s  a n d  G ene  Expr essio n  Studies  27
1.4 Aims a nd  O b jec tives  o f  the  Stu d y  31
i
33
34
37
37
37
38
38
38
39
39
39
40
41
41
42
43
43
46
49
50
51
52
54
54
54
55
55
55
55
56
56
Contents-
T o x ic o lo g ic a l  Id en tific a tio n  o f  O e d e m a , In fla m m a tio n  and  
R epa ir
In tr o d uc tio n
Materials  and  S to c k  So lu tio n s
2.2.1 A nimals  and  Materials
2.2.2 Sto c k  S o lutio ns  
M ethods
2.3.1 Exper im en ta l  M odels  of Pulm onary  Injury  a n d  Repair
2.3.2 A d m in istra tio n  of Bleomycin
2.3.3 Ha r v e s tin g  of Experim ental  Animals
2.3.4 D issectio n  of Experim ental A nimals
2.3.5 Lung  Lavag e
2.3.6 D eter m inatio n  o f  Free  C ell Numbers
2.3.7 Lavag e  Pr o tein  Deter m in a tio n  - T he Bradford  Assay
2.3.8 C ell Pro liferatio n  A ssay  - T ritiated  T hym idine  Uptake
2.3.9 Statistical  A nalysis  
R e s u lts
2.4.1 As s e s s m e n t  of O edem a  an d  Inflam m ato ry  Respo nse
2.4.2 T hy m id ine  In c o rpo ratio n  A ssay  to  Mo n ito r  C ellular Repair  
Discussion
C o n c lu sio n s
H is to c h e m ic a l  a n d  E lectro n  M ic r o sc o pic  Iden tif ic a tio n  
of  O e d e m a , In fla m m a tio n  a nd  R epa ir
In tr o d u c tio n
Materials  a nd  S to ck  S o lu tio n s
3.2.1 Materials  and  S uppliers
3.2.2 Sto c k  So lutio ns  
M ethods
3.3.1 Exper im en ta l  M odels  of Pulm onary  Injury  a n d  Repair
3.3.2 5-B r o m o -2 -D e o x y -U ridine  Inc o rpo ratio n
3.3.2.1 In V ivo Inco rpo ratio n
3.3.2.2 Ex Vivo Inco rpo ratio n
3.3.3 Pr o c e s sin g  T issue  fo r  Lig ht  M ic r o sc o py
56
57
58
58
59
60
60
60
61
62
62
63
63
66
68
73
76
77
78
80
80
82
82
83
85
85
85
85
86
87
87
88
Contents-
3.3.3.1 F ixation of Lung  T issue
3.3.3 2 T issue  Pr o cessing
3.3.3.3 Paraffin  Em bedding
3.3.3.4 S ectio ning
3.3.4 Haem atoxylin  and  Eo sin  Stain
3.3.5 Br o m o d eo xyu r id in e  Detec tio n
3.3.6 Pro c essin g  T issue  fo r  T ran sm issio n  Electron  M icro sco py
3.3.6.1 F ixation  of Lung  T issue
3.3 6.2 T issue  Pro cessing
3.3.6.3 S ectio ning
3.3.6.4 C o u n te r  Staining  
R e s u lts
3.4.1 Br o m o d e o xy u r id in e  Detection  of C ell Proliferation
3.4.2 Haem ato xylin  a nd  Eo sin  V isualisation  of T issue
3.4.3 T RANSMISSION ELECTRO N M IC R O SC O PIC  ANALYSIS OF T ISSUE
D isc ussio n
C o n c lu s io n s
A n a lysis  of  T r a n sc r ip tio n a l  C h a n g es  in Ea r ly  O edem a  
a n d  In fla m m a tio n
In tr o d u c tio n
Ma terials
4.2.1 Materials  and  Suppliers
4.2.2  Sto ck  So lutions
4.2.2.1 Ma croarray
4.2.2.2 Q uantitative  PCR  
M ethods
4.3.1 RNA Ex tractio n  a n d  Preparatio n
4.3.1.1 RNA Isolation  using  T ri-reag ent  Pro to co l
4.3.1.2  RNA Isolation  using  R N easy  Kit
4.3.1 .3  DNase  T r eatm ent  of th e  RNA
4.3.1.4  Q uantifying  the  RNA Isolate
4.3.1.5  C hecking  Integ rity  o f  RNA: R unning  an  A g aro se  G el
4.3.2 Macr o a rrays
Contents-
4.3.2.1 Preparation  o f  the  M em branes  8 8
4.3.2.2 P rep ara tio n  o f  32P -Labelled  F irs t  S tra n d  c DNA Probe 8 8
4.3.2.3  Hybridisatio n  of  the  Probe  to  the  A rray  89
4.3.2.4  Pro c essin g  the  Ph o s ph o r im a g er  Screen  89
4.3.2.5  Str ip p in g  the  M embranes  89
4.3.3 Ex pr es s io n  Analysis  of  W hole  Lung  T issue  90
4.3.4 Data  No rmalisation  90
4.3.5 Initial  Data  A nalysis Using  M ic r o s o ft  Excel  92
4.3.5.1 Ra n g e : Low  N um ber  o f  Sam ple  Replicates  92
4.3.5.2  Two Standard  Deviatio ns : H igh Num ber  of  Sam ple  
Replicates  94
4.3.5.3 T -t e s t : Lo w  o r  H igh Num ber  of Sam ple  R eplicates  95
4.3.6 Fu rther  A nalysis w ith  Atlas Navigato r™ 1.0 95
4.3.7 V isual Data  M in ing  w ith  S potfire  Pro 3 97
4.3.8 Phylo g enic  Tree  - G ene  C lustering  98
4.3.9 Q-PCR to  C o n fir m  A ltered  Ex pr es s io n  of Im po rtant  G enes  98
4.3.9.1 RT-PCR 100
4.3.9.2  L ig ation  of  PCR Pro d u c t  into  Plasmid  V ecto r  100
4.3.9.3  T ran sfo rm atio n  into  E.coli 101
4.3 9.4 Sc r e e n in g  T ransfo rm ants  fo r  Inserts  101
4.3.9  5 Plasmid  DNA Purificatio n  101
4 .3.9.6 S erial D ilution  of Standards  102
4.3 9.7 Q-PCR of Experim enta l  G enes  102
4.4 R e s u lts  103
4.4.1 Isolation  and  Preparation  of RNA 103
4.4.2 Macro a rray  104
4 .4 .2 .1 Macroarray  O ptim isa tio n  104
4.4.2 2 Macr o a rray  A nalyses  105
4.4.3 Excel  A nalysis  106
4.4.3.1 Standard  D eviatio n  M eth o d  106
4.4.3  2 T -T est  M etho d  107
4 .4 .3.3 Standard  D eviatio n  / T -t e s t  C om parison  108
4.4.3.4  Rang e  / Standard  Deviatio n  C o m pariso n  1 1 0
4.4.4 Na v ig a to r  A nalysis  111
iv
Contents-
4.4.5 S potfire  A nalysis 114
4.4.6 Ph y l o g e n ic T ree  - C lustering  116
4.4.7 Q uantitative  PCR 117
4.5  D isc ussio n  121
4.5.1 Macroarray  O ptim isa tio n  121
4.5.2 Data  Normalisation  and  A nalysis  122
4.5.3 G ene  C hanges  O ccu rring  in M ild O edem a  123
4.5.4 G ene  C lustering  124
4.5.5 Q -PC R  125
4.6  C o n c lu sio n s  126
5.0 A n alysis  of T r a n sc r ip tio n a l  C hanges  in Pe r s is te n t  and
S evere  O edem a  127
5.1 In tr o d uc tio n  128
5.2 Materials  and  M eth o d s  129
5.2.1 Materials  an d  S uppliers  129
5.2.2 M etho ds  129
5.3 R esu lts  130
5.3.1 R elevant  G enes  Identified  D uring  Pr o g ressive  O edem a  130
5.3.1.1 Stan d a r d  Deviatio n  and  T-te st  A nalysis  130
5.3.1.2 Phylo g enic  T ree C lustering  133
5.3.2 R elevant  g en es  Identified  D uring  S evere  O edem a  135
5.3.2.1 Standard  Deviation  and  T-te st  A nalysis  135
5.3.2.2 Phylo g enic  T ree  C lustering  139
5.3.3 C o m pariso n  of  G ene C hanges  in Pro g ressive  v er su s  S evere  O edem a  141
5.3.4 Co m pa r iso n  of G ene C hanges  in M ild ver su s  Pro g ressive  and
S evere  O edem a  143
5.4 D is c u ssio n  144
5.4.1 Pr o g r essive  O edem a  144
5.4.2 S evere  O edem a  149
5.5 C o n c lu sio n s  153
V
Contents
6.0 IMMUNOHISTOCHEMICAL ANALYSIS OF LUNG SECTIONS 155
6.1 In tr o d u c tio n  156
6.2 Materials  158
6.2.1 Materials  and  S uppliers  158
6.2.2 Sto c k  So lutio ns  158
6.3 M ethods 159
6.3.1 Preparatio n  of T issue  for  Im m u n o h is to c h e m istr y  159
6.3.2 An tig en  Unmasking  159
6.3.3 Blocking  Endo g eno us  Peroxidase  Activ ity  159
6.3.4 Im m uno h isto c h em istr y  160
6.3.5 Image A nalysis  160
6.3.6 Statistical  A nalysis 162
6.4 R e su lts  163
6.4.1 LM o f Lung  T issue  Sectio ns  163
6.4.2 Im age  Analysis  o f Lung  T issue  S ectio ns  165
6.5 D isc u ssio n  166
6.6 C o n c lu sio n s  167
7.0 G e n e ra l Discussion 168
7.1 O verv iew  169
7.2 C h a ra c te r is a tio n  o f  Bleomycin M o d e l 170
7.3 Id en tifica tio n  o f  B io lo g ica l M a rk e rs  171
7.4 C onclusions 173
7.5 F u tu re  W o rk  174
8.0 R e fe re n c e s  176
9.0 Appendix
vi
Acknowledgements
A c k n o w le d g em en ts
Firstly I’d like to thank AstraZeneca for funding this research and making the 
whole project possible! Thanks also to Dr. Victor Oreffo for arranging 
everything at AZ and for being involved right from the start with all the 
planning! Your input was invaluable!
I’d like to say a huge thank you to Prof. Roy Richards for saving me from 
Bath, and restoring my faith in scientists!! I’m so glad I had the opportunity to 
work (and drink!) with you! Your support, guidance and wisdom over the last 
three years have made it an enjoyable experience that I’ll never forget! To Dr. 
Kelly BeruBe for being a source of knowledge (and entertainment!) throughout 
my PhD, but especially for stepping in to take over at the last minute! You’ve 
been an absolute star!!
Everyone in W2.01 over the years, you know who you are! You’re a great 
bunch, I couldn’t have asked for better people to spend the last few years 
with! Leona, for being there right from the start and always keeping me 
company over a much needed drink! And I can’t thank you enough for 
persuading me to talk to Roy in the first place!! To Helen for being my 
‘radioactive twin’ and keeping me sane in our little windowless room! Massive 
thanks to Martina for a multitude of things! For some fantastic times in NZ, for 
taking me horse riding and for getting worse hangovers than me! Of course I 
can’t forget Keith, who has been a constant source of knowledge (about 
everything from PCR to bleeding radiators!) and helped me out of many a 
sticky situation!! You’re ail great! Thanks!
Rich, I’m sure you know anyway, but thank you for everything!!
Finally I’d like to say an enormous thank you to my entire family! Especially to 
my mum and my sister Chloe (and not just for your editorial skills!). You’ve 
been there through thick and thin and I wouldn’t be where I am today if it 
hadn’t been for you both! Thank you!
D e c la r a tio n
This work has not previously been accepted for any degree and is not 
concurrently submitted in candidature for any degree.
Signed ..., (candidate)
Date  I .$. I .Q. 7$ / P 5
S ta t e m e n t  1
This thesis is the result of my own investigations, except where otherwise 
stated. Other sources are acknowledged by footnotes giving explicit 
references. A bibliography is appended.
Signed ... J . . .............................(candidate)
Date ... ! .&/ / . .0 5 .......................................
S t a t e m e n t  2
I hereby give consent for my thesis, if accepted, to be made available for 
photocopying and for inter-library loan, and for the title and summary to be 
made available to outside organisations.
Signed ..   .... (candidate)
Date  ! . ^ J .  . . . . . . . . . . . . . . . . . . . . . . .
vili
Publications and Communications
P u b lic a tio n s
Balharry, D., Oreffo, V. and Richards, R. J. (2005). Use of Toxicogenomics for 
Identifying Genetic Markers of Pulmonary Oedema. Toxicology and Applied 
Pharmacology 204, 101 -108.
Wise, H., Balharry, D., Reynolds, L J., Sexton, K. and Richards R J. (2004). 
Conventional and Toxicogenomic Assessment of the Acute Pulmonary Damage 
Induced by the Instillation of Cardiff PM10 into the Rat Lung. Science of the Total 
Environment, In Press
P u b lis h e d  A b s tr a c ts
Balharry, D., Oreffo V. and Richards, R. J. (2004). Gene Expression Analysis of 
Lung Toxicity, Abstracts of the British Association for Lung Research, Summer 
Meeting, 2003, Brighton, UK. Experimental Lung Research 30(6), 503-534
Balharry, D., Oreffo V. and Richards, R. J. (2004). Bioinformatic Analysis of 
Genetic Expression during Mild Pulmonary Oedema. Toxicology 202 (1-2), 58
Balharry, D., Oreffo V. and Richards, R. J. (2003). Gene Profiling of Lung Toxicity, 
Abstracts of the British Association for Lung Research, Summer Meeting, 2002, 
Dublin, Ireland, Experimental Lung Research 29(6), 413-444
C o m m u n ic a t io n s
Gene Profiling of Lung Toxicity AstraZeneca Science Day, Alderley Park, UK, 2005
mRNA Expression Profiling of Mild and Severe Pulmonary Oedema. 3rd Annual 
International Conference on Bioinformatics, Auckland, NZ, 2004
Gene Expression Analysis of Lung Toxicity, AstraZeneca Science Day, Alderley 
Park, UK, 2004
Gene Expression Analysis of the Early and Peak Phase of Pulmonary Oedema, 
British Association for Lung Research, Summer Meeting, Leicester, UK, 2004
ix
Abbreviations
A b b r e v ia t io n s
1° Primary antibody
2D SDS PAGE Two dimensional sodium dodecyl sulphate polyacrylamide gel 
electrophoresis
Ach Acetylcholine
AQP Aquaporin
BAL Broncho-alveolar lavage
BCIP 5-bromo-4-chloro-3-indolyl phosphate
bFGF Basic fibroblast growth factor
BM Basement membrane
bp Base pairs
BrdU 5-Bromo-2-deoxy-uridine
BSA Bovine serum albumin
CaMK Calcium/calmodulin dependent kinase
cAMP Cyclic adenosine monophosphate
CART Cocaine/amphetamine-induced rat transcript
CC Cocoacrisp
CDC Cell division control
cDNA Complementary DNA
CDS Complementary DNA sequence
Ci Curies
conc. Concentration
cpm Counts per minute
CRISP Cysteine-rich secreted protein
Ct Cycle threshold
dATP Deoxyadenosine triphosphate
dCTP Deoxycytidine triphosphate
dGTP Deoxyguanosine triphosphate
DNA Deoxyribonucleic acid
DNase Deoxyribonuclease
dNTP Deoxynucleotide triphosphate
DTT Dithiothreitol
dTTP Deoxythymidine triphosphate
ECM Extracellular matrix
E.coli Escherichia coli
EDTA Ethylenediaminetetracetic acid
EPO Erythropoietin
FGF Fibroblast growth factor
Gi phase Gap 1 phase (of cell cycle)
G2 phase Gap 2 phase (of cell cycle)
GABA Gamma aminobutyric acid
GCS-F Granulocyte colony stimulating factor
gDNA Genomic DNA
GDNF Glial cell line-derived neurotrophic factor
Abbreviations
GFs Growth factors
GLUR Glutamate receptor
GM-CSF Granulocyte-macrophage colony-stimulating factor
GNRP Guanine nucleotide release/exchange factor
GP Glycoprotein
GPCR G-protein-coupled receptor
GRP-R Gastrin releasing peptide receptor
GTP Guanosine triphosphate
GTPase Guanosine triphosphatase
H & E Haematoxylin and eosin
IA Image analysis
IFN Interferon
IL Interleukin
INF Intrinsic factor
IP Intraperitoneal
IPTG Isopropylthiogalactoside
IT Intratracheal
IV Intravenous
JNK c-Jun-N-terminal-kinase
kb Kilo bases
kDa Kilo Daltons
keV Kilo electron-volts
KRP Krebs ringer phosphate
L:B ratio Lung parenchyma:body weight ratio
LB Luria broth
LCCL domain Domain-family first discovered in Limulus factor C, Coch-5b2
and Lgl1
LFC Lavage free cells
Lgi Late gestation lung protein
LM Light microscopy
LP Lung parenchyma
LPS Lipopolysaccharide
M phase Mitotic phase (of cell cycle)
MCT Monocarboxylate transporter
MMLV-RT Moloney murine leukaemia virus reverse transcriptase
MR Mineralocorticoid Receptor
mRNA Messenger ribonucleic acid
n Number of replicates
NBT Nitroblue tetrazolium
NCBI National Centre for Biotechnology Information
NGF Nerve growth factor
NK Natural killer
NM Neuromedin
NMR Nuclear magnetic resonance
P2Y Purinoceptor 2Y
PBS Phosphate buffered saline
xi
Abbreviations
PCR Polymerase chain reaction
PKC Protein kinase C
PLA Phospholipase A
Prl Preprolactin
PYY Peptide YY
Q-PCR Quantitative PCR
RAD Ras associated with diabetes
RBC Red blood cell
Rn Reporter number
RNA Ribonucleic acid
RNase Ribonuclease
RT Reverse transcription
RT-PCR Reverse transcription PCR
RTU Ready to use
rxn Reaction
S phase DNA synthesis phase (of cell cycle)
SC Subcutaneous
SCP Secretory component
sd Standard deviation
SDS Sodium dodecyl sulphate
SEM Scanning electron microscopy
Sg Secretogranin
SKR Substance K receptor
SP-A Surfactant protein-A
SP-B Surfactant protein-B
SP-C Surfactant protein-C
SP-D Surfactant protein-D
SSC Saline-sodium citrate buffer
STX2 Syntaxin 2
SV Synaptic vesicle
SVAT Synaptic vesicle amine transporter
SYT Synaptotagmin
TBE T ris-borate-ethylenediaminetetracetic acid
TBS Tris buffered saline
TEM Transmission electron microscopy
TIFF Tag image file format
TM Tubular myelin
TNF Tumour necrosis factor
UV Ultraviolet
v/v Volume to volume
VEGF Vascular endothelial growth factor
VIP Vasoactive intestinal polypeptide
VIP-R Vasoactive intestinal polypeptide receptor
w/v Weight to volume
X-Gal 5-bromo-4-chloro-3-indolyl-b-D-galactosidase
Abstract
A b s tr a c t
Bleomycin is a potent anti-tumour compound used in the treatment of 
squamous cell carcinomas. An unfortunate side effect of this drug is 
pulmonary toxicity. The onset of this damage manifests as mild oedema and 
inflammation which eventually develops into pulmonary fibrosis. The ability to 
correctly identify patients showing early signs of lung injury could significantly 
reduce the morbidity associated with bleomycin treatment. As such, this study 
was undertaken to identify genetic markers of early oedema and inflammation.
A model of mild pulmonary injury was induced by bleomycin. Conventional 
quantitative analysis of broncho-alveolar lavage was used to indicate the 
severity of the oedematous response, whilst morphological changes were 
identified by histology and electron microscopy. Macroarrays were used to 
measure the expression of multiple genes during mild, progressive and severe 
oedema. Following normalisation and statistical analysis, gene expression 
patterns were compared from saline- and bleomycin-treated rats. A variety of 
genes were differentially expressed during each model, with the number 
increasing with the severity of the oedema. A cluster and two individual genes 
were consistently expressed across two of the models of oedema. The 
magnitude of the changes in gene expression were quantified and confirmed 
by quantitative PCR.
In summary, complete toxicological and histological characterisation of the 
bleomycin-induced model of pulmonary injury successfully identified specific 
endpoints of injury. This model proved to be ideal for studying differential 
gene expression in response to drug-induced pulmonary oedema. A cluster 
of ion channels and trafficking genes has the potential to act as a biomarker. 
Two specific genetic markers (Na+/CI- betaine/GABA transporter, 
glucocorticoid receptor), and a protein marker (cocoacrisp) have been 
identified for the oedema. In addition to these genes and protein being 
potential biomarkers of injury, they are also prospective targets for clinical 
treatment.
Introduction
C hapter  1:
In tr o d u c tio n
Introduction
1.1 Th e  R e s p ir a t o r y  S y s t e m
1.1.1 O v e r v ie w
The term “respiration” is used to describe two related processes: (1) cellular 
respiration and (2) mechanical respiration. Energy production by the 
metabolism of organic molecules is known as cellular respiration. This 
process requires oxygen, which is obtained via mechanical respiration. 
Mechanical respiration is carried out by the respiratory system. The primary 
function of the respiratory system is to remove excess carbon dioxide that is 
generated as a metabolic waste product from blood, as well as providing 
molecular oxygen for cellular oxidation.
The respiratory system is comprised of proximal conducting airways and a 
distal respiratory region (Harkema et al., 1991). The conducting system 
transports inspired and expired air to and from the lungs. The respiratory 
portion acts as an interface for passive exchange of gases between the 
atmosphere and the blood. The complete system is divided anatomically into 
two parts, the upper and lower respiratory tracts, which are separated by the 
pharynx (Figure 1.1).
Pharynx
Upper Respiratory Tract
■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ I
Lower Respiratory Tract
■
Figure 1.1 The structure of the respiratory system indicating the separation between the 
lower and upper respiratory tract (Reproduced with permission of Dr. K BdruBd).
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The upper respiratory tract is made up of a series of interconnected spaces: 
the nasal cavity, the paranasal sinuses and the nasopharynx. Its primary 
function is filtering, humidifying and adjusting the temperature of inspired air. 
It is also involved in detoxification of harmful gases, and entrapment of 
potentially harmful bacteria and viruses. The majority of these functions are 
achieved by the respiratory mucous membrane or respiratory mucosa. The 
respiratory mucosa consists of a pseudostratified, columnar epithelium 
containing numerous goblet cells, supported on a loose collagenous layer, the 
lamina propria (Figure 1.2).
Ciliated
CellGoblet
Cell
Figure 1.2 The characteristic structure of the pseudostratified, ciliated, columnar respiratory 
epithelium lining. M: Mast cell, E: Elastin, G: Goblet cell, C: Ciliated cell (Reproduced from 
‘Histology of Respiratory Tract’ Lectures, Cardiff University, with the permission of Dr. K. 
BdruBd,).
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The lower respiratory tract begins at the larynx and continues into the thorax 
as the trachea. The trachea then divides repeatedly into smaller and smaller 
airways to reach the alveoli (Figure 1.3).
Lymph Nodes 
Right Bronchus
Right Lung 
Right Upper Lobe
Right Middle Lobe 
Right Lower Lobe
Diaphragm
Bronchiole 
Alveolus (Air Sac)
Pulmonary Vein
Pulmonary Artery
Trachea
Ribs
Left Bronchus
Left Upper Lobe 
Left Lower Lobe
Pleura
Pleural Space 
Cilia 
Surfactant
Capillaries
Figure 1.3 The structure o f the lower respiratory tract (Adapted from the American Lung 
Association Website, 2002).
The trachea first divides into left and right primary bronchi, which supply the 
lungs. Human lungs consist of five lobes; the left lung is split into two lobes, 
whilst the right lung is separated into three. Each primary bronchus branches 
into the secondary or lobar bronchi which supply the lobes of the lung. These 
then divide further to form tertiary or segmental bronchi that supply the 
bronchi of each lobe. The tertiary bronchi undergo numerous divisions to 
produce bronchioles, the smallest of which are called terminal bronchioles. 
The terminal bronchioles mark the end of the purely conducting portion of the 
tract.
The gaseous exchange region is derived from further branching of the 
terminal bronchioles. This results in a series of transitional airways, the 
respiratory bronchioles and alveolar ducts. These airways end in dilated 
spaces called alveolar sacs, which open into the alveoli (Figure 1.4). The unit
4
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of lung structure consisting of a terminal bronchiole and its respiratory 
bronchioles and alveoli is sometimes called the acinus (Young and Heath,
2000).
Bronchiole
Alveolar
Septa
Alveoli
Figure 1.4 Scanning electron micrograph of the distal respiratory region from normal rat lung 
(Lung sample donated by Dr. K BdruBd, image taken by D. Balharry and M. Hicks, 2004).
The structural characteristics of each type of airway are distinct from each 
other, but there is a gradual transition from one type to the next. The lining of 
the trachea and bronchi consists of a pseudostratified, columnar epithelium 
containing ciliated cells and goblet (mucous secreting) cells (Breeze and 
Wheeldon, 1977). This progresses to a simple, cuboidal, non-ciliated form in 
the smallest airways.
1.1.2 S tr u c t u r e  a n d  F u n c tio n  o f  the  R e s p ir a t o r y  B r o n c h io le s
The terminal bronchioles are the smallest passages of the conducting portion 
of the respiratory tree, and are not significantly involved in gaseous exchange. 
These terminal bronchioles divide to form short, thinner-walled branches
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called respiratory bronchioles. The respiratory bronchioles contain a small 
number of single alveoli in their walls. The epithelium of the respiratory 
bronchioles is totally lacking in goblet cells, and instead largely consists of 
ciliated, cuboidal cells and smaller numbers of non-ciliated cells called Clara 
cells (Figure 1.5).
Ciliated cells
Clara cells
Figure 1.5 Scanning electron micrograph of the surface of a respiratory bronchiole from 
normal rat lung. Shows ciliated cells interspersed with Clara cells (Lung sample donated by 
Dr. K BdruBb, image taken by D. Balharry and M. Hicks, 2004).
In the furthest areas of the respiratory bronchioles, Clara cells are the 
predominant cell type. Clara cells produce some of the protein components of 
surfactant (Walker et al., 1986) and are enriched with phase I and phase II 
biotransformation enzyme systems, which can detoxify noxious substances 
(Baron et al., 1988). They can also act as progenitor cells, in that they are 
able to divide, differentiate and replace other damaged cell types (Evans et 
al., 1976). Each respiratory bronchiole divides further into several alveolar 
ducts, which have numerous alveoli opening along their length. Each alveolar 
duct ends in an alveolar sac, which in turn opens into several alveoli.
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1.1.3 S TRUCTURE AND FUNCTION OF THE ALVEOLI
Respiratory alveoli are the structures in which molecular oxygen and carbon 
dioxide are exchanged in the lung. Each alveolus consists of a pocket which 
is lined by flattened epithelial cells and opens at one side. Most of the 
alveolar wall is comprised of a network of pulmonary capillaries. The 
capillaries are enmeshed in elastin and fine collagen fibres and are supplied 
by pulmonary vessels that follow the airways. The collagen and elastin fibres 
supporting the capillaries condense around the opening of each alveolus. 
They join with those around the openings of adjacent alveoli to form a three- 
dimensional supporting network for the whole lung parenchyma.
The alveolar wall has two basement membranes, one associated with 
endothelial cells and one with epithelial cells. Where the wall becomes very 
thin these two basement membranes fuse into a single basement membrane 
(BM). At this point the wall is composed only of a type I pneumocyte cell, a 
single fused basement membrane, and a single endothelial cell. This thin wall 
facilitates gas exchange between the channel of blood and the alveolar 
spaces (Figure 1.6).
Nucleus
Endothelial Fused Basement
Membrane Capillary 
Endothelium
Epithelial 
Nucleus
Type 1 Erythrocyte
Epitheial Cell
Capillary
Figure 1.6 Transmission electron micrograph of an alveolar wall. It shows a capillary with 
erythrocytes that is separated from the alveolar space by a layer of tissue consisting of type I 
epithelium, endothelium and interstitial space (Image from West, 1992).
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The alveolar walls contain small openings about 8pm in diameter, called 
alveolar pores or pores of Kohn. These allow pressure equalisation between 
alveoli, and provide air circulation should a bronchiole become obstructed.
In addition to the blood vessels and supporting tissue, the alveolar wall also 
consists of surface epithelial cells. The epithelium provides a continuous 
lining to each alveolus and consists mainly of two cell types (Figure 1.7). 
Most of the alveolar surface is covered by large squamous cells called type I 
epithelial cells. The second type of epithelial cell makes up 60% of cells in the 
lining epithelium. It is known as the type II, or granular pneumocyte and is 
rounded in shape. Consequently, type II cells occupy a much smaller 
proportion (about 5%) of the alveolar surface area. The alveolar interstitium 
also contains other cells such as fibroblasts and lymphoid cells.
Macrophage
Capillary
Type II cell
Type I cell
Alveolus
Endothelial Cell
Figure 1.7 Light microscopic image showing complete alveolar unit (Reproduced from 
‘Histology of Respiratory Tract’ Lectures, Cardiff University, with the permission of Dr. K. 
BdruBd,).
Type I pneumocytes constitute part of the extremely thin gaseous diffusion 
barrier, whereas the cytoplasm of type II pneumocytes is filled with vesicles 
containing phospholipid in the form of lamellar bodies. These bodies are 
discharged into the alveolar space where they contribute to the surfactant 
layer. Surfactant reduces the surface tension within the alveoli, preventing 
alveolar collapse during expiration.
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The extremely high levels of differentiation of type I pneumocytes suggest that 
these cells are incapable of division and cannot change their phenotype 
(Williams, 2003). Type II pneumocytes retain the capacity for cell division and 
therefore function as stem cells for type I cells in response to damage to the 
alveolar lining (Miller and Hook, 1990).
Although the upper airways filter most particulate matter from inspired air, 
small particles such as carbon can reach the alveoli. Here they are engulfed 
by large phagocytic cells (macrophages) found in the alveolar wall or free in 
the alveolar space.
1.1.3.1 TYPE I (MEMBRANOUS) PNEUMOCYTE
This cell type covers 95% of the surface area of the alveolar wall but accounts 
for only 40% of the number of epithelial cells. The primary function of the type 
I cell is to enable gas exchange between the alveolar space and the 
pulmonary capillaries. Type I pneumocytes are flat cells which contain a 
flattened, central nucleus. This is surrounded by broad cytoplasmic 
extensions. These cytoplasmic flaps are between 0.1 and 0.3pm thick, to 
minimise the diffusion distance between the alveolar air space and pulmonary 
capillary blood. A perivascular region within the cell contains all the 
organelles (Weibel, 1978). The airway and alveolar epithelium is the primary 
barrier to diffusion of electrolytes and small solutes from the lung vasculature. 
Proteins and fluids can be actively transported across type I epithelium to 
maintain normal functioning of the lung (Johnson et al., 2002; Kreda et al.,
2001).
Whilst the highly specialised structure of the type I cell is ideal for the function 
of gas exchange, it also makes the cell more susceptible to injury. Damage to 
these cells can lead to exudation of fluid and proteins which then collects in 
air spaces (Godwin, 1995). Type I cells have no mitotic potential and cannot 
regenerate; therefore, another mechanism is required for repair of damage 
caused to the lung surface.
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1 .1 .3 .2  TYPE II (GRANULAR) PNEUMOCYTE
Type II cells are spherical pneumocytes most commonly located at a 
branching point of the alveolar septum (Figure 1.8). The main identifying 
characteristics of these cells are the numerous lamellar inclusion bodies and 
many microvilli on their free surface (Telford and Bridgman, 1995). The Golgi 
apparatus is extremely well developed, so that segments of it appear in all 
parts of the cell. The endoplasmic reticulum is predominantly granular, and 
extends through the cell and occupying space between the other organelles 
and the lamellar bodies. The cytoplasm is filled with small vacuoles 
representing the characteristic lamellar bodies. These are membrane-bound 
and the lamellae within them are composed mainly of phospholipids.
Lamellar Body
Nuclear Pore
Nucleus
Basement Membrane
Mitochondrion
Endoplasmic  
Reticulum
Microvillus
Figure 1.8 A type II pneumocyte from human lung. Cytoplasmic organelles can be seen 
(Image from Scarpelli, 1988).
Type II cells have had four major functions attributed to them: 1) synthesis 
and secretion of surfactant; 2) xenobiotic metabolism; 3) transepithelial 
movement of water; and 4) regeneration of the alveolar epithelium following 
lung injury (Castranova et al., 1988).
Production of surfactant is facilitated by the exocytotic release of phospholipid 
stored as lamellar bodies. On the alveolar surface it combines with other 
carbohydrate- and protein-containing secretory products (some of which are
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derived from Clara cells) to form a tubular lattice of lipoprotein known as 
tubular myelin (Gil and Reiss, 1973). Type II cells are also related to the 
bronchiolar Clara cell in that they contain biotransformation enzymes enabling 
breakdown of chemicals reaching the alveolar surface (Devereux et al., 1989). 
The movement of water molecules is regulated by type II cells, primarily by 
the active transport of sodium (Goodman et al., 1983) but also by the 
presence of aquaporins (Kreda et al., 2001). When type I cells are damaged, 
type II cells divide, migrate and spread along the denuded basement 
membrane. The epithelium is reformed by proliferation of these cells, and 
subsequent differentiation into either normal type II or squamous type I cells 
(Bishop, 2004).
1.1 .3 .3  P o r e s  o f  K o h n  (In te r a lv e o la r  P ores)
Adjacent alveoli have numerous interalveolar connections or pores (Figure
1.9).
Interalveolar Pores
20 pm
Figure 1.9 Scanning electron micrograph showing pores of Kohn in alveoli from normal rat 
lung (Lung sample donated by Dr. K BeruBe, image taken by D. Balharry and M. Hicks, 
2004).
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These allow ventilation of a partially deflated lung to occur to some extent. 
The pores allow passage of other materials such as fluid, bacteria and 
inflammatory cells. Fluid can spread rapidly to adjacent alveoli through these 
pores (Godwin, 1995).
1 .1 .3 .4  A l v e o l a r  M a c r o p h a g e
Alveolar macrophages constitute only a small percentage of the cells in the 
alveoli, but they represent the main cellular host defence mechanism in the 
alveolar space (Bowden, 1984). They are responsible for the phagocytosis of 
microorganisms and other particulate matter that has reached the alveoli. 
They can be found on the surface of alveolar lining cells as well as in the 
supporting tissue of the alveolar septa.
The macrophage population is derived primarily from blood monocytes, 
although some arise from mitotic division of macrophages already resident in 
the lungs (Shellito et al., 1987). The macrophage is capable of rapid 
proliferation and release into the airways, in response to a number of natural 
and experimental stimuli (Bowden, 1976). They are large cells, 10-12pm in 
diameter (Telford and Bridgman, 1995) and are usually recognisable by their 
numerous pseudopodia. The pseudopodia are used for macrophage 
movement and for phagocytosis. After the engulfment of material, the 
majority appear to migrate into the airways, where they are carried up the 
mucociliary escalator and disposed of by coughing and swallowing 
(Langenback et al., 1990). Others may pass into the interstitium and exit via 
the blood vessels or lymphatics, often accumulating in the regional lymph 
nodes (Lehnert eta l., 1986).
Macrophages have also been shown to be involved in immune responses to 
insult to the lung. They release many factors including chemotactic factors 
and cytokines. Some of these cytokines can recruit neutrophils and 
inflammatory proteins, whilst others can interact with T lymphocytes for cell- 
mediated immune response (Lohmann-Matthes eta l., 1994).
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1 .1 .3 .5  P u l m o n a r y  S u r f a c t a n t
The entire alveolar surface is lined with a thin fluid known as pulmonary 
surfactant. The principal function of surfactant is the maintenance of low 
surface tension at the air-liquid interface and prevention of alveolar collapse. 
Pulmonary surfactant overcomes the effect of surface tension in the lung that 
would otherwise cause two alveolar surfaces to adhere, and stabilises alveoli 
for efficient gas exchange.
Surfactant consists of approximately 90% lipid and 10% protein, with small 
amounts of carbohydrate (Lynn et al., 1974). Surfactant phospholipids are 
stored in lamellar bodies within the type II cell, and secreted by exocytosis. 
After the lamellar bodies have been released into the alveolar space, they 
unravel into a characteristic cross-hatched structure termed tubular myelin 
(Figure 1.10). The organisation of tubular myelin (TM) is carried out by 
several of the proteins in surfactant (SP-A, SP-B and SP-C) (Daniels and 
Orgeig, 2003). The protein component of pulmonary surfactant is made up of 
four surfactant proteins (SP-A, SP-B, SP-C and SP-D). These proteins are 
synthesised in alveolar type II cells (Yano et a l., 2000). Surfactant proteins 
SP-A and SP-D can also bind and activate alveolar macrophages, influencing 
a number of events such as chemotaxis and secretion of inflammatory 
cytokines (Wright and Youmans, 1993).
After the transition into TM, the lipid and protein components separate as the 
lipid is inserted into the monolayer at the air-liquid interface. It is this lipid 
structure that provides the surface film which regulates the surface tension of 
the liquid lining of the lung (Rooney eta l., 1994).
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Lam ellar Tubular
Bodies Myelin
Figure 1.10 Transmission electron micrograph showing lamellar bodies unravelling to form 
tubular myelin in rat lung (Image taken by D. Ba I harry and M. Hicks, 2004).
Surfactant is subsequently broken down into small aggregate vesicles through 
mechanical or biological actions. Inactivated surfactant is cleared from the 
alveolar space by removal of these small aggregate particles (Veldhuizen, 
1997). Seventy to eighty percent of surfactant is taken up and reused by type 
II cells, whilst the remaining surfactant is phagocytosed by alveolar 
macrophages. (Trapnell and Whitsett, 2002).
1.1.4 Th e  P a th w a y s  o f  L ung  in j u r y
Injury to the lung parenchyma elicits a typical sequential pattern of response 
(Figure 1.11). The first response is at the alveolar surface. This may become 
altered by abnormal leakage of fluid into the alveoli (oedema) or by 
breakdown of the mechanisms designed to remove the liquid and particulate 
matter from the alveolar lumen (clearance failure) (Lewis et al., 1987). This 
may be followed by an inflammatory response leading to microscopic changes 
in vascular calibre and blood flow. Chronic inflammation responses may lead 
to excessive or abnormal tissue remodelling (hyperplasia, metaplasia).
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Bioreactive Material
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Epithelial Cell Damage
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\
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PROGRESSIVE
f Epithelial Metaplasia L} Interstitial Fibrogenesis 1
Figure 1.11 Response endpoints of damaged respiratory tissue. Sections highlighted in red 
are the areas investigated in this study.
If the toxicant leading to lung injury is not removed, a common response is the 
formation of too much collagenous material on the interstitial tissue 
(pulmonary fibrosis) or a loss and redistribution of tissue elements 
(emphysema).
1.1.4.1 O edem a
The maintenance of lung fluid balance and the correct hydration state of the 
interstitium is essential for normal functioning of the lung. As such, the 
integrity of both the capillary endothelial and the alveolar epithelial barriers is 
very important. The capillary endothelium is highly permeable to water and 
many solutes, including small molecules and ions, however the alveolar 
epithelium is not (Taylor and Gaar, 1970). Consequently, any fluid or protein 
which has leaked onto the lung is actively pumped from the alveolar surface 
to the interstitial space (Al-Bazzaz, 1986). In normal lungs, the tissue fluid is 
then removed through the alveolar interstitium into the pulmonary lymphatic 
channels (Mehta etal., 2004).
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Capillary damage is the most important factor in the development of 
pulmonary oedema. Many chemical agents can disrupt the endothelial barrier 
by forming intercellular gaps and making them extremely permeable (Lum and 
Malik, 1994). Oedema ensues because of the increased movement of fluids 
and proteins through the damaged membrane. Two stages are recognised in 
the formation of pulmonary oedema (West, 2000). The first is interstitial 
oedema (Figure 1.12), which is characterised by the appearance of oedema 
fluid in the perivascular connective tissue which later spreads to form blebs 
from the capillary endothelium. Some widening of the interstitium of the 
alveolar wall occurs. This change is followed by intra-alveolar oedema where 
the oedematous fluid accumulates in the airway instead of the interstitial 
space (Figure 1.12). Overloading of the lymphatics may prompt this transition 
from interstitial to alveolar oedema. The pressure in the interstitial space is 
increased so much that fluid spills over into the alveoli (West, 2000).
Interstitial Oedema
Thickening Fluid
Figure 1.12 Haematoxylin and eosin stained lung section(x160 magnification) (image taken 
by D. Balharry, 2002). Tissue has interstitial oedema and some intra-alveolar oedema, where 
the oedematous fluid containing plasma proteins, cell debris and macrophages accumulates 
in the airway instead of the interstitial space.
The fluid containing plasma proteins, fibrin and disintegrated cell organelles 
moves across the alveoli as they are filled one by one. Macrophages cover 
the sites of alveolar epithelial cell destruction.
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1.1 A .2 INFLAMMA TION
Inflammation is the tissue response to injury. Its purpose is to repair, restore 
and, if necessary, remodel the injured tissue. Lung injury triggers an 
inflammatory response that includes migration and activation of both resident 
and circulating inflammatory cells, and production of cytokines and growth 
factors. This inflammatory cascade results in microscopic alterations that 
include changes in vascular calibre and blood flow, tissue oedema and 
leukocyte emigration (Swaisgood et al., 2000). Initial recruitment of 
inflammatory cells into the alveolar spaces is brought about by 
chemoattractant agents derived from the injured lung tissue. If the damage is 
acute, the inflammatory cell infiltrate is predominantly made up of 
polymorphonuclear cells (mainly neutrophils) (Grattendick et al., 2002). The 
duration of the response to injury is short, leading to resolution, healing and 
repair.
If there is repeated exposure to toxic agents, there may be a switch to chronic 
inflammation responses. Vascular remodelling and sustained leukocyte influx 
are the most prominent features of chronic inflammatory diseases (Ezaki et 
al., 2001). During chronic inflammation the acute neutrophilic response is 
replaced by a lymphocyte predominant response (Izbicki et al., 2002). The 
increased permeability of the pulmonary epithelium and endothelium results in 
movement of plasma proteins and ultimately the formation of fibrin clots in the 
alveoli. The degradation products of this fibrin can act as chemoattractants 
for leukocytes (Richardson et al., 1976). In this instance, the inflammatory 
response could be augmented by the recruitment of new inflammatory cells. 
In a similar manner, the adherence of lymphocytes to the endothelium can 
lead to further induction of cytokines, which may also increase leukocyte 
traffic and recruitment of phagocytic cells during inflammation (Berman et al.,
1990). Neutrophils, macrophages and lymphocytes are well documented as 
sources of endothelial cell mitogens (Ezaki et al., 2001). The increased 
number of these inflammatory cells could lead to endothelial cell proliferation 
resulting in enlargement of the airway vasculature. These changes to the cell 
structure could be a further stimulus leading to the sustained influx of
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leukocytes which initiates tissue remodelling (Murphy et al., 1999). This may 
then lead to an abnormal tissue restoration (hyperplasia, metaplasia) resulting 
in altered function or failure to function normally, as in fibrosis or emphysema 
(Jeffery, 2000).
1 .1 .4 .3  A l v e o l a r  P r o t e in o s is
Phospholipidosis (alveolar lipoproteinosis or alveolar proteinosis) is a form of 
response to a variety of noxious agents. The condition is characterised by a 
build-up of large amounts of phospholipid and protein in the alveoli (Hook, 
1991). The accumulated material is rich in tubular myelin, membranous 
vesicles and lamellated structures resembling lamellar bodies. This suggests 
that the disease state results from aberrant accumulation of pulmonary 
surfactant (Onodera et al., 1983). An accompanying intense hyperplasia of 
type II pneumocytes in alveolar walls has been found by some investigators 
(Witschi, 1976). The hyperplasia alone does not account for the increase in 
extracellular surfactant, although a large number of hypertrophic type II cells 
have also been identified. These hypertrophic cells have been shown to 
produce phospholipids and SP-A at an elevated rate (Miller and Hook, 1988). 
Respiratory bronchioles and alveolar walls are usually of normal thickness but 
may be slightly thickened due to a lymphocytic infiltration. In addition, 
intracellular lipid, identified as cholesterol or cholesterol ester, is also found in 
the alveolar walls (Spencer, 1985).
One of the indicators of lipoproteinosis is the massive accumulation of foam 
cells in the alveoli of the lung (Gonzalez-Rothi and Harris, 1986). These cells, 
which are alveolar macrophages, contain large amounts of phospholipids and 
other lipids which have been engulfed from the extracellular spaces (Figure 
1.13). The build up of phospholipids in alveolar macrophages has been 
shown to severely impair phagocytic activity (Gonzalez-Rothi and Harris, 
1986). This can lead to reduced alveolar clearance and decreased resistance 
to infection. Extracellular accumulation of this surfactant-like material also 
interferes with normal cellular functions and impairs gas exchange (Hook,
1991).
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Pseudopodia
Phospholipids
Figure 1.13 Transmission electron micrograph showing a foamy macrophage in rat lung. 
(Image taken by D. Balharry and M Hicks, 2004)
Under normal conditions in the lung, the rate at which phospholipids are 
synthesised is equal to the rate at which they are used, which in turn is equal 
to the rate at which they are cleared from the lung (Hook, 1991). During 
pulmonary alveolar phospholipidosis the rates of biosynthesis, secretion and 
clearance of phospholipids have been shown to be elevated by varying 
amounts (Dethloff et al., 1989). The imbalance between synthesis, secretion 
and clearance leads to increases in the levels of phospholipids in the lung. 
This only helps to potentiate the effects of the disease.
1.1.4.4  P u lm o n a r y  F ib r o sis
Pulmonary fibrosis is most likely to ensue if the cause of the initial lung 
damage persists. Fibrosis is a serious, debilitating disease. A number of 
drugs are known to induce pulmonary fibrosis in humans. These include 
bleomycin, busulfan and mitomycin. Fibrosis is usually signified by a 
significant increase in total lung collagen. Primary damage to the lung leads 
to oedema and inflammation as previously described. This includes an 
increase in the number of macrophages. These macrophages can secrete a 
variety of potentially fibrogenic cytokines (Richards et al., 1991). 
Lymphocytes have also been shown to generate fibroblast chemotactic
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factors, and influence both fibroblast proliferation and collagen synthesis 
(Postlethwaite et al., 1984). The first stage of fibrosis occurs at areas of 
extensive epithelial damage. As previously described, increased permeability 
of the pulmonary epithelium and endothelium results in movement of fibrin 
into the alveoli. Continuing injury to the lung and continuous influx of fibrin 
can overwhelm the fibrinolytic system. Fibroblasts may then migrate from the 
interstitium across the denuded epithelium where they surround areas of 
influxed fibrin. Subsequently, additional collagen is secreted (Adamson, 
1984). More commonly, fibroblast proliferation and secretion of collagen is 
observed within the pulmonary interstitium. The extent of fibroblast post- 
translational modification may determine the ratio and types of collagen 
produced. Finally, cross-linking enzymes bring about the maturation of the 
collagen (Richards et al., 1991). Associated with these extensive areas of 
interstitial fibrosis is the appearance of proliferated, cuboidal type II cells 
(Adamson, 1984).
1.2 B le o m y c in
1.2.1 S tructure and  Mechanisms  o f  To xicity
Bleomycins are a family of compounds produced by Streptomyces verticillis. 
Bleomycins show antibiotic and potent anti-tumour effects which have given 
them an important place in cancer chemotherapy. They are used extensively 
in the management of squamous cell carcinomas, malignant lymphomas and 
testicular teratomas, usually as part of a combination of drugs 
(NetDoctor.co.uk, 2001). They are cell cycle specific in their anti-tumour 
effect, acting predominantly in the G2 and M phases of the cell cycle 
(Barranco et al., 1973). Unfortunately, the use of bleomycin in the treatment 
of these diseases is limited by its toxic effects, the most serious being 
pulmonary injury. This is thought to be primarily due to the lack of a specific 
bleomycin metabolising enzyme known as bleomycin hydrolase in the lung 
(Lazo and Humphreys, 1983).
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All bleomycins have the same bleomycinic acid background (Figure 1.14). 
The bleomycin molecule is made up of a bithiazole component which partially 
intercalates into the deoxyribonucleic acid (DNA) helix, parting the strands, 
and pyrimidine and imidazole structures, which bind iron and oxygen forming 
an activated complex. This complex is capable of releasing damaging 
oxidants in close proximity to the polynucleotide chains of DNA (Dorr, 1992). 
This may lead to chain scission or structural modifications leading to release 
of free bases or their propenal derivatives (Wu et a l., 1983). Some of the 
DNA strand damage may repair, but usually the cell cycle is affected, often 
leading to cell death.
NH,
NH.
Bithiazole
Pyrimidine
NH
Imidazole
Sugar moities
H
Figure 1.14 Simplified model o f bleomycin showing active sites. The bithiazole ring 
intercalates with DNA, whilst the pyrimidine and imidazole structures bind iron and oxygen.
Bleomycin can also cause cell damage independent of its effect on DNA by 
inducing lipid peroxidation (Ekimoto et al., 1985). This may be particularly 
important in the lung, and in part account for its ability to cause alveolar cell 
damage and subsequent pulmonary inflammation. Bleomycin has also been 
shown to inhibit the entry of cells into mitosis (Vig and Lewis, 1978).
Bleomycin is thought to exert its cytotoxic effect by cleaving DNA in an 
oxygen and metal ion-dependent process. Bleomycin binds to a variety of 
metals, including copper, manganese, vanadium, iron and cobalt. The iron 
complex is probably the most important in vivo, but DNA can be cleaved by 
the vanadium and manganese complexes. The complex of bleomycin with
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iron has been most extensively investigated. Bleomycin simultaneously binds 
DNA and Fe(ll) (Stubbe and Kozarich, 1987). In the presence of molecular 
oxygen, hydroxyl radicals are released. Following this, DNA damage and 
oxidation of Fe(ll) occurs. This oxygen-ligated, ferric-bleomycin complex is 
termed 'activated bleomycin’, and is thought to be the DNA-attacking species. 
The bleomycin metabolising enzyme, bleomycin hydrolase, is a cytosolic 
aminopeptidase which is thought to react with bleomycins. The resulting 
metabolite is unable to bind metals such as iron, rendering it inactive 
(Doelman and Bast, 1990).
Activated bleomycin is formed in two distinct steps. A transient oxygen-iron- 
bleomycin complex is formed. This yields a further species (activated 
bleomycin) by a single electron reduction. The reduction of the oxygen-iron- 
bleomycin complex to activated bleomycin is thought to be brought about by 
ferric-bleomycin. However, in the absence of DNA, the oxygenation of ferric- 
bleomycin results in the formation of a self-inactivating complex.
The two functional components of the bleomycin molecule necessary for its 
DNA damaging effects are two thiazole rings at one end of the molecule and a 
pyrimidine-imidazole moiety at the other. The two thiazole rings and the NH2- 
terminal residues contribute to DNA binding, whilst the pyrimidine and 
imidazole moieties are responsible for dioxygen activation and iron chelation. 
The positively charged bithiazole moiety interacts with the negatively charged 
polynucleotide chain of DNA. This delivers the ‘active’ iron-oxygen
components to appropriate DNA, and creates the subsequent damage 
(Duncan, 1989). DNA damage includes deoxyribose modification and the 
release of free bases without scission. However, single and double strand 
scission does occur at the C3'-C4' bond of the sugar residue. This occurs at 
a limited number of sites, with preferential cleavage at G-C and G-T 
sequences.
Other mechanisms of toxicity have been suggested. Fe(lll)-bleomycin has 
been shown to initiate decomposition of long chain unsaturated fatty acids 
(present in cell membranes) releasing a powerful oxidising agent, singlet
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oxygen. Enhanced lipid peroxidation by complexes of bleomycin with Fe(ll) 
and Fe(lll) has been observed (Ekimoto eta l., 1985).
In order to damage DNA, bleomycin must enter cells, penetrate the nucleus 
and become activated in close proximity to DNA. Bleomycin has been shown 
to enter cells and the amidification of the C-terminal carboxyl group appeared 
to be important for this.
Peak pulmonary levels of bleomycin occur 45-60 minutes after subcutaneous 
injection. However, this represents less than 1% of the injected dose. 
Following intratracheal instillation of the drug, 95% of the administered dose 
can be detected, but this falls to 1% by 24 hours (Hay et al., 1991).
1.2.2 Th e  evolution  o f  Bleom ycin-Induced  L ung Injury
The pathological changes in the lung parenchyma following intratracheal 
instillation of bleomycin include cellular infiltration, pulmonary oedema, 
changes to type II pneumocytes and interstitial fibrosis (Brown etal., 1988).
The initial morphological damage seen after treatment with bleomycin 
appears as damage to the pulmonary endothelial cells. This occurs in the 
form of endothelial cell swelling and blebbing (Aso et al., 1976). 
Subsequently, there is loss of the type I epithelium. This destruction of the 
type I cells is the most critical event following bleomycin administration. As 
this barrier is broken down oedema fluid is allowed access to the interstitium, 
and the permeability of the vascular endothelium is altered (Adamson, 1984). 
As such, the lung injury that develops in the initial 48 hours following 
intratracheal bleomycin is characterised histologically by perivascular 
oedema, capillary congestion and alveolar wall thickening. The oedema is 
predominantly interstitial, with only minimal intra-alveolar oedema. There is 
an inflammatory cell infiltrate in the alveolar walls and spaces, together with 
intra-alveolar haemorrhage. The influx of cells includes a 10-fold increase in 
the number of macrophages and monocytes, lymphocytes, 
polymorphonuclear leukocytes and occasional plasma cells (Hay et al., 1991).
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They are found mainly in the perivascular, peribronchiolar and alveolar 
interstitium, and only occasionally in the intra-alveolar space. Another 
indicator of the acute phase of bleomycin-induced lung injury is a measure of 
the vascular permeability using radiolabelled markers such as 125l-albumin. 
This provides a sensitive index of oedema (Hay et al., 1987). Some areas of 
alveoli are entirely denuded of epithelium. Necrosis of capillary endothelium 
is also observed. Despite the severity of lung injury, the process is patchy, 
with some normal areas of lung interspersed. At this early stage, there is no 
sign of fibrosis.
Following the early response induced by intratracheal bleomycin instillation, 
extracellular matrix glycoprotein tenascin and collagen, messenger ribonucleic 
acids (mRNA) are induced (Zhao eta l., 1998). Tenascin is principally induced 
following the increased influx of activated inflammatory cells, during the early 
inflammatory stage. Tenascin is induced only in areas of tissue inflammation 
in the alveolar septal walls and secondary septal tips. The induction of 
tenascin could ensure the reparative phase is initiated, by providing invading 
cells with migratory pathways. Tenascin may participate in tissue 
inflammation and remodelling by modulation of cell migration and proliferation, 
and by mediating cell adhesion. This then regulates mesenchymal-epithelial 
interactions. Tenascin is a unique, early-response extracellular matrix 
component to bleomycin-induced pulmonary injury. The development of 
fibrosis is associated with a decrease in tenascin but an increase in collagen 
(Zhao eta l., 1998).
A common but not inevitable consequence of early phase oedema and 
inflammation is marked alveolar and bronchiolar epithelial cell proliferation 
(Miller and Hook, 1990). The type II cells undergo atypical structural changes 
and pneumocyte proliferation (hyperplasia). These cells are found either 
attached to the alveolar wall or free within the alveolar spaces. The alveolar 
epithelium undergoes squamous metaplasia and becomes cuboidalised 
(Richards et al., 1991; Folkesson eta l., 1998; Figure 1.15).
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Figure 1.15 TEM image showing alveolar epithelium lined by cuboidal, hyperplastic type II 
cells after bleomycin treatment. Enlarged lamellar bodies are indicated by arrows (Image 
reproduced from Folkesson et al., 1998, with permission).
A minimal collapse of the alveoli can occur. Alveolar obliteration takes place 
when the alveolar space becomes obstructed with inflammatory cells or 
atypical type II cells. Metaplasia is accompanied by lymphocyte infiltration, 
focal areas of interstitial fibrosis and minimal intra-alveolar fibrosis (Brown et 
al., 1988). The fibrotic lesions show the typical thickening of the alveolar wall. 
This is characterised by the presence of abnormal production and deposition 
of collagen, and other matrix components in the interstitium (Swaisgood et al., 
2000). The excessive amount of fibrous tissue that is laid down in the 
interstitium consists of a variety of components. It is chiefly comprised of 
proteins and glycoproteins, of which the most abundant are collagens. 
Collagen synthesis and deposition usually occurs within seven days of 
bleomycin administration. There is no change in the proportion of collagen 
types I and III, suggesting a proportional increase in both (Hay et al., 1991).
The peribronchial areas of fibrotic lungs contain an additional network of blood 
vessels. The architecture of the alveolar capillaries is modified by the 
occurrence of interstitial fibrosis of the alveolar wall (Peao et al., 1994). This
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leads to oedema of the capillary endothelium, resulting in fibroblasts and 
lymphocytes accumulating around areas of fibrosis. In response to 
bleomycin, alveolar macrophages secrete a fibroblast growth factor. These 
fibroblasts or their secreted collagen fibres can influence epithelial cell growth 
and differentiation. Epithelial cells secrete a product which has a fibroblast 
inhibitory effect on normal cells (Young and Adamson, 1993). This product is 
not secreted in a fibrotic lung in which excess fibroblast growth occurs. In a 
reciprocal interaction, epithelial cell proliferation is promoted by exposure to a 
product of lung fibroblasts. This indicates that a fibroblast-derived factor is 
capable of stimulating epithelial growth and so may accelerate repair (Young 
and Adamson, 1993). Fibroblasts could be exposed to numbers of mediators 
released by resident cells, or those entering tissues from the circulation.
1.2.3 A nimal M odels o f  Bleom ycin -Induced  L ung Injury
A large amount of the information gathered about the in vivo effects of 
bleomycin has been acquired using animal models. Interstitial fibrosis after 
repeated bleomycin administration has been reported in many different 
species, including humans, pigs (Balazs et a/., 1994), rabbits (Catravas et al., 
1983), hamsters (Starcher et al., 1978), rats (Thrall et al., 1979) and mice 
(Aso et al., 1976). The overall fibrotic response is morphologically very similar 
between different species (Lazo et al., 1990). This ability to reproducibly 
cause a similar condition in different experimental animals has led to 
bleomycin becoming one of the most commonly used agents to study the 
pathogenesis of pulmonary fibrosis. Despite the consistent development of 
pulmonary fibrosis, there appear to be some differences in sensitivity to 
bleomycin treatment. For example, the pulmonary fibrotic response in rabbits 
is less than that seen in mice with approximately equal doses (Lazo et al., 
1981). The age of the experimental animal may also be important. 
Bleomycin does not show pulmonary toxicity to young mice (Umezawa, 1979), 
and when bleomycin is administered to newborn lambs there is no evidence 
of pulmonary fibrosis (Pitt et al., 1991). Although the basis for this 
unresponsiveness is unclear, it is well known that antioxidant defence 
mechanisms are enhanced in the neonate (Frank, 1985). Furthermore,
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bleomycin hydrolase activity is greater in the lungs of newborn mice in 
comparison to mature mice (Umezawa, 1979). The varying susceptibility of 
animal models to bleomycin can be thought of as advantageous, in that it 
allows a fuller depiction of the various stages and levels of a toxic response 
(Kaminski et al., 2000a). Genetically modified animals can be used to alter 
the response to insult, to gain an even better understanding of the disease 
processes (e.g. Kaminski eta l., 2000b, Swaisgood eta l., 2000).
Interstitial pulmonary fibrosis has been reported after multiple intravenous 
(IV), subcutaneous (SC), intraperitoneal (IP) or intratracheal (IT) doses (Lazo 
et al., 1990). The relationship between the route of bleomycin administration 
and the development of fibrosis has been best studied in mice. With both IV 
and IP administration, large amounts of bleomycin are required to generate a 
reproducible, measurable fibrotic response (Lazo et al., 1990). Repeated SC 
injections of bleomycin will produce interstitial pulmonary fibrosis, but again 
this requires a high dose (Filderman et al., 1988). The IT route of 
administration requires a relatively small dose to produce a rapidly 
progressing fibrotic response (Bakowska and Adamson, 1998). Measurable 
fibrosis occurs much sooner using IT administration, than seen with systemic 
routes of administration.
Further well-characterised models use a single IT instillation of bleomycin to 
generate pulmonary injury. This model initially induces lung inflammation that 
is followed by oedema and the progressive destruction of normal lung 
architecture (e.g. Kaminski et al., 2000a). However, this model rarely 
progresses to the fibrotic state.
1.3 To x ic o g e n o m ic s  a n d  G e n e  Ex p r e s s io n  S tudies
Genomics is the structural, functional and comparative analysis of genomes 
and gene products from a wide variety of organisms. The purpose of 
genomics is not to simply identify the component parts, but to understand how 
these components work together to comprise functioning cells and organisms.
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The characterisation of the genetic responses of cells and tissues to a variety 
of toxicant and chemical insults is known as toxicogenomics. An important 
step in the pursuit of this is defining gene expression profiles. This compares 
patterns of expression in different tissues and developmental stages, in 
normal and diseased states, or in distinct in vitro conditions. This can be 
accomplished using reverse transcription polymerase chain reaction (RT- 
PCR), RNase protection assays, or Northern blot analysis, but these methods 
focus on only a few genes at a time. A more recent approach for analysing 
multiple genes simultaneously is the hybridisation of entire complementary 
DNA (cDNA) populations to nucleic acid arrays. The arrays are most 
commonly used to simultaneously measure levels of expression (mRNA 
abundance) for thousands of genes. For the majority of genes, changes in 
mRNA abundance are related to changes in protein concentration (Lockhart 
and Winzeler, 2000). The degree of mRNA expression is very informative 
about the state of a cell and the activity of genes. The transcription of 
genomic DNA (gDNA) to produce mRNA is the first step in protein synthesis, 
therefore the expression profile of a collection of genes is a major determinant 
of cellular phenotype and function. The differences in gene expression are 
indicative of both morphological and phenotypic differences, as well as of 
cellular responses to environmental stimuli. In terms of understanding the 
function of genes, knowing when, where, and to what extent a gene is 
expressed is key to understanding the activity and biological roles of its 
encoded protein. In addition, changes in the expression patterns can provide 
information about regulatory mechanisms and broader cellular functions and 
biochemical pathways (Lockhart and Winzeler, 2000).
The construction of microarrays and macroarrays is based on immobilising 
DNA sequences (which may be oligonucleotides or polymerase chain reaction 
(PCR) amplified cDNA) at specific locations on a solid support. A labelled 
cDNA copy of an RNA probe is hybridised to the DNA molecules attached to 
the array (Figure 1.16). This method exploits the specificity and affinity of 
complementary base pairing.
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Figure 1.16 A summary of the array technique. Total cellular RNA is isolated from the 
sample. Reverse transcription generates a radiolabelled probe prior to hybridisation to the 
array membrane. Hybridisation is visualised and quantified using a phosphorimager screen. 
For details, see Chapter 4.
Following quantification, the extent of differential hybridisation to each 
individual sequence on the array can be determined by phosphorimager 
analysis (or similar techniques). The relative abundance of each of the gene 
sequences in two or more biological samples can be compared (Brown and 
Botstein, 1999). Arrays can contain sequences selected to investigate 
specific endpoints or pathways, or include genes representing a wide range of 
biological processes. A number of ‘housekeeping genes’ are included to aid 
in normalisation of data. The expression of housekeeping genes is expected 
to be stable under a wide range of conditions.
Arrays can only measure changes at the mRNA level and therefore cannot 
confirm changes in levels of the functional protein encoded by the gene. In 
addition, post-translational protein modifications such as phosphorylation, 
which may have profound influence on protein function, will not be directly 
measured by array analysis (Pennie, 2000). However, protein-based 
approaches are generally more difficult, less sensitive and have a lower
29
Introduction
throughput than RNA based ones. In view of this, array technology is used to 
study a wide range of applications, including investigating normal biological 
and disease processes, profiling differential gene expression, and discovering 
potential therapeutic and diagnostic drug targets
The first natural step for extracting useful information from the generated data 
is to examine genes with a significant differential expression in two individual 
samples. This technique of examining the extremes of responses does not 
address the full potential of genome-scale experiments. A holistic approach 
to analysis of genomic data that can detect patterns and relationships in 
multiple sets of data is required. This generates a more integrated 
understanding of the process being studied. As yet there is no consensus as 
to the best method for analysis of micro and macroarrays (Mocellin et al., 
2004). However, the visualisation of large sets of array data is a popular 
method of analysis. This includes principal component analysis, singular 
value decomposition, multidimensional scaling and various clustering 
techniques (Slonim, 2002). Clustering applies to a wide range of methods 
used for organising multivariate data into groups with roughly similar patterns 
of expression (pairwise average linkage cluster analysis: Eisen, 1998; 
hierarchical clustering: Brown and Botstein, 1999; K-means clustering: 
Katsuma et al., 2001). A number of techniques for analysis of arrays have 
been emerging but often these require the involvement of a specialist 
statistician (Cunningham et al., 2000; Lee et al., 2000; Nadon and 
Shoemaker, 2002).
In 2001, availability of a comparatively inexpensive conventional product for 
worldwide use in laboratories became available. This relatively simple 
technique for analysis of macroarray data used the Atlaslmage™ 1.0 software 
for analysis directly from the phosphorimage. Preliminary work with this 
product demonstrated that by combining a series of analysis techniques with 
this software, significant genetic responses could be detected (Reynolds and 
Richards, 2001).
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1.4 A im s  a n d  O b je c t iv e s  o f  th e  S tu d y
The aim of this study was to develop a better understanding of the 
mechanisms of early bleomycin-induced lung injury, and specifically to identify 
biomarkers for pulmonary oedema, inflammation and epithelial repair. To 
accomplish this, an animal model of bleomycin-induced injury was employed.
Conventional toxicological and histological approaches were used to 
characterise the model and obtain different endpoints of injury. Once these 
had been established the new gene array technique was utilised to evaluate 
global gene expression patterns of the various stages of pulmonary damage 
and repair.
In detail, the sequential steps of this study were as follows:
• Identification of the progressive stages of oedema/inflammation and 
repair using pulmonary lavage techniques, cellular counting methods 
and assays for alveolar surface proteins and cellular proliferation 
(Chapter 2).
• Use of histological analysis to confirm the morphological changes 
occurring during oedema, inflammation and cellular repair following 
bleomycin-induced damage. Study of the detailed cellular changes 
occurring to the microstructure of the lung using transmission electron 
microscopy (TEM). Determination of the location and cell types 
involved in cellular repair by optimisation of the procedure for labelling 
replicating cells (Chapter 3).
• Use of the toxicology and histology information (Chapters 2 and 3) to 
characterise the progressive severity of the bleomycin-induced model 
of pulmonary injury (Chapter 3).
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• Optimisation of mRNA extraction from lung tissue and the macroarray 
procedure (Chapter 4).
• Global expression analysis of multiple samples of saline lung tissue for 
comparison with mild bleomycin-induced damage (Chapter 4).
• Development of bioinformatic systems for analysing data generated by 
the array process (Chapter 4).
• Confirmation of the gene expression studies and bioinformatic analysis 
using quantitative RT-PCR (Chapter 4).
• Application of gene expression studies and bioinformatic analysis to 
progressive and severe pulmonary oedema (Chapter 5).
• Identification of genetic markers, individual genes or gene clusters, for 
mild, progressive and severe oedema (Chapters 4 and 5).
• Use of immunohistochemistry to evaluate the potential of a novel lung 
protein to act as a biomarker for pulmonary oedema (Chapter 6).
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C h a pter  2:
T o x ic o lo g ic a l  Identific a tio n
of
O e d e m a , Inflam m a tio n  an d  R epair
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2.1 In t r o d u c t io n
Bleomycin is known to cause pulmonary toxicity and was therefore used to 
induce sequential lung damage in rats. This model of lung injury was utilised 
to obtain global gene expression profiles of specific events during pulmonary 
injury, such as oedema and inflammation followed by subsequent repair.
Prior to gene profiling (Chapter 4), toxicological identification of oedema, 
inflammation and repair mechanisms needed to be established. To this end, 
rats were instilled with bleomycin and the extent of pulmonary injury was 
monitored over three weeks. From this preliminary study, three and seven 
days post-dosing were chosen for further investigation. Previous studies 
(outlined below) have indicated that significant oedema occurred at these time 
points, and that repair mechanisms were elevated by day seven.
In response to pulmonary damage, an initial oedema reaction caused by 
damage to type I cells is observed. Increased permeability of the epithelium 
allows oedema and inflammatory cell infiltrate to enter the alveoli (i.e. 
neutrophils, macrophages and lymphocytes). The maximum level of cellular 
infiltrate has been reported to occur three days post-bleomycin instillation 
(Adamson and Bakowska, 1999). Another study used the accumulation of 
albumin in the interstitial tissues as a measure of vascular permeability. This 
resulted in an increase in the interstitial space, which peaked at three days 
(Hay et al., 1987). In agreement with these studies, Savani et al., 2000, used 
hyaluronan content, macrophage numbers and motility as markers for injury, 
which showed significant increases two to seven days after bleomycin 
instillation. In a separate investigation, Savani et al., 2001, state that 
maximum respiratory distress (monitored by measuring respiratory rate) 
occurred seven days post-instillation. This was verified by increased surface 
tension of broncho-alveolar lavage (BAL) and a significant drop in surfactant 
proteins. Jang et al., 2004, also used respiration rate as a measure of lung 
injury in bleomycin-treated rats, and observed maximal damage at four and 
seven days. A further study in rats measured the extent of pulmonary injury
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using nuclear magnetic resonance (NMR): The lung water content was
shown to be significantly increased one week post-bleomycin instillation 
(Cutillo et al., 2002). Collectively, these experiments indicate that oedema 
consistently occurs between three and seven days after bleomycin-induced 
pulmonary injury.
The subsequent repair phase following oedema and inflammation is marked 
by alveolar and bronchiolar epithelial cell proliferation. After type I cell injury 
the type II cells proliferate and differentiate to restore normal lung architecture. 
In an earlier study by Smith and Wyatt (1981), diamine putrescine was shown 
to be actively accumulated in lung tissue slices, as well as in epithelial cells in 
vivo (Wyatt et al., 1988). Putrescine is believed to be important in the control 
of cell proliferation and differentiation, and therefore acts as a marker for type 
II hyperplasia/epithelial repair. Seven days after bleomycin-induced injury in 
the rat lung, putrescine accumulation was noted to be significantly increased 
above saline-treated controls (Housley and Richards, 1996). This indicated 
that the repair phase was under way seven days after the onset of pulmonary 
injury.
Once the model of lung injury was established using instillation of bleomycin, 
toxicology techniques were used to assess the level of oedema and 
inflammation. In conjunction with these techniques, a method for determining 
the level of cellular repair was also required. This was achieved by utilising 
cell proliferation as a marker for repair.
During the S phase of the cell cycle, a cell will undergo DNA synthesis to 
replicate its genome. By using DNA replication as an indicator for 
proliferation, it is possible to label cells as they enter the S phase. If labelled 
DNA precursors are present as cells undergo DNA synthesis, the labelled 
nucleotide is incorporated into the daughter cell DNA. Traditionally, 3H- 
thymidine (Kuo et al., 2001) incorporation assays have been used to measure 
cellular proliferation, and the subsequent accumulation of this compound 
within the tissue is detected by liquid scintillation counting.
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In summary, the primary objectives of the studies described in this chapter 
were to optimise the thymidine assay for monitoring lung cell proliferation and 
to link this with conventional toxicological measurements of bleomycin- 
induced lung damage.
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2.2 M a t e r ia l s  a n d  S t o c k  S o l u t io n s
2.2.1 A nim als  and  M aterials
Supplier:
Charles River Ltd, Kent 
Rhone Merieux, Essex
Material:
Male Sprague Dawley Rats 
(pathogen free, 200-250g)
Euthatal
Halothane
Kyowa Hakko (UK) Ltd, Slough Bleomycin (PL no. 12196/0005)
Sigma-Aldrich, Dorset
Amersham, Buckinghamshire
Bradford Reagent (B6916)
Methyl-3H-Thymidine in 2% Ethanol (1 mCi/ml)
Packard BioScience, Groningen, Soluene-350
*~*°^ anc* Opti-Fluor-Scintillation Fluid
2.2.2 S tock  S olutions
Bleomycin solution
Bovine Serum Albumin 
(20 mg/ml)
One Ampoule in 0.15M Saline 
(1 unit/1 ml Saline)
Dilute to Range 0-10 pg/ml
Krebs Ringer Phosphate solution 130 mM Saline
5.2 mM Potassium Chloride
10 mM Sodium Hydrogen Phosphate (Anhydrous)
11 mM Glucose
1.9 mM Calcium Chloride (Dihydrate)
1.29 mM Magnesium Sulphate (Heptahydrate) 
pH 7.4
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2 .3  M e th o d s
2.3.1 Experim ental  m o dels  o f  pulm o nary  In ju r y  a n d  Repair
Preliminary studies utilised a single dose of bleomycin sulphate (Section 
2.3.2) to induce mild pulmonary oedema. The progress of the injury was 
monitored using lung parenchyma:body weight ratio (Section 2.3.4) over 22 
days. This time course was used to determine the most appropriate point for 
further studies. Initially, three days post-dosing was chosen as a suitable time 
to study early phase injury (n=9). To investigate more severe pulmonary 
injury, and potentially some repair processes, seven days post-dosing was 
also studied (n=6). In a further study, severe injury, possibly leading to 
lipoproteinosis and fibrogenesis, was generated utilising a double dose of 
bleomycin (Brown et a/., 1988). The second dose was administered seven 
days after the first. Studies were carried out three (n=6) and seven days 
(n=6) after the second dose. A final investigation was carried out three weeks 
(n=6) after the second dose, in the anticipation that some resolution of the 
disease might have occurred.
2.3.2 A d m inistration  of B leomycin
Animals were treated with 0.5 units of bleomycin sulphate suspended in 0.5ml 
0.15M saline. Sham controls received only 0.15M saline (0.5ml). Prior to 
treatment with either bleomycin or saline, rats were lightly anaesthetised with 
Halothane. The dose was administered via non-invasive intratracheal 
instillation (Reynolds and Richards, 2001). This ensured that every animal 
received the same quantity of drug directly to the target tissue. In agreement 
with the Local Ethical Committee and the Home Office Project Licence the 
recovery time of the rats was monitored before returning them to their cage. 
Animals were also closely monitored every two hours for six hours, and twice 
a day thereafter, using a post-procedure pain and distress score sheet 
(Wolfensohn and Lloyd, 1998).
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2.3.3 Harvesting  of Experim ental  A nimals
Sham and bleomycin-treated rats (200-250g) were anaesthetised with 
Halothane and then administered a lethal intraperitoneal injection (1-2ml) of 
Euthatal. The rats were subsequently weighed and cardio-respiratory death 
confirmed prior to dissection.
2.3.4 D issectio n  of  Experim ental A nimals
The fur on the abdominal cavity of harvested experimental rats was washed 
with ethanol (70% v/v) and the ventral surface skin removed. The peritoneal 
cavity was opened by midline incision and the major dorsal blood vessels cut. 
A tracheotomy was performed and a Luer Cannula, attached to a 20ml 
syringe, securely tied into place in the trachea. The diaphragm was then 
opened and the ventral portion of the rib cage and thymus removed.
A Luer cannula attached to a gravity feed of sterile saline was then fed into 
the pulmonary artery and the right atrium was cut upon expansion to allow 
fluid to exit. The lungs were perfused via artificial ventilation with 8-10ml of air 
by means of the syringe attached to the Luer Cannula of the trachea. 
Ventilations (usually 8-10) were continued until the pulmonary circulation was 
clear of all blood, to produce white parenchymal lung tissue.
The heart was removed and the lungs and trachea dissected free from the 
carcass. The oesophagus and any fatty tissue were dissected from the lungs 
and trachea. Any mucoidal material or blood clots on the exterior of the tissue 
were removed by means of absorbent tissue. The lung parenchyma was 
weighed to calculate the L:B ratio. An increased L:B ratio was used as an 
early indicator of lung damage.
2.3.5 L ung  Lava g e
The lungs were lavaged (five to eight times) by means of a Luer cannula 
attached to the trachea (Figure 2.1) with 6-8mls of 0.15M saline, and the BAL
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fluid pooled in a centrifuge tube and maintained on ice. Following infection or 
inflammation, the number of large free cells within the lavage will usually 
increase. The free cell count was obtained by counting a sample of the BAL 
using a standard haemocytometer (Section 2.3.6).
Figure 2.1 Demonstration of saline lavage technique. A syringe full of saline is attached via a 
Luer cannula to the trachea. Saline is gravity fed into the lung until fully inflated. The saline is 
then poured off via the cannula into a collecting tube.
During oedema the cellular membranes breakdown or become compromised. 
This leads to an influx or increased transport of plasma proteins to the lung 
surface. The concentration of these proteins was determined by the Bradford 
assay (Section 2.3.7). The number of macrophages and the concentration of 
protein within the lavage serve as an assessment of the respiratory health of 
the animal. The intact cells and surface proteins were collected then 
separated from the BAL fluid by centrifugation (at 300 x g) and stored (-80°C) 
for use in later experiments. After lavaging, the five lobes of the lungs were 
separated, flash frozen in liquid nitrogen and stored at -80°C for use in gene 
profiling studies.
2.3 .6 D e t e r m  in  a tio n  o f  F r e e  Cell  N um b ers
A standard haemocytometer was used for counting cells. Phase contrast 
microscopy was used to aid cell identification. Contaminating red blood cells
10ml Syringe
Saline
Luer Cannula
Retort Stand
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were recognisable by their characteristic biconcave disc morphology and 
small size. These cells were sometimes found in lavage samples but 
comprised a small proportion of the total cell population and were not included 
in any subsequent cell counts. Damaged cells and debris were identified as 
grey or black outlines and were not included during any cell counts. The large 
free cell population was determined primarily by the number of macrophages 
present, distinguishable as the larger cells. Neutrophils were sometimes 
present in the lavage sample, and were included in the count of the free cell 
population.
2.3 .7 La v a g e  Protein  Determ ination  -  Th e  Bradford  A ssay
Bradford reagent can be used to determine the concentration of proteins. The 
protein dye complex that is formed causes a shift in the dye absorption 
maximum from 465nm to 595nm. The change in absorption at 595nm is 
therefore proportional to the protein concentration (Bradford, 1976).
A set of standards were made up using bovine serum albumin (BSA) ranging 
from 0 to 10pg/ml. BAL (supernatant from 300 x g centrifugation) was diluted 
10 or 20-fold in saline, and 200pl added to each well of a 96-well plate. Fifty 
microlitres of Bradford reagent was then added to each sample. The 
absorbance was read at 590nm using a plate reader. Assays were performed 
in triplicate for each animal and the mean value recorded.
2.3.8 Cell P roliferation  A ssay  -  Tritiated  Thym idine  Uptake
The occurrence of cellular repair in the lung was monitored ex vivo. This was 
achieved by measuring the level of cellular proliferation and differentiation by 
the use of a labelled nucleoside (tritiated thymidine). Thymidine is involved in 
DNA synthesis and therefore acts as a suitable marker for epithelial repair. 
Each sample was carried out in triplicate, and saline-instilled animals were 
used as a comparison.
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After the lungs were excised, the largest lobe was manually cut into 500|jm 
slices. Krebs Ringer Phosphate solution (KRP, 500pl) was added to each 
well of a 24-well plate, and a tissue slice placed into the well. Control wells 
were included which contained no tissue. The wet weight of tissue in each 
well was recorded and was usually between 20-40mg. A further 495pl KRP 
was added. The tissue samples were allowed to equilibrate at 37°C for 10 
minutes. After the 10 minute incubation, 5pl tritiated thymidine (50pCi/ml) was 
added to a final concentration of 0.25pCi. The addition of the tritiated 
thymidine made a total volume of 1ml per well. The samples were then 
incubated at 37°C for a further 30 minutes. An equivalent 24-well plate with 
500pl KRP in each well was prepared and stored on ice. After 30 minutes the 
incubated tissue was transferred to the chilled plate and washed copiously 
with KRP solution. The washed samples were then transferred into a vial 
containing 1ml soluene (tissue solubiliser) and placed in a boiling water bath 
for 30 minutes. Once cooled, 10ml of scintillant was added and well mixed. 
At the same time, 500pl was removed from control samples (containing no 
tissue) and added to a vial containing 10ml scintillant. All samples were 
counted in a scintillation counter 24 hours after addition of scintillant. 
Thymidine uptake was calculated as the number of nanomoles incorporated 
per lung in 30 minutes.
Thymidine uptake = ^cpm (tissue) x conc. (nmol)^
slice wt (g) x cpm (medium)
x total LP weight (g)
2.3.9 S tatistical A nalysis
The statistical difference between data points was determined using a two- 
tailed Student’s t-test.
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2.4 R e s u l t s
2.4.1 A s s e s s m e n t  o f  O ed e m a  a n d  In f la m m a t o r y  R e s p o n s e
A preliminary study was carried out over three weeks to identify the peak of 
early phase oedema. Lung parenchyma:body weight ratio (L:B ratio) was 
measured at regular intervals over three weeks after a single bleomycin/saline 
instillation (Figure 2.2). The L:B ratio is used as an indication of lung health. 
During infection, injury or inflammation, an influx of cells and protein together 
with tissue retention of excess water will cause an increase in the lung weight, 
reflected in an elevated ratio (Richards and Curtis, 1984).
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Figure 2.2 Comparison between L:B ratios of saline (+ )  and bleomycin (M) instilled rats 
over a three week time course. Days 1, 11, 15 and 22: n=3; Days 3 and 7: n=9. Error bars 
indicate one standard deviation. * Significant (p< 0.05) ** Significant (p< 0.001)
The most significant differences from control was observed at three 
(p=0.0004) and seven (p=0.0086) days post-bleomycin instillation. This 
corresponds with the predicted peak of injury as reported in previous studies 
(Adamson and Bakowska, 1999; Hay e ta l, 1987; Savani e ta l, 2001; Jang et
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a/., 2004). Subsequent studies were carried out at three and seven days 
post-single or double instillation. A final time point was also carried out three 
weeks after a second bleomycin instillation to monitor possible resolution of 
the injury.
The following parameters were recorded for each rat; body weight, L:B ratio, 
total surface protein concentration, and the lavage free cell (LFC) count from 
the lavage sample. The body weight was carefully monitored, as a failure to 
gain weight is evidence of damage to the overall health of the rat. The Home 
Office project licence regulations permit a failure to gain weight of up to 20% 
before termination of the experiment is considered. The weight of all the rats 
prior to instillation with bleomycin or saline was approximately 200g. Figure 
2.3A shows that there are significant effects on the body weight after 
bleomycin instillation, particularly after a second dose. However, throughout 
the experiment, the average difference in weight between saline and 
bleomycin-treated rats rose to a maximum of 17% (20% is maximum 
acceptable). In general, recovery was rapid with no signs of adverse health 
effects.
The saline and bleomycin-treated groups were compared for each of the 
toxicological effects. A two-tailed Student’s t-test was used to determine the 
statistical relationship between the two groups. All data are shown in Table
2.1 and Figure 2.3.
Saline Bleomycin t-test (p-value)
Days post L:B LFC Protein L:B LFC Protein L:B LFC Protein
instillation ratio <x106) (mg/rat) ratio (x106) (mg/rat) ratio (x106) (mg/rat)
3 I 0.0046 5.92 2.35 0.0071 7.93 3.55 0.003 0.03 0.003
7 0.0041 5.14 1.27 0.0068 11.55 13.29 0.0001 0.016 0.0001
10 (*3) 0.0041 7.31 1.65 0.0076 13.81 14.11 0.0000003 0.010 0.0003
15 (*8) 0.0037 5.13 1.72 0.0085 3.73 13.58 0.0011 0.002 0.000002
29 (*22) 0.0034 3.51 1.63 0.0053 6.03 8.07 0.0025 0.038 0.0031
Table 2.1 Comparison of the toxicological data between the saline and bleomycin-instilled 
lung; n=6 (except day 3: n=9). * Days post-second instillation.
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Figure 2.3 Comparison between the saline ( ♦  ) and bleomycin ( ■  ) instilled lung. n=6 
(except day 3: n=9). Error bars indicate one standard deviation. * Significant: p< 0.05, 
** Significant: p< 0.001.
At all time points measured, for all toxicological markers of injury, the 
bleomycin-treated tissue was significantly different from the controls. After the 
single dose of bleomycin, the difference in L:B ratio between saline and 
bleomycin-treated samples remained constant. However, after the second 
instillation the difference had increased, and continued to rise up to seven 
days after dosing. For both protein concentration and free cell counts the 
difference between control and bleomycin-treated samples was relatively low 
three days after the first instillation, but greatly increased by seven days. The 
protein levels remained fairly constant from seven days onwards, with the
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second instillation appearing not to increase the effect further. The difference 
in free cell numbers also remained unaffected three days after the second 
instillation. However, seven days after the second dose the number of free 
cells had dropped to significantly lower levels than control.
These data clearly indicate that oedema and mild inflammation were occurring 
after both single and double instillations of bleomycin, and were not fully 
resolved by 21 days after the second instillation.
2.4.2 Thymidine In c o rp o ra t io n  A s s ay  to  M o n ito r  C e l lu la r  R ep a ir
In addition to the toxicological measurements described above, concurrent 
studies were carried out to assess the levels of cellular repair using tritiated 
thymidine. The optimum thymidine concentration and incorporation time was 
determined using untreated tissue. Thymidine was added at concentrations of 
0.25 and 0.5pCi. After addition of the tritiated thymidine, the tissue was 
incubated at 37°C for 15, 30, 45, 60 and 120 minutes (Figure 2.4).
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Figure 2.4 Incorporation o f 0.25pCi ( + )  tritiated thymidine and 0.5pCi (M ) tritiated thymidine 
by lung slices over differing incubation periods.
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There was no significant difference between the incorporation of either 
concentration, so further experiments were carried out using 0.25 pCi tritiated 
thymidine and incubated for 30 minutes.
A preliminary assay was carried out over two weeks following a single 
bleomycin instillation (Figure 2.5). Three biological replicates were taken at 
each time point, and each of these was assayed in triplicate (n=9).
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Figure 2.5 Thymidine incorporation of saline (+ )  and bleomycin (M) instilled lung at various 
time points post-single intratracheal instillation. Error bars indicate one standard deviation.
* Significant: p< 0.05
At the early time points, when oedema is maximal, there was very little 
difference in radiolabel incorporated by slices from saline or bleomycin-treated 
samples. However, five days after instillation, a significant increase (p=0.045) 
in thymidine incorporation was observed. This difference between saline and 
bleomycin-treated samples remained significant for approximately four days 
(day 7: p=0.036, day 9: p=0.014), with the largest difference occurring nine 
days after treatment. At days 11 and 15, thymidine incorporation was 
identical in both saline and bleomycin-treated lung slices.
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A further radiolabelling experiment was carried out in parallel with the above 
toxicology studies. Lung slices were prepared three and seven days after a 
single instillation. A second dose was instilled at seven days, and more 
samples measured at three, eight and 22 days post-second instillation. The 
results from this experiment are shown in Figure 2.6.
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Figure 2.6 Thymidine incorporation of saline (+ )  and bleomycin (M) instilled lung. n=18. 
Error bars indicate one standard deviation. * Significant: p< 0.05, ** Significant: p< 0.001.
Seven days after a single dosing, total thymidine uptake in bleomycin-treated 
lung was significantly higher than in saline controls (p=0.001). The greatest 
change was observed eight days (day 15) after the second bleomycin dose 
(p=0.000002). By day 29 (three weeks after second instillation) thymidine 
uptake was still significantly raised (p=0.007).
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Conventional toxicology methods were successfully used to determim 
extent of lung injury (Section 2.4.1). Increased L:B ratio and protein lev 
bleomycin-treated tissue pointed to oedema, whilst elevated numbers o 
cells denoted inflammation of the lung tissue. After a single instillatio 
oedema indicators showed a very significant increase in the bleomycin-tn 
samples. The LFC count was also significantly increased. This confi 
that mild oedema and inflammation were occurring three days after instill! 
After seven days the oedema and inflammation appeared to have worse 
with a large increase in the protein levels and number of free cells. The 
study, using L:B ratio as the only marker for oedema showed a retu 
normal levels two weeks after a single bleomycin dose.
After a second bleomycin instillation the L:B ratio had increased by three 
and peaked after seven days. The protein concentration and free 
numbers remained significantly raised, but did not differ greatly from the 
seven (single dose) levels. However, unlike the single dose model whict 
returned to normal by day 15, the oedema markers were still signific 
elevated three weeks after the double-bleomycin instillation.
Initial thymidine incorporation assays after a single bleomycin instill 
showed a significant increase in cellular proliferation from day five contir 
to day nine. This had returned to control levels by day 11, confirming 
transient nature of the single dose model.
A similar trend was observed after a double dose of bleomycin. Seven 
after the second instillation, thymidine uptake was significantly increasi
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bleomycin-treated tissue. Contrary to the initial study, there was no evidence 
of the thymidine uptake returning to control levels by day 11; uptake was still 
significantly different three weeks after the second instillation. These data 
confirm that cellular proliferation was induced seven days after dosing (acute 
repair), and that these repair processes were still functioning three weeks 
(chronic) after a double bleomycin dose. To improve the accuracy of the 
thymidine uptake assay, a microtome could be used to slice the lung. It has 
previously been shown that the method of slicing the tissue, manually or 
mechanically, greatly affects the accumulation of radiolabelled compounds 
(Smith, Wyatt and Cohen, 1982).
2.6 C o n c lu s io n s
These studies are in agreement with the previously reported findings 
described in Section 2.1. The toxicology studies showed that after a single 
bleomycin dose, oedema and mild inflammation were occurring three and 
seven days after instillation. Cellular proliferation reached maximum levels 
nine days post-dosing, but was fully repaired by 11 days (transient oedema 
model). After a double dose, the oedema observed was far more severe, and 
again peaked at seven and three days. Whilst significant levels of cellular 
repair were observed eight days post-dosing, the injury was not resolved by 
22 days after the second dose (persistent oedema model). Thus, the 
distinction between the models of bleomycin-induced lung damage was 
successfully achieved.
Before proceeding with the genomic expression analysis of the tissue 
(Chapter 4), lung samples from parallel experiments to those reported in this 
chapter were processed for histology and electron microscopic analysis 
(Chapter 3).
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C h a pter  3:
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Id en tif ic a tio n  of 
O e d e m a , Infla m m a tio n  an d  R epair
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3.1 In t r o d u c t io n
A model of pulmonary injury was established using instillation of bleomycin, 
and partially quantified using conventional toxicology (Chapter 2). These 
quantitative biochemical investigations primarily utilised broncho-alveolar 
lavage (BAL) techniques. Data gathered in this way reflects the changes at 
the lung surface, which may not always represent the overall changes to the 
lung. Under certain circumstances, for example when lipoprotein
accumulation and interstitial wall thickening are very severe, the alveoli may 
not be washed out efficiently. In addition, lavage techniques provide little 
information on the cellular or interstitial changes occurring throughout the 
disease processes.
Histological analysis was used to complement the previous studies (Chapter 
2) and increase understanding of the progression of injury. In this manner, 
morphological changes in the lung were detected. To study the detailed 
cellular changes occurring to the microstructure of the lung, transmission 
electron microscopy (TEM) was employed. In conjunction with these
techniques, a method for determining the location and cell types involved in 
cellular repair was also required. This was again achieved by utilising cell 
proliferation as a marker for repair.
Experiments have shown that the thymidine analogue 5-bromo-2-deoxy- 
uridine (BrdU) is incorporated into newly formed cellular DNA in a similar 
manner to the incorporation of thymidine (Roche, 2000). The incorporated 
BrdU can then be detected by a quantitative cellular enzyme immunoassay 
using monoclonal antibodies directed against BrdU. This allows identification 
and semi-quantification of the cells undergoing replication in the tissue.
A number of authors (Quinlan et a i,  1995; BeruBe et al., 1996; Gallagher and 
Gottleib, 2001) have reported the successful use of BrdU labelling in lung 
tissue. However, preliminary investigations of the available literature 
indicated that no simple, standardised technique for successful and efficient in
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vivo labelling of tissue was available. Consequently, a series of experiments 
were undertaken in an attempt to optimise the BrdU technique in bleomycin- 
treated rats, and implement a set protocol for all subsequent studies.
The primary objectives of the studies described in this chapter were to identify 
the type of lung injury generated by the bleomycin model and to optimise the 
BrdU incorporation assay to monitor the repair mechanisms. By investigating 
the morphological changes in the lung, in combination with the toxicology 
data, the aim was to obtain clear differentiation between models of injury and 
cellular repair for use in later genomic investigations.
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3 .2 M a t e r ia l s  a n d  S to c k  S o lu tio n s
3.2.1 M a t e r ia l s  a n d  S u p p l ie r s
Raymond A Lamb, Sussex 1% Aqueous Eosin (LAMB/100-D)
Roche Diagnostics Ltd, Sussex 5-Bromo-2-Deoxy-Uridine Labelling and
Detection Kit II (1 299 964)
Sigma-Aldrich, Dorset 5-Bromo-2-Deoxy-Uridine (B5002) 
Poly-L-Lysine Coated Glass Slides (P0425) 
Mayer’s Haematoxylin (51275)
Fisher Scientific, Leicestershire Toluidine Blue (34860-0050)
BDH Laboratory Supplies, Dorset Aquamount (362262H)
DPX Mountant (36029)
Agar Scientific, Essex Sodium Cacodylate (R1102)
25% Glutaraldehyde (R1010)
Osmium Tetroxide (R1015)
Propylene Oxide (R1080)
Araldite CY212 (R1040)
200-mesh, 3.05mm Copper Grids (G246) 
2% Uranyl Acetate (R1260)
Reynold’s Lead Citrate (R1210)
3.2.2 S t o c k  S o l u t io n s
10% Neutral buffered formalin
EM fixative 
(pH 7.4)
3% Glutaraldehyde 
0.1M Cacodylate 
3mM Calcium Chloride
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3.3 M e th o d s
3.3.1 Experim ental  models  o f  pulm onary  In ju r y  an d  R epair
Concurrent studies were carried out with those described in Sections 2.3.1- 
2.3.4. Bleomycin was instilled intratracheally to induce pulmonary damage. 
Samples were taken three and seven days after a single bleomycin dose for 
all the studies described in this chapter. Samples were also collected three, 
seven and twenty one days after a double instillation of bleomycin for TEM 
and haematoxylin and eosin (H and E) staining.
3.3.2 5-Brom o -2-D eoxy-U ridine  Incorporation
As a cell is about to divide it undergoes DNA synthesis and replicates its 
genome. If a labelled DNA precursor is present it will be incorporated into the 
new cellular DNA. The integrated precursor can then be detected by a 
quantitative enzyme immunoassay. This facilitates visualisation of 
proliferating cells at an isolated time point. The precursor used in this case 
was 5-bromo-2-deoxy-uridine (BrdU).
Two approaches were adopted, one of which involved in vivo labelling of lung 
cells. This was achieved either by directly injecting BrdU into the 
intraperitoneal (IP) cavity as described by Quinlan et al (1995), or using a new 
approach by intratracheally (IT) instilling the compound into the lung. A 
second ex vivo method was tried whereby the treated lung was removed from 
the rat and subsequently inflated and instilled with BrdU.
3.3.2.7 In  V ivo In c o r p o r a  tio n
BrdU was administered via intraperitoneal injection or intratracheal instillation. 
This was done at three and seven days post-instillation of bleomycin. The 
animals were injected intraperitoneally with 100mg/kg body weight (Quinlan et
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a/., 1995), the equivalent to 26mg/rat, or instilled intratracheally with 
300|jg/rat. The BrdU was then incorporated in vivo into proliferating cells.
The length of time for maximum incorporation of BrdU in vivo was uncertain, 
so two time points were chosen for initial investigation. Incorporation of BrdU 
for one hour was recommended for in vitro studies (Roche, 1999, pack insert). 
As the present experiments were in vivo, it was considered five hours should 
allow sufficient time for the BrdU to enter the lungs from the peritoneal cavity. 
Twenty-four hours was also chosen as a time point (Quinlan et a i, 1995). 
After this time the lungs were excised and stored as described in Section 
3.3.3.1.
3.3.2.2 Ex Vivo In c o r p o r a  t io n
The animals were sacrificed seven days after bleomycin treatment. The lungs 
were excised as detailed in Section 2.3.4. BrdU was diluted in cell culture 
medium to a concentration of 10pmol/l. The intact lung was then filled with 
BrdU solution via a syringe and cannula. The lung was tied off to prevent the 
BrdU leaking out, and incubated for 60 minutes at 37°C in a saline bath. After 
this time the BrdU solution was poured off via the cannula and replaced with 
10% neutral buffered formalin (Section 3.3.3.1).
3.3.3 Processing  Tissue  for  L ig h t  M icro sco py
3.3.3.1 F ix a t io n  o f  L u n g  T is s u e
The lungs were excised as detailed in Section 2.3.4. Lung tissue was treated 
in vivo or ex vivo with BrdU as described in Section 3.3.2. All tissue to be 
processed for light microscopy (LM) was left untreated. The intact lung was 
filled with 10% neutral buffered formalin via a syringe and cannula (Figure 
3.1). The inflated lung was then immersed in 10% neutral buffered formalin at 
4°C for at least 24 hours in preparation for tissue processing (Section 3.3.3.2).
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10ml Syringe
ThreadFixative
Luer Cannula
Figure 3.1 Inflation of lung with fixative. Fixative is forced into the lung via a syringe and 
cannula to the trachea. Trachea is then tied off with thread and immersed in more fixative.
Tissue processing, sectioning and staining for LM was carried out by a 
histotechnologist, Mr Derek Scarborough, at the School of Biosciences, 
Cardiff University. A brief overview of these procedures has been outlined 
below in Sections 3.3.3.2 to 3.3.3.4.
3.3.3.2 Tis s u e  P r o c e s s in g
Once the tissue has been fixed (Section 3.3.3.1), it must be processed into a 
form in which it can be made into thin microscope sections. This was 
achieved by embedding tissues in paraffin, which is similar in density to tissue 
and can be sectioned at anywhere from 3 to 10 microns. The main steps in 
this process are ‘dehydration’, ‘clearing’ and ‘paraffin infiltration’. Prior to 
tissue processing, the fixed tissues were placed into processing cassettes that 
were used to carry the tissues through the various stages of dehydration, 
clearing and paraffin infiltration. The cassettes were then loaded into a basket 
which was placed inside a fully enclosed Vacuum Tissue Processor (Leica 
TP1050, Leica UK). Automation consisted of the movement of the tissues 
through the various agents on a preset time scale.
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Wet-fixed tissues, such as the lung samples from this study, cannot be 
directly infiltrated with paraffin. The water from the tissues must be removed 
by ‘dehydration’ via a series of alcohols (e.g. 70% to 95% to 100%). Following 
dehydration, the next step was ‘clearing’ and consisted of replacement of the 
alcohol (Fisher Scientific), with a substance that would be miscible with the 
paraffin. The common clearing agent was xylene and the tissues were 
processed through several changes of xylene (Fisher Scientific). The 
‘cleared’ tissue was then placed into a vacuum to remove all air pockets. The 
final step in processing was to infiltrate the tissue with molten paraffin wax 
(Raymond A Lamb) at 60°C; several changes of wax were used.
3.3.3.3 P a r a f f in  E m b ed d in g
It was important for the tissue to be fully supported by paraffin wax to prevent 
the tissue shredding during sectioning. To achieve this, the lung tissue was 
placed into a plastic ‘embedding mould’, and a Leica EG1140 Embedding 
Centre (Leica UK) was used to surround the tissue in warm paraffin wax. 
After allowing the wax to set (30 minutes on a cold plate), the tissue was 
removed from the embedding mould and the sample was ready for sectioning.
3 .3 .3 .4  S e c t io n in g
Following tissue processing and paraffin embedding, the lung tissue had to be 
cut into sections that could be placed on a glass slide for the purpose of LM. 
Sectioning was achieved using a Leica RM2135 microtome (i.e. a knife with a 
mechanism for advancing a paraffin block standard distances across it). The 
embedded lung tissue samples were placed on ice to ensure uniform sections 
were obtained. The ice hardens the wax and softens the tissue so the entire 
sample is of the same consistency for sectioning. The tissue was then cut 
into 5pm sections using the microtome.
Once the sections were cut, they were floated on a warm water bath (40- 
50°C) that facilitated the removal of wrinkles and air bubbles produced during 
sectioning. The paraffin embedded sections of lung tissue were then collected
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onto a glass microscope slide (Raymond A Lamb). The slides used were 
coated in poly-L-lysine to improve adhesion of sections. The samples were 
then left to bind to the slides on a hot plate for 15-30 minutes, then in an oven 
at 37-45°C for a minimum of 24 hours.
In order to allow water soluble dyes to penetrate the sections, the embedding 
process must be reversed to remove the paraffin wax from the tissue. 
Therefore, before any staining could be done, the slides were ‘dewaxed’ by 
running them through xylene followed by a series of graded alcohols (100% to 
70%).
3.3.4 H a e m a t o x y u n  a n d  E o s in  S t a in
To evaluate the lung architecture by LM the tissue sections were stained with 
Haematoxylin and Eosin (H and E), a routine stain chosen for its ability to 
stain various cellular components of tissue. Haematoxylin is a basic dye that 
stains nuclear heterochromatin and cytoplasm rich in ribonucleoprotein blue. 
Eosin is an acid dye that stains cytoplasm, muscle and connective tissue 
various shades of pink.
The dewaxed tissue sections were stained with Mayer’s haematoxylin 
(Raymond A Lamb) for 1.5 minutes. Sections were washed in running tap 
water for five minutes, and then stained with 1% aqueous eosin (Raymond A 
Lamb) for 10 minutes. This was followed by a final 20 second wash in 
running tap water.
The stained section on each slide was covered with a glass cover-slip (Fisher 
Scientific) to protect the tissue from being scratched. This also provided 
better optical quality for viewing under the LM and preserved the tissue 
section for archival purposes. The stained slides were dehydrated by 
reversing the dewaxing step (i.e. series of graded alcohol to xylene), at which 
time permanent mountant DPX (Fisher Scientific) was placed over the 
sections followed by a coverslip. The stained sections were then ready to view 
by LM.
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3.3.5 Brom odeoxyuridine  D etection
The dehydrated and dewaxed sections which had not been stained with H 
and E were rehydrated by washing with wash buffer (phosphate buffered 
saline [PBS]). The sections were then covered with an anti-Brdll primary 
antibody and incubated in a humidity chamber for 30 minutes at 37°C. The 
humidity chamber was used for all further incubations to prevent drying of the 
tissue samples. After further washing in PBS, the slides were incubated with 
an alkaline phosphatase-linked secondary antibody for 30 minutes at 37°C. 
The sections were washed once more (PBS) and then incubated with colour 
substrate solution (nitroblue tetrazolium [NBT] and 5-bromo-4-chloro-3-indolyl 
phosphate [BCIP]) for 1-10 minutes at room temperature. After a final wash 
with PBS the stained sections were mounted in Aquamount (BDH laboratory 
supplies), a water based fixative. The samples were then viewed via light 
microscopy (LM). Cells stained a blue/black colour due to alkaline 
phosphatase dependant precipitation of NBT/BCIP were identified as having 
incorporated BrdU.
3.3.6 Processing  Tissue  for  Transm ission  Electron  M icroscopy
3.3.6.1 F ix a tio n  o f  Lung Tissue
The lungs were excised as detailed in Section 2.3.4. The upper right lobe of 
the lung was selected for examination by transmission electron microscopy 
(TEM). This region of the lung was chosen as it is the first lobe to be 
challenged by inhaled xenobiotics. The lobe was tied off from the rest of the 
lung and rapidly instilled with cold (4°C) glutaraldehyde (3%) fixative (Section 
3.2.2). The lobe was then removed and immersed in fresh fixative for 1 hour 
at 4°C. This method of fixation preserves the cellular structure of the tissue 
by cross-linking proteins via their amine groups. The glutaraldehyde fixative 
was replaced with phosphate buffer and washed overnight.
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Tissue processing, sectioning and staining for TEM was carried out by an 
electron microscopist, Mr Mike Turner, at the School of Biosciences, Cardiff 
University. A brief overview of these procedures has been outlined below in 
Sections 3.3.6.2 to 3.3.6.4.
3.3.6.2 Tissue P ro c e s s in g
Once the tissue had been fixed (Section 3.3.6.1), it had to be processed into a 
form that was suitable for TEM. This was achieved by embedding the fixed 
lung tissue in a resin (Araldite) that acts as a support matrix for the lung 
tissue. This permitted ultra-thin (e.g. 60 to 90nm) sections to be cut.
Prior to tissue processing, a piece of fixed lung tissue was excised from the 
lobe and cut into 1mm cubed pieces. The tissue cubes were placed into a 
squat glass sample vial that was used to carry the tissues through the various 
stages of post-fixation, dehydration and resin infiltration. The sample vials 
were kept on a rotating wheel inside a fume cupboard.
Post-fixation was carried out by osmicating (1% osmium tetroxide [Agar 
Scientific] in phosphate buffer) for 60 minutes at 4°C. The tissue was then 
passed through a series of graded alcohols, (30%-90%: 15 minutes in each, 
then 2 x 100%: 30 minutes each). Once dehydrated, the lung tissue samples 
were placed into new sample vials and immersed in propylene oxide (Agar 
scientific) for 30 minutes. This was followed by overnight rotation in a fume 
cupboard in a 50/50 mix of propylene oxide and Araldite CY212 (Agar 
Scientific). During this time the propylene oxide dissipated leaving only the 
Araldite. The following day the tissue was infiltrated with Araldite for eight 
hours.
Finally, the tissue samples were embedded in Araldite. This process involved 
placing one cube of tissue into a plastic embedding capsule and topping up 
the capsule with fresh Araldite. The capsule was then placed into a resin 
oven and polymerised at 60°C for 48 hours.
61
Histochemical and EM Identification of Oedema. Inflammation and Repair
3 .3 .6 .3  S e c t io n in g
Following resin polymerisation, the capsule was cut away from the 
resin/tissue block using a razor blade. Excess resin was trimmed from the 
blocks until the tissue was exposed. Semi-thin survey sections (2pm) were 
taken using a glass knife and mounted onto glass slides (Sigma-Aldrich), and 
the tissue stained with toluidine blue (Fisher Scientific). This stain helps to 
reveal cellular architecture. Appropriate areas for ultra-thin sectioning were 
identified from the semi-thin sections and the blocks trimmed accordingly. 
The resin blocks were sectioned to 60-90nm on an LKB 3 Ultramicrotome 
using a diamond knife. Sections were expanded on the water trough and 
collected onto clean 200-mesh, 3.05mm copper grids (Agar Scientific).
3.3.6 .4  C o u n te r  S ta in in g
Prior to visualisation of the tissue sections via TEM, heavy metal staining or 
‘counter staining’ was required to help resolve the ultrastructure of the lung 
tissue. Counter staining was achieved by using Reynold’s lead citrate and 2% 
aqueous uranyl acetate. These heavy metal stains are general purpose and 
not very specific. Uranyl acetate stains membranous structures and 
structures containing nucleic acids. The lead in lead citrate binds to RNA- 
containing structures and hydroxyl groups of carbohydrates.
Droplets of each stain were placed in rows on the sterile side of parafilm and 
the grids were floated section side down on a given drop. Sections were 
stained for 10 minutes with uranyl acetate, followed by staining with Reynolds 
lead citrate for five minutes. Finally, the grids were washed by transferring 
over three drops of filtered de-ionised water. The grids were allowed to air dry 
at room temperature in filter paper-lined Petri dishes prior to viewing in the 
TEM. The sections were imaged using a JEOL 1210 TEM at an acceleration 
voltage of 80 keV.
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3 .4  R e s u l t s
3.4.1 Brom odeoxyuridine  D etection  o f  Cell Proliferation
Proliferating cells labelled with bromodeoxyuridine (BrdU) were identified as 
having a dark blue/black colouration. These labelled cells were counted 
manually under a light microscope. The difference in number, location and 
type of proliferating cells was studied three and seven days after exposure to 
bleomycin. These were compared to appropriately treated saline-instilled 
tissue from control animals.
The initial optimisation studies were carried out using the in vivo treated 
sections. The colour differential between the labelled and unlabelled cells 
was greatly affected by the length of incubation with the colour substrate. The 
recommended length of time was 15 to 30 minutes exposure. To get an 
indication of how rapidly the samples would take up the stain, an initial 
incubation of 20 minutes was carried out. This proved to be too long, and the 
tissue was over stained. A series of time points were covered in the second 
study including one, two, five, seven and ten minutes (results not shown). Up 
to five minutes exposure to the colour substrate resulted in under staining. 
Incubation for seven and ten minutes generated the clearest results, with ten 
minutes fractionally better. Only those exposed for ten minutes are shown in 
Figure 3.2.
As well as monitoring the level of cellular proliferation, these preliminary in 
vivo studies also investigated the effectiveness of the different modes of BrdU 
administration. The length of time after intratracheal administration of BrdU 
had a large effect on the amount of BrdU signal that was observed. The 
amount of BrdU detected was lower in the samples that were sacrificed after 
24 hours (results not shown). The tissue sections shown in Figure 3.2 were 
sacrificed five hours after BrdU instillation and 24 hours after intraperitoneal 
injection.
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Figure 3.2 Lung sections treated with saline or bleomycin. Labelled in vivo with BrdU (x160 
magnification). A: three days after bleomycin treatment, BrdU administered intraperitoneally 
(IP); B: seven days after bleomycin treatment, BrdU administered via IP; C: three days after 
bleomycin treatment, BrdU administered intratracheally (IT); D: seven days after bleomycin 
treatment, BrdU administered via IT; E: three days after saline treatment, BrdU administered 
via IT; F: seven days after saline treatment, BrdU administered via IT. Arrows show labelled 
cells.
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In vivo incorporation of BrdU resulted in rather indistinct images of BrdU 
labelled cells. Despite incubating with the colour substrate for a variety of 
times, the differentiation between labelled and unlabelled cells was not clear.
The in vivo data was compared with the ex vivo technique of BrdU 
incorporation seven days after treatment with bleomycin (Figure 3.3). The 
initial study was carried out with three time points. The sections were 
incubated with the stain for five, ten and fifteen minutes. Over-staining 
resulted after 15, and to a lesser extent ten, minutes exposure. After five 
minutes exposure clearer definition of the labelled cells is seen. The 
distinction between the labelled and unlabelled cells was clearer with the ex 
vivo technique.
Figure 3.3 Lung sections seven days post-treatment. Labelled ex vivo with BrdU (x160 
magnification). A: Saline treated; B: Bleomycin treated. Arrows show labelled cells.
The lack of distinction between labelled and unlabelled cells made 
quantification of the data very difficult. However, it appeared that seven days 
after bleomycin-treatment there were approximately four times more labelled 
cells than in saline-treated tissue. It should also be noted that a number of 
free cells located in the airspaces seemed to be incorporating BrdU.
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3 .4 .2  Ha em a  to xylin  a n d  E o s in  Vis u a lis a  tion  o f  Tis s u e
Haematoxylin and eosin staining was carried out on tissue sections from 
every time point. This was done as visual confirmation to the basic toxicology 
described in Chapter 2. The results are shown in Figure 3.4 and 3.5.
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Figure 3.4 Lung sections after a single instillation. Stained with Haematoxylin and Eosin 
(x100 magnification). A: three days post-saline instillation; B: three days post-bleomycin 
instillation; C: seven days post-saline instillation; D: seven days post-bleomycin instillation.
After a single instillation the alveolar structure was normal in both the control 
samples. There was no evidence of interstitial thickening or septal swelling 
and the airspaces were all clear. However, by day three after a single 
bleomycin dose (Figure 3.4 B) there was widespread thickening of the 
interstitium and some swelling of the septa. By day seven (Figure 3.4 D) this 
damage was more extensive and there was also evidence of some cellular 
infiltrate and inflammatory cells.
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Figure 3.5 Lung sections after a double instillation. Stained with Haematoxylin and Eosin 
(x100 magnification). A: three days after second saline instillation; B: three days after second 
bleomycin instillation; C: seven days after second saline instillation; D: seven days after 
second bleomycin instillation; E: 21 days after second saline instillation; F: 21 days after 
second bleomycin instillation.
After a double saline instillation (Figures 3.5 A, C, E) there were small areas 
of interstitial and septal thickening, but generally the alveolar structure was 
normal. However, three days after a double bleomycin dose (Figure 3.5 B) 
there were huge changes to the tissue. The alveolar interstitium was greatly 
thickened and the septa were swollen. Large amounts of cellular infiltrate and
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debris were in the airspaces. In addition, large regions of the tissue showed 
disorganised lung architecture. Seven days after the second bleomycin 
instillation (Figure 3.5 D) the effects had lessened, although there was still 
widespread damage to the tissue. There were a number of focal regions 
where the tissue structure was still disorganised. By 21 days after the second 
bleomycin dose (Figure 3.5 F) the tissue was still showing some evidence of 
injury. The interstitium and septa remained swollen in several areas, and 
some cellular infiltrate was observed. There also continued to be evidence of 
a few small focal areas where the tissue showed disorganised structure.
3.4.3 Transm ission  Electron  M icroscopic  A nalysis  of Tissue
Tissue sections for TEM were taken three and seven days after both single 
and double instillations of bleomycin and three weeks after the double dose. 
Representative examples of the data are shown in Figures 3.6-3.8.
Parenchymal tissue after a single dose of saline showed normal 
microstructure (Figures 3.6 A and B, 3.7 A and 3.8 A). There were occasional 
blebs in the type I cells (intracellular oedema) and some small areas of fibrous 
deposition in the septa.
Three days after a single instillation of bleomycin there was clear evidence of 
cytoplasmic blebbing (Figure 3.6 C) resulting in focal areas of intracellular 
oedema. The capillary endothelium and type I cells showed regions 
containing elevated numbers of caveolae (plasmalemmal vesicles) (Figure 3.6 
C). There were also focal areas where some build-up of fibres could be seen. 
The septa all showed signs of damage, with thickening of the interstitium and 
fibrous deposition at the ends (Figure 3.7 B). After seven days the damage 
was more widespread. There were larger areas where fibres had 
accumulated, and the continuing presence of membrane blebbing and 
caveolae. Some macrophages (Figure 3.7 C) and inflammatory cells were 
present in the alveolar airspaces. At both time points a number of flattened 
type II cells were observed (Figure 3.8 B).
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Figure 3.6 TEM images showing normal (A & B) and damaged (C & D) tissue. A: Alveoli showing thin walls and clear airspaces; B: Alveolar wall showing 
normal epithelium and endothelium, and a fused basement membrane; C: Alveolar wall showing signs of early damage including thickened interstitium, 
blebbing and caveolae; D: Alveolar wall showing signs of severe damage including accumulation of fibres, cellular influx and disorganised architecture.
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Figure 3.7 TEM images showing A: Normal septa; B: Damaged septa showing thickened interstitium, fibrous deposits and caveolae; C: Normal macrophage; 
and D: Foamy macrophage.
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Figure 3.8 Type II pneumocytes at different stages of repair. A: Normal type II after saline 
instillation; B: Flattened type II after bleomycin instillation; C: Cuboidal type II after bleomycin 
instillation.
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After the second bleomycin instillation, heightened blebbing and caveolae 
activity was noted. Three days after the second dose, widespread thickening 
of the interstitium and increased fibre deposition had occurred. Large regions 
of the tissue showed completely disorganised architecture, as well as an influx 
of inflammatory cells (Figure 3.6 D). There was also the appearance of 
several cuboidal type II cells (Figure 3.8 C) and a number of flattened type II 
cells with empty lamellar bodies (Figure 3.8 B). By seven days this level of 
injury had reduced, but a great deal of disorganisation and inflammatory cells 
still persisted. At this time point the first foamy macrophages were observed 
(Figure 3.7 D). A number of flattened type II cells could still be seen, with an 
increasing number of cuboidal cells. After 21 days (post second instillation) 
the injury had markedly reduced. However, there were still large areas with 
thickened interstitium and accumulation of fibres. Debris could be seen in the 
airspaces along with a number of foamy macrophages. Cuboidal and 
flattened type II cells were regularly observed.
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3.5 D is c u s s io n
Histological examination was employed to investigate morphological or 
structural changes in the lung, induced by bleomycin. In conjunction with this, 
immunohistochemical assays were carried out to assess the re- 
epithelialisation of the tissue in response to injury. Both light and electron 
microscopy were used during this investigation.
Immunohistochemical analysis of tissue sections was carried out to determine 
the number and type of cells involved in repopulating the damaged tissue. 
The techniques required to obtain consistent uptake and identification of 
BrdU-labelled cells were optimised. This was partially successful, although 
clearer images may have been achieved by counter staining the sections with 
haematoxylin (Quinlan et al., 1995). After the initial in vivo studies, it was 
considered that perhaps the BrdU was not reaching the target cells. A second 
possibility was that the cells were successfully targeted, but the period of time 
allowed for BrdU incorporation was too great. This would result in dispersion 
of the BrdU as the cells continued to replicate. To overcome these 
possibilities an ex vivo labelling technique (Section 3.3.2.2) was applied. In 
this way, the BrdU was delivered directly onto the tissue to be studied, 
ensuring the target cells were reached. This enabled a shorter incubation 
period, which reduced the opportunity for continued proliferation resulting in 
dissipation of BrdU. Ex vivo was also preferable as it removed the need to 
give a second treatment to the rat.
An objective analysis of BrdU incorporation showed that there were 
approximately four times more proliferating cells in bleomycin treated lungs in 
comparison to saline treated lungs after seven days (Section 3.4.1). 
However, after three days of exposure to bleomycin no difference was 
observed. This is in agreement with the thymidine uptake assay (Section 
2.4.2) and supports the premise that, although some repair of the damaged 
tissue was occurring after one week, at three days the repair process had not 
yet begun. A number of free cells also appeared to be labelled. This could be
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due to their recent recruitment into the lung, and continued differentiation into 
their final cellular structure.
The information gained from these experiments was difficult to obtain, and the 
images were not sufficiently clear for the studies to be continued on the 
remaining time points.
The toxicology results (Chapter 2) were supported by the histological data. 
Three days after a single bleomycin instillation the lung tissue was showing 
signs of focal damage. Injury progressively worsened up to seven days after 
dosing, with more widespread damage and some cellular infiltrate and 
oedematous fluid in the alveolar airspaces. This clearly represented 
interstitial damage progressing onto focal areas of intra-alveolar oedema after 
a single bleomycin instillation. However, unlike the toxicology data, which 
showed no marked increase in the levels of protein or free cells, following the 
second dose of bleomycin the effect on the lung pathology was markedly 
worse. This disparity between the toxicology data and the information 
observed here could be due to the failure of the lungs to lavage properly 
before toxicological analysis. Three days after the second instillation, cellular 
infiltrate, oedema fluid and interstitial and septal swelling was observed 
throughout the tissue. There were also large areas of the sections which 
showed complete destruction of the normal architecture of the lung. These 
effects were reduced seven days after treatment, but there were still focal 
areas of disorganised tissue architecture. These features indicated that 
severe interstitial and intra-alveolar oedema was occurring. Three weeks 
after the second bleomycin dose the tissue was still showing evidence of 
injury. There continued to be some interstitial and septal swelling, although 
the cellular infiltrate was no longer apparent. There also remained some very 
small regions of tissue where the disorganised structure had not been fully 
restored. This confirmed the toxicology data, that after 21 days, the tissue 
was still not fully repaired, and had not returned to its normal state.
To study the ultrastructure of the damaged tissue, TEM was used. The 
resulting images clearly demonstrated that oedema and inflammation was
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occurring in the bleomycin treated tissue. Evidence of repair and re- 
epithelialisation was also observed.
The earliest indicator for increased permeability in the lung was the formation 
of membrane blebs in the plasma membrane of type I epithelial cells. These 
blebs filled with intracellular fluid which was eventually released onto the lung 
surface. This corresponded with an increased number of caveolae 
(pinocytotic vesicles) in the endothelium and type I cells. This produced rapid 
transfer of plasma products and fluid to the alveolar surface. It also led to 
deposition of fibres (collagen and elastin) in the interstitium as injury 
progressed. One of the more severe indicators of oedema was the disruption 
of normal tissue architecture. There was a lack of recognisable features, with 
the tissue being filled with the debris of dead cells, plasma products and 
inflammatory cells, making it difficult to identify the types of cell within the 
interstitium.
The TEM observations suggested that during the early stages of repair in the 
lung, the damaged type I epithelium were replaced by cells from the type II 
population. The type II cells became flattened and gradually lost their lamellar 
bodies. These cells appeared to develop into type l-like cells to restore the 
normal lung architecture. During persistent injury (as seen with the double 
dose model) re-epithelialisation was extensive. This resulted in the formation 
of cuboidal type II cells which produced a thickened epithelial layer. These 
cells actively made surfactant by releasing the lamellar bodies onto the 
surface of the lung. This led to lipoproteinosis, as surfactant accumulated in 
the alveolar airspaces. A good indicator of lipoproteinosis was the presence 
of ‘foamy’ macrophages in the airspaces.
There were numerous flattened type II cells in all bleomycin treated samples. 
A small number were also detected after saline treatment, from seven days 
onwards. Several cuboidal cells and foamy macrophages were observed 
seven and 21 days after bleomycin treatment. This signified that both acute 
and chronic repair mechanisms were functioning.
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3 .6  C o n c lu s io n s
This information on the pathology of the lung increased understanding of the 
oedema model, and combined with the toxicological data, enabled the 
progressive severity of injury at each time point to be determined (Figure 3.9).
Single dose Double dose Single dose Double dose Double dose 
Day 3 ^  Day 21 ^  Day 7 ^  Day 7 ^  Day 3
Severity of Injury
Figure 3.9 The progressive levels of injury within the bleomycin model as determined by 
conventional toxicology, histology and TEM.
One of the main objectives of this study was to identify early genetic markers 
for oedema. As such, three and seven days after a single bleomycin dose 
were chosen for genetic analysis. These samples provided the opportunity to 
study both the development of injury and mild oedema whilst allowing some 
insight into the repair mechanisms. Moreover, a comparison between mild 
(early) and severe oedema could aid the understanding of the mechanisms 
behind the onset of oedema, so three days after a second bleomycin dose 
was also selected (Chapter 4).
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C hapter  4:
A nalysis  of T r a n sc r iptio n a l  C hanges
in
Ea r ly  O ed em a  an d  Inflam m atio n
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4.1  I n t r o d u c t io n
The primary objective of this study was to investigate differential gene 
expression at the transcriptional level during the development of pulmonary 
oedema and inflammation. A model for bleomycin-induced injury to rat lung 
was previously characterised using conventional toxicology (Chapter 2) and 
histology (Chapter 3). Experiments were designed to identify early molecular 
markers for events in pulmonary injury. As such, this initial study was carried 
out in tissue taken at the first time point, three days after a single instillation.
In order to examine global gene expression in lung tissue, macroarray 
technology was applied. This allows the expression of multiple mRNAs to be 
examined. Clontech Atlas rat cDNA expression macroarrays were used for 
this study. This system was chosen because it is readily available and offers 
reproducibility to a range of laboratories at relatively low cost. It had also 
proven successful in previous investigations of toxicant effects in the lung 
(Reynolds and Richards, 2001). The Clontech arrays are composed of 
hundreds of cDNAs spotted onto a positively charged nylon membrane. 
Plasmid and bacteriophage DNAs are included as negative controls and to 
confirm hybridisation specificity. Several housekeeping genes are also 
incorporated as positive controls. Atlas arrays specifically include genes that 
are known to play key roles in many biological functions. Targeted primers 
specific to each type of array are used to generate radiolabelled cDNA. The 
probes are hybridised to the oligonucleotides on the array and detected by 
phosphorimager screens.
Optimisation of the macroarray procedure for lung tissue was undertaken. 
The validity of information obtained from an array is dictated by the yield and 
purity of isolated RNA. Techniques for isolation of RNA were refined and 
developed to meet these requirements. Purification of the labelled probe and 
hybridisation of this probe to the membrane was also investigated. Finally, 
the differential gene expression detected by these new macroarray 
techniques was confirmed by quantitative polymerase chain reaction (Q-PCR)
78
Analysis of Transcriptional Changes in Early Oedema and Inflammation
for a selection of genes. The optimised procedures were applied to 
oedematous lung tissue isolated from rats three days after bleomycin 
treatment versus saline controls.
There are currently no well established techniques for bioinformatic analysis 
of macroarray data (Mocellin et a/., 2004). One of the main objectives of this 
study was to develop a simplistic method for interpreting the large volume of 
data generated by macroarrays.
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4.2 M a t e r ia ls
4.2.1 M a terials and  Suppliers
Supplier: Materials:
Qiagen, West Sussex RNeasy Mini Kit (74104)
(containing all appropriate buffers and solutions) 
QIAshredders (79654)
RNase-Free DNase Set (79254)
(containing DNase I and appropriate buffer) 
QuantiTect SYBR Green PCR Kit (204143)
BDH, Dorset p-Mercaptoethanol (436022 A)
Clontech, Oxford Atlas™ Rat 1.2 Array System (7854-1)
(containing all required solutions and preparations) 
Advantage 2 PCR Kit (30 rxns) (639207)
Sigma-Aldrich, Dorset Agarose (Type 1A)(A0169)
10x TBE* (T4415)
Ethidium Bromide (10 mg/ml) (E1510) 
Loading Dye (G2526)
*Diluted to 1x TBE in distilled water, prior to use 
Tri-reagent™ (T9424)
Salmon Testes DNA (9.5 mg/ml) (D7656) 
GenElute™ Agarose Spin Columns
Amersham, Buckinghamshire [a-32P]dATP (10 pCi/mmol) (PB 10204)
Storage Phosphor Screen (63-0034-89)
Invitrogen, Paisley Random Primers (48190-011)
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Supplier: Materials:
Promega, Southampton MMLV-RT
5x Reaction Buffer (M1701) 
dNTPs (U120-123)
RNase Inhibitor (RNasin, N251)
E.coli JM109 Competent Cells, >108cfu/pg (L2001) 
pGEM®-T Vector System I (A3600)
Wizard® Plus SV Minipreps DNA Purification 
System (A1340)
ABgene, Surrey Thermo-fast® 96 Detection Plates (AB-1100) 
Ultra Clear Cap Strips (AB-0866)
Sigma-Genosys, Suffolk Primer Sequences for PCR:
Primer name Primer sequence Fragment length
D50497
Forward
Reverse
T GGCAGACGCT CTT GGG CG AGAG  
CACCACCG GAAAGCCGCTGTACG
23 (bases) 
23 (bases)
227
Z11690
Forward
Reverse
C G C C G C T CG CGCCT CAT GAT C 
CGAAGACACCGCT GGT CAT CCAG
21 (bases) 
23 (bases)
190
L31622
Forward
Reverse
G AAGTTT CG CT CAT GGACCT ACG AC  
A G T G G TTT GCGACGAAT GAT GAAGT C
25 (bases)
26 (bases)
192
X 15467
Forward
Reverse
T GAGAACAT CTT ACT CAGC ACT CTT GAG  
CG AT CAAT G G C G TT CACAT CAGT CAAG
28 (bases) 
27 (bases)
264
U37101
Forward
Reverse
A G C T G C T G C T G T GGCACAGT GCAC  
G C A G TT G G C T CAG G CACTTT GT CT G
24 (bases)
25 (bases)
297
V01217
Forward
Reverse
C C C TC T G AACCCT AAGGCCAACCG  
GT G G T G GT G AAG CT G TAGCCACG C
24 (bases) 
24 (bases)
285
Table 4 .1 Oligonucleotide (desalted) primer sequences for PCR
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Supplier: Software:
Clontech, Oxford Atlaslmage 2.0
Atlas Navigator™ 1.0 (Silicon Genetics)
Microsoft, USA Excel 2003
Minitab Ltd, Coventry Minitab (version 13.32)
Spotfire AB, Goteborg, Sweden Spotfire Pro 3 for Windows (version 3.3.4)
4.2.2 S tock S olutions
4 .2.2.1 M a c r o a r r a  y
10x denaturing solution 
2x neutralising solution 
Wash Solution 1
Wash Solution 2
1 M Sodium Hydroxide 
10 mM EDTA
1 M Sodium Hydrogen Phosphate (pH 7.0) 
(Store at room temperature)
2x SSC 
1% SDS
(Store at room temperature)
0.1x SSC 
0.5% SDS
(Store at room temperature)
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Array Master Mix:
1 reaction (rxn) Double rxn*
5x Reaction Buffer
2.0 4.0
(250 mM Tris-HCI [pH 8.3], 375 mM KCI, 15 mM MgCIJ 
10xdNTPM ix
1.0 2.0
(5 mM each dCTP, dGTP, dTTP)
32P dATP 3.5 5.0
DTT (Dithiothreitol) (100mM) 0.5 1.0
Total Volume(|jl): 7.0 12.0
Total required per array (inc. MMLV-RT**) (pi) 8.0 13.0
Table 4.2 Preparation of Master Mix solution (macroarray procedure detailed in Section 
4.3.2). All volumes in pi.
*Double rxn mix is prepared if  2 pg isolated RNA is in a volume o f water greater than 2 pi.
**1 p i Moloney Murine Leukaemia Virus Reverse Transcriptase (MMLV-RT) added per 
reaction after incubation.
4.2.2.2 Q u a n t it a  t iv e  PCR 
Reverse Transcription (RT) reaction mix:
1 rxn
MMLV-RT (200 units/pl) 2.0
5x Reaction Buffer 6.0
Random Hexamer (100 pmol/pl) 0.5
dNTPs (10mM) 1.5
RNase Inhibitor (RNasin, 40 units/pl) 1.0
Total TlTo
Table 4.3 Preparation for the reaction mix (RTprocedure carried out in Section 4.3.9.1). One 
reaction generates 30pl cDNA. All volumes in pi.
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PCR reaction mix:
50 pi rxn 20 pi rxn
cDNA 2 0.8
10x Reaction Buffer 5 2.0
dNTPs (50x) 1 0.4
Primer 1 1 0.4
Primer 2 1 0.4
Polymerase Mix (Taq, MgCI2) 1 0.4
PCR Grade Water 39 15.6
Total 50 20.0
Table 4.4 Preparation for the PCR mix used in Section 4.3.9.1. All volumes in pi. 
Ligation master mix:
1 rxn
PCR Product 3
2x Ligation Buffer 5
pGEM-T Vector (50ng) 1
T4 DNA Ligase 1
Total 10
Table 4.5 Preparation for the ligation mix used in Section 4 3.9.2. All volumes in pi. 
SYBR Green PCR master mix
50 pi rxn 20 pi rxn
Plasmid DNA 1 0.4
2x SYBR Green PCR Master Mix 25 10.0
Primer 1 1 0.4
Primer 2 1 0.4
PCR Grade Water 22 8.8
Total 50 20.0
Table 4.6 Preparation for the SYBR green PCR master mix used in Section 4.3.91. 
volumes in pi.
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4 .3  M e th o d s
4.3.1 RNA Extraction  an d  Preparation
4 .3 .1 .1  R N A  I SOLA TION USING TRI-REAGENT™  PROTOCOL
RNA from whole lung tissue was isolated using Tri-reagent™ (Sigma-Aldrich) 
as outlined in the Sigma Technical Bulletin (Sigma-molecular-biology, 1994). 
This is a single step, liquid phase separation procedure, which allows the 
simultaneous extraction of RNA, DNA and protein. The technique is based on 
an extraction outlined by Chomczynski and Sacchi (1987) and works well on 
large or small amounts of starting material.
Briefly, whole lung tissue isolated from the rat was snap frozen in liquid 
nitrogen and ground to a fine powder using a pestle and mortar. The cells 
were then lysed in Tri-reagent™, a mono-phase solution of guanidine 
thiocyanate and phenol, by mixing thoroughly with a pipette to form a 
homogenous lysate. All insoluble material and high molecular weight DNA 
was removed by centrifugation (12,000 x g). After the addition of chloroform, 
the solution was mixed thoroughly and then centrifuged (12,000 x g). This 
resulted in the separation of the solution into three layers, a red organic phase 
(protein), an interphase (DNA) and colourless upper aqueous phase (RNA). 
The aqueous layer was carefully removed and an equal volume of 
isopropanol added. After centrifugation (12,000 x g) the RNA precipitate 
formed a pellet. The pellet was washed in ethanol, then reformed by 
centrifugation (12,000 x g). The pellet was air dried to remove all residual 
ethanol before being resuspended in RNase/DNase-free water (20-30pl).
4 .3 .1 .2  R N A  Is o l a t io n  u s in g  R N e a s y K it
The RNeasy Mini kit (Qiagen) was used to isolate total cellular RNA from rat 
lung tissue. Under high salt conditions, long RNA molecules are bound to a 
silica gel based membrane. Once bound, the RNA was washed and eluted 
utilising microspin technology. The purified RNA could then be used in a
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number of molecular biology techniques (RNeasy manual, 2001). This 
technique can be applied to extract RNA from a small amount of starting 
material. All the buffers used (Buffer RLT, RPE and RW-1) were supplied in 
the kit.
The lung tissue from saline and bleomycin-treated rats was snap frozen in 
liquid nitrogen and stored at -80°C to prevent any initial degradation of the 
RNA. The frozen tissue sample was powdered in liquid nitrogen with a pestle 
and mortar, and then lysed in RLT Buffer (contains guanidine isothiocyanate). 
The sample was homogenised by passing the lysate (several times) through a 
20-gauge needle fitted to a syringe, followed by centrifugation (>8,000 x g, 
two minutes) in a QIAshredder column. This reduces the viscosity of the 
lysates, increasing the efficiency of RNA for binding to the RNeasy 
membrane. Ethanol was added to promote selective binding of the RNA to 
the membrane. The entire sample was loaded in successive aliquots onto the 
RNeasy mini column and centrifuged in a bench top centrifuge (>8,000 x g, 15 
seconds, room temperature). The eluant was discarded and the column 
washed with wash buffers provided in the kit, (RW-1 and RPE buffer) in order 
to remove all contaminants. The column was centrifuged in a fresh collecting 
tube to eliminate any residual traces of ethanol from the RPE buffer, which 
would contaminate the purified RNA. The RNA was eluted from the RNeasy 
column into a sterile eppendorf with RNase/DNase-free water (30pl).
4 .3 .1 .3  D N a s e  T re a t m e n t  o f  th e  RN A
The RNase-Free DNase Set (Qiagen) was used to treat the RNA to ensure 
there were no DNA contaminants in the sample. The kit provides on-column 
digestion of DNA during RNA purification. RNA is treated with DNase I while 
bound to the silica-gel membrane. The DNase is then removed in subsequent 
wash steps. The removal of contaminants from the RNA is particularly 
important for obtaining reproducible results with the Atlas macroarrays. Poor 
quality RNA can result in a high background on the membrane, and/or an 
inaccurate hybridisation pattern. The procedure is detailed in the RNeasy 
Mini Handbook (Qiagen, 2001).
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The lysis, homogenisation and loading into the RNeasy mini column were 
carried out as indicated in Section 4.3.1.2. DNase I was diluted in Buffer RDD 
(both provided in the kit) and mixed gently to avoid denaturation of the DNase. 
After washing the column with a reduced volume of RW1 buffer, DNase I 
solution was applied to the column and incubated for 25 minutes. The DNase 
I was then removed by a second wash with Buffer RW1. Washing with RPE 
buffer and elution was then performed as described in Section 4.3.1.2.
4 .3 .1 .4  Q u a n t if y in g  t h e  R N A  I so la  te
The purity and yield of all RNA samples were assessed regardless of 
extraction procedure using the GeneQuant™ (Pharmacia). Purity was 
established by measuring the 260:280nm absorption ratio. A ratio of 2.0 was 
indicative of a very pure RNA sample (GeneQuant RNA/DNA Calculator User 
Manual). However, a ratio of over 1.8 was considered acceptable for 
subsequent gene analysis. Lower ratios can indicate contamination in the 
sample. The yield of the sample was deduced from the absorbency of the 
sample at a wavelength of 260nm.
4 .3 .1 .5  C h e c k in g  In t e g r it y  o f  R N A : R u n n in g  a n  A g a r o s e  G el
A sample of the RNA (1-2pg) was run on a 1% Agarose gel (0.5g in 50ml 1x 
TBE with 3pl of 10mg/ml Ethidium bromide). Each well was loaded with 1- 
2pg RNA, 2pl loading dye, and made up to a total of 10pl in high purity 
RNase/DNase free water. The gel was electrophoresed (approximately 40 
minutes, 90 volts) and viewed under UV using the Syngene™ Gel doc 
System.
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4.3.2 Macroarrays
4 .3 .2 .1  P r e p a r a  t io n  o f  t h e  M e m b r a n e s
The macroarray membranes (Clontech) were washed with deionised water 
and placed in individual hybaid bottles. Hybridisation solution (minimum 5ml 
per membrane) was pre-warmed to 68°C and added to the hybaid bottles 
containing the membranes. Heat denatured salmon testes DNA 
(0.5mg/membrane) was added to the hybridisation solution in the hybaid 
bottles and the membranes were left to prehybridise. Prehybridisation took 
place at 68°C for at least 30 minutes, with rotation to ensure the solution was 
evenly distributed across the membrane.
4 .3 .2 .2  P r e p a r a  t io n  o f  32P -L a b e l l e d  F ir s t  S tr a n d  cD N A  P r o b e
Isolated RNA (2pg), free from genomic contamination, was mixed with 10x 
CDS primer mix (1 |jl). The master mix stock (Table 4.2) and the RNA/primers 
were heated to 70°C. The solutions were cooled to 48°C and MMLV reverse 
transcriptase was added to the master mix (MMLV-RT is denatured above 
48°C). The master mix containing MMLV-RT was added to each RNA sample 
and then immediately heated at 48°C for 25 minutes to allow cDNA synthesis. 
The reaction was terminated using 10x termination mix and placed on ice.
Labelled cDNA probe was purified from unincorporated 32P-labelled nuclides 
and small cDNA fragments by column chromatography. The Atlas 
NucleoSpin® Extraction Kit was used for purification. This kit incorporates 
small-scale column chromatography and centrifugation to give quick, 
reproducible separation of labelled probe from contaminants. The probe was 
eluted in a low-salt buffer and the radioactivity checked with a Geiger counter. 
Denaturing solution (10x) was added and the solution placed at 68°C for 20 
minutes to allow full denaturation of the cDNA probe. C0t-1 DNA and 2x 
neutralisation solution were added and placed at 68°C for a further 10 
minutes.
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4 .3 .2 .3  H y b r id is a  t io n  o f  t h e  P r o b e  to  t h e  A r r a  y
The denatured, radiolabelled probe was added into the prehybridisation 
solution to avoid getting concentrated probe on the membrane. The 
membrane was then hybridised overnight (68°C) with continuous agitation. 
The membranes were subsequently washed until the radioactive counts 
dropped to 10-20 counts per minute (cpm). Wash solution 2 (Section 4.2.2.1) 
was used for a very stringent wash, or wash solution 1 for a less stringent 
wash. Wash solution 1 was used initially to determine the level of washing 
required. Then wash solution 1 or 2 was used as necessary. The membrane 
was removed, wrapped well to prevent drying, and placed under a 
phosphorimager screen (Amersham) within a cassette and left (room 
temperature) for two to seven days depending on the final radioactivity on the 
membrane.
4 .3 .2 .4  P r o c e s s in g  th e  P h o s p h o r im a g e r  S c r e e n
The exposed phosphorimager screen was scanned (50 micrometer 
resolution) and the resultant image analysed using the Atlaslmage 2.0 
(Clontech) computer software. This generated a report that was saved as a 
Microsoft Excel file and used for further analysis.
4 .3 .2.5 S t r ip p in g  t h e  M e m b r a n e s
The cDNA probe was stripped from the membrane prior to storage at -20°C. 
The membranes were boiled vigorously in 0.5% SDS solution (5-10 minutes) 
and rinsed in wash solution 1. The membrane was checked for radioactivity 
(cpm<5) before sealing in a bag for storage at -20°C. The phosphorimager 
screen was cleaned by exposure to bright light (15 minutes) and stored at 
room temperature until required.
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4.3.3 Expression  A nalysis  of Who le  L ung  Tissue
RNA was isolated, using the RNeasy Mini kit (Qiagen) (Section 4.3.1.2) from 
whole lung tissue. Rat lung tissue was obtained from animals sacrificed three 
days post intratracheal instillation. On day 0, sham control animals received
0.5ml of 0.15M saline, and experimental animals received 0.5 units bleomycin 
(Bleo-kyowa) in 0.5ml saline. Animals (n=9) were assessed by conventional 
toxicology for oedema (Chapter 2) and used for genetic analysis. Saline 
treated animals (n=9) were studied for comparison.
4.3.4 Data  N ormalisation
The information on all 18 rats (n=9 saline and n=9 bleomycin treated) 
generated by the Atlaslmage 2.0 software was imported into Excel. An 
adjusted intensity value was calculated by subtracting the background 
intensity from the spot intensity. The adjusted intensity was taken to be a 
quantitative measure of gene expression. This adjusted intensity value was 
used for all further calculations.
Numerous statistical techniques were available to make comparisons 
between groups of data. However, to obtain meaningful results from most of 
these tests, the distribution of the data must be known. Preliminary statistical 
analysis in Minitab™ 13.32 (Minitab Ltd) indicated that the data were not 
normally distributed across the arrays. This was determined by the Anderson- 
Darling normality test. An example of this for one gene is shown in Figure 
4.1.
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Anderson-Darling 
Normality Test
p-value: 0.024
I I I I I
1000 3000 5000 7000 9000
Spot Intensity
Figure 4.1 Normality test for one gene applied to raw array data. This was carried out for a 
representative selection of genes from the array. For normally distributed data p> 0.05.
This led to the initial component of the analysis, which was to normalise the 
data. The aim of normalisation was to eliminate the variability occurring from 
experimental differences such as the age of the radioisotope label, or the 
length of time the membrane was exposed to the phosphorimage screen.
Firstly, a Iog10 transformation (Nadon and Shoemaker, 2002) reduced the 
skewness of the data. Global normalisation was then carried out by dividing 
the spot intensity of each gene by the median spot intensity of the whole array 
(Balharry et a/., 2005). This resulted in data where each gene was 
comparable across all replicates, and could be used for further analysis. This 
is illustrated in Figure 4.2.
Anderson-Darling 
Normality Test
p-value: 0.556
I i I I I I I
0.90 0.95 1.00 1.05 1.10 1.15 1.20
Spot Intensity
Figure 4.2 Normality test for one gene applied to log 10 transformed, normalised array data. 
This was carried out for a representative selection of genes from the array. For normally 
distributed data p> 0.05.
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4.3.5 Initial Data  A nalysis Using  M icro so ft  Excel
After the arrays were analysed as a whole, the data were then analysed on a 
gene by gene basis. This was to identify any genes that responded 
consistently and significantly to the treatment. This was carried out as 
detailed in Section 4.3.5.
Altered gene expression was quantified as a ratio of adjusted intensities as a 
further method of quantifying altered gene expression. Ratio was calculated 
for up-regulated genes by dividing bleomycin gene intensity by saline gene 
intensity. For down-regulated genes, saline was divided by bleomycin 
intensity, and a minus sign was placed in front of the resulting ratio. This 
generated a figure that was representative of fold change in expression. The 
positive or negative sign indicated up or down-regulation of the gene. 
Previous experiments have shown that over 75% of genes with a ratio change 
of 1.5 or more can be confirmed by reverse transcription polymerase chain 
reaction (RT-PCR) (Treadwell and Singh, 2004; deVos et al., 2003). The 
lower threshold for identifying relevant genes was therefore set at a ratio of 
1.5.
4.3.5.1 Ra n g e : Lo w  N u m b e r  o f  Sa m p l e  R e p l ic a  tes
Numerous statistical techniques are available to make comparisons between 
groups of data. However, to obtain meaningful results from these tests, the 
distribution of the data must be known. In the early stages of these studies, 
with a low number of experimental replicates, it was not possible to establish 
the shape of distribution, or to identify outliers. A different method of 
determining significant differences in gene expression, which took into 
account the intra-group variability, was required.
This first method developed was necessarily simple to allow for the limited 
sample size. For each gene, the normalised intensity values from each of the 
three saline arrays were plotted on a single graph. The three data points from 
the bleomycin arrays were plotted alongside these on the same graph. If
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there was a clear separation between the range of the bleomycin array points 
and the range of the saline points, the gene was considered relevant for 
further study (Figure 4.3).
2.0
1.5
1.0
0.5 -
♦ Control 1 
■ Control 2 
▲ Control 3 
oTest 1 
□ Test 2 
a Test 3
Gene No.
1 2 
Not Relevant Not Relevant Up-regulated Down-regulated
Figure 4.3 The ‘range’ method of gene selection. Genes 3 and 4 show a clear difference 
between the groups, indicating these genes are relevant for further study. Data is for 
illustrative purposes only and not taken from experimental data.
Of the genes selected by this method, several criteria were used to identify 
which genes were most appropriate for use as markers in further studies.
• Large separation between the two groups made it unlikely that 
experimental error could cause a false overlap
• A narrow range of measured intensities suggested low variability in 
expression between samples
• A high ratio between the saline and bleomycin groups suggested the effect 
of treatment was large (the mean values of adjusted intensity were used to 
calculate expression ratios)
• Groups of functionally related genes exhibiting similar behaviour 
suggested the results were less likely to be anomalous.
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As well as considering the above criteria, it was important to take into account 
the biological significance of the genes.
4 3.5.2 Two S tan d ard  D e v ia t io n : H ig h  N u m b e r  o f  Sa m p l e  R ep lic a te s
As the study continued a higher number of replicates were obtained, and it 
became possible to expand on the range method to give a more statistically 
relevant analysis.
For each gene, the mean normalised intensity value from each of the nine 
saline arrays was plotted on a graph ± two standard deviations (±sd). Two 
standard deviations was the interval chosen because for each gene, if the 
data are normally distributed, 95% of the population will fall within ±2sd from 
the mean. The mean ±2sd established the range of normal gene expression 
against which the oedema samples could be compared. If the mean of all 
nine of the oedema samples fell outside the two standard deviations limits, the 
gene was considered relevant for further study (Figure 4.4) (Balharry et at., 
2005).
2.2
2.0
1.8
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
I
% bleomycin mean 
£  control replicates 
g  control mean 
| 2sd
Gene 1 Gene 2 Gene 3
Figure 4.4 The 2sd method of gene selection. Gene 1 is not significantly altered by 
bleomycin treatment, genes 2 and 3 are relevant for further study. Gene 2 is down-regulated, 
and gene 3 is up-regulated. Data is for illustrative purposes only and not taken from 
expehmental data.
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4.3.5.3 T -t e s t : L o w  o r  H ig h  N u m b e r  o f  S a m p l e  R e p l ic a  tes
A third method for determining significant differences between the control and 
oedema samples was also carried out in Excel. This was an established 
statistical technique, the two-tailed Student’s t-test, which is frequently used 
during array analysis (Dong et al., 2002; Katsuma eta l., 2001; Bartosiewicz et 
a i, 2000). Genes with a p-value of less than or equal to 0.05 were selected 
as statistically relevant.
Of the genes selected by these methods (Section 4.3.5), those with a gene 
expression ratio of over 1.5 fold were accepted to be the most significant (the 
mean values of adjusted intensity were used to calculate expression ratios).
4.3.6 F u r t h e r  A n a l y s is  w it h  a t l a s  N a v ig a t o r ™ 1.0
Atlas Navigator (Clontech) was designed specifically for analysis of Clontech 
Atlas macroarrays. It provided a convenient method for visualisation of the 
complex expression data generated by Atlaslmage.
The ‘New Experiment Wizard’ was used to import data directly into Navigator 
from Atlaslmage reports. The arrays were not normalised by Navigator as 
this had previously been carried out manually (Section 4.3.4). Default gene 
lists allowed graphical representation of all genes included on the array. 
Additional lists allowed only genes belonging to a particular functional group 
to be viewed. Some of the main functional gene groups present on the 
Clontech Atlas™ Rat 1.2 Macroarray are shown in Table 4.7.
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Rat 1.2 Macroarray (7854-1)
Apoptosis associated proteins 
Cell adhesion receptors 
Cell cycle
Cell receptors (by activities)
Cell receptors (by ligands)
Cell signalling, extracellular communication 
Cytoskeleton-motility proteins 
DNA binding and chromatin proteins 
Extracellular transport-carrier proteins 
Intracellular transducers-effectors-modulators 
Membrane channels and transporters 
Metabolism
Post translational modification-protein folding 
Protein turnover 
Trafficking-targeting proteins 
T ranslation
DNA synthesis, recombination and repair 
Functionally unclassified 
Immune system proteins 
Oncogenes and tumour suppressers 
Stress response proteins 
T ranscription
Housekeeping genes_______________________
Table 4.7 Summary of the main functional gene classes on the Atlas™ Rat 1.2 macroarray
A new gene list was created to include only the genes identified as relevant 
using the strategies outlined in Section 4.3.5.
The genes were plotted on a graph with bleomycin dose along the x-axis 
(control dose=0, bleomycin dose=0.5 units/0.5ml saline). Relative intensity 
(ratio) was plotted on the y-axis. Relative intensity (ratio) for each gene was 
defined as the normalised adjusted intensity divided by the normalised 
adjusted intensity of an arbitrarily selected array.
Each gene was represented as a line, the gradient of which represented the 
ratio change between saline and bleomycin samples (Figure 4.13 in Results 
section). This technique was used to study the combined results of the nine 
saline arrays with the nine bleomycin arrays.
To study the genetic response to different levels of oedema, each set of 
arrays was separated according to their pathology. The L:B ratio (Chapter 2)
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was chosen as a single indicator of oedema. The difference in gene 
expression at these various levels of oedema was compared (Figure 4.14 in 
Results section).
4 .3 .7 V is u a l  Da  ta M in in g  w ith  Sp o tf ir e  P r o  3
Spotfire Pro was developed to visually explore large data sets. The layout of 
the display facilitated identification of trends within the data, including clusters 
and anomalies. The information was formatted in Excel and exported into 
Spotfire. The data were coloured according to any of the discrete variables,
i.e. each functional classification is a different colour (Figure 4.15). Discrete 
variables were also allocated a check box, so each category could be viewed 
separately. For example, it is possible to view only those genes associated 
with apoptosis. Any of the variables (gene code, gene name, ratio, intensity 
difference, etc.) could be chosen for either of the axes. Genes were allocated 
to the x-axis, with either intensity difference or ratio on the y-axis. Data were 
filtered into three categories using the Bin Wizard. The limits were defined 
according to ratios: less than -1.5, between -1.5 and 1.5, and greater than 1.5. 
This meant that it was possible to view all the data in any format, without the 
presence of genes with ratio changes of less than 1.5 (Figure 4.5).
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Figure 4.5 Spotfire data. A: Raw data; B: Data which has been filtered to remove genes with 
less than a 1.5 ratio change.
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4.3.8 P h y l o g e n ic  Tr e e  -  G e n e  C l u s t e r in g
In order to identify clustering of the genes, and to represent this graphically, 
the data were analysed using a phylogenic tree predictor (Tree Top). The 
sequence data for all the genes previously determined as relevant were 
formatted in Microsoft Word and inserted into ‘Tree Top’ (Genebee, 2001). 
The protein sequence of each gene was determined using NCBI (National 
Centre for Biotechnology Information), and imported into Word with no 
spaces. This information was copied directly into the website. Analysis was 
carried out using the cluster algorithm. The output graph was shown in 
slanted format. Tree top organises the genes according to the similarity 
between the sequences and produces a simple graphical representation 
(dendogram) as illustrated by Figure 4.19 in the Results section. More 
complex versions of this are available (phylogenic trees), but were not 
necessary in this instance, as only simplistic clustering according to 
functionality was required.
4.3.9 Q-PCR to  C o n f ir m  A l t e r e d  E x p r e s s io n  o f  Im p o r t a n t  G e n e s
Q-PCR makes use of the RT-PCR technique. This is one of the most 
sensitive techniques for mRNA detection and quantification currently 
available, and can be used to quantify mRNA levels from very small samples 
(Ahmed, 2002; Sugita eta l., 2003).
At the start of the RT-PCR reaction, reagents are in excess, and amplification 
occurs at an exponential rate. The point at which the reaction rate enters the 
linear phase of amplification is extremely variable, even among replicate 
samples. To obtain accurate information it is necessary to measure the 
samples whilst in the early stages of the exponential phase. To achieve this, 
real-time PCR is used. A fluorescent reporter compound (SYBR Green) is 
incorporated into the DNA during the PCR reaction. By detecting the levels of 
this reporter, real-time PCR measures the amount of DNA that is generated 
during every cycle of the PCR reaction (Figure 4.6). From this it is possible to
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determine the point at which the samples increase significantly above a 
predetermined baseline level (Ct).
100 pg 
10 pg
1 pg
100 fg 
10 fg 
Unknown
Rn
Cycle threshold
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35
Cycle
Figure 4.6 Example data for real-time RT-PCR. Shows an exponential increase in the 
amount of cDNA present in each sample (Rn, Reporter number).
Firstly, a standard curve was constructed from RNA extracted from untreated 
lung tissue (Figure 4.7). The samples were of known concentrations (1 Ofg- 
10Opg), and were plotted against their Ct values.
24
Ct
16
15     -------------------
10 100 1000 10000 100000
R N A  c o n c e n tra t ion  (fg)
Figure 4.7 Standard curve resulting from data in Figure 4.6. Standards Unknown (M).
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This was used as a reference for interpolating information for RNA of 
unknown concentrations. This technique was carried out on five of the genes 
selected by the methods outlined in Section 4.3.5.
4.3.9.1 RT-PCR
The same samples of RNA used in the array procedure were used to 
synthesise cDNA by a reverse transcription reaction. RNA (2pg) was diluted 
in sterile water to a total volume of 19.5pl and heated to 70°C for three 
minutes. The sample was replaced on ice combined with the reaction mix 
(Table 4.3). This was incubated at 37°C for two hours. Next, a 50pl rxn PCR 
reaction (Table 4.4) was carried out as detailed in the Atlas Arrays RT-PCR 
User Manual (Clontech, 2001). This involved a two-stage PCR reaction:
Initial denaturation 
Denature
Anneal and extend 
Final extension
95°C (1 minute)
i
95°C (30 seconds) <«-
i
68°C (1 minute) —
i
68°C (1 minute)
x 30 cycles
The PCR product was then loaded onto a 2% agarose gel, and extracted 
using Sigma GenElute agarose spin columns.
4.3.9.2 L ig a  t io n  o f  PCR P r o d u c t  in t o  P la s m id  V e c to r
Purified PCR product was ligated into a pGEM-T plasmid vector using the 
pGEM-T vector system I from Promega. This method is detailed in the 
Promega Technical Manual (Promega, 1999). In brief, the ligation master mix 
was prepared as detailed in Table 4.5 and incubated overnight at 4°C.
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4 .3 .9 .3  Tr a n s f o r m a  t io n  in t o  E. c o l i
The tubes containing the ligation reaction were centrifuged and 2|jl was 
transferred to a fresh tube. Frozen E.coli JM109 competent cells were 
thawed on ice for five minutes and gently mixed by flicking. Thawed 
competent cells (50pl) were added to the ligation reactions and mixed gently 
by pipetting. The tubes were placed on ice for 20 minutes. The samples 
were heat shocked for 45-50 seconds at 42°C then returned to ice for two 
minutes. Luria broth (LB) (950pl) was added to each tube, and incubated with 
shaking for 1.5 hours at 37°C. The transformed E.coli (100pl and 200pl 
respectively) was plated on to pre-prepared LB/ampicillin/IPTG/X-Gal agar 
plates. The remaining media was centrifuged and the pellet resuspended in 
100pl of LB. This was also plated out, and all three plates were cultured 
overnight at 37°C.
4 .3 .9 .4  S c r e e n in g  Tr a n s f o r m a n t s  f o r  In s e r t s
Successful cloning of an insert into the pGEM-T vector interrupts the coding 
sequence of (3-galactosidase. This results in a colour change between clones 
which contain PCR product, and those that do not. Recombinant clones can 
therefore be identified by a white colouring, compared to uncloned vectors 
which remain blue.
LB (10ml) containing 1 mg/ml ampicillin was inoculated with a white colony, 
and incubated overnight at 37°C. The culture containing the recombinant 
clones was plated onto LB agar/ampicillin plates and sent for sequencing 
whilst the remainder was stored as a 20% glycerol stock.
4 .3.9.5 P l a s m id  DNA P u r if ic a t io n
Purification of plasmid DNA from the bacterial cells was undertaken using the 
Wizard Plus SV Minipreps DNA Purification System. LB containing the 
recombinant E.coli (1.5 ml) was centrifuged (10000 x g) for five minutes. The
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resulting pellet was resuspended in 250pl resuspension buffer and vortexed. 
Cell lysis solution (250pl) was added and mixed by inverting. The sample was 
incubated at room temperature until the cell suspension had cleared 
(maximum of five minutes). Alkaline protease solution (10pl) was added and 
mixed by inverting, then incubated at room temperature for five minutes. After 
incubation, 350pl neutralisation solution was added and immediately mixed by 
inversion. The sample was then centrifuged at maximum speed for 10 
minutes, and the cleared lysate decanted into a prepared spin column. This 
was centrifuged at maximum speed for one minute. The columns were then 
washed with 750pl column wash solution and centrifuged for a further one 
minute. A final wash was carried out by adding 250pl column wash solution to 
the column and centrifuging for two minutes. To elute the plasmid, 50pl 
nuclease-free water was added to the column, and centrifuged for one minute. 
The concentration of DNA in the resultant eluant was measured using a 
GeneQuant™ (Pharmacia).
4 .3 .9 .6  S er ia l  D il u t io n  o f  S t a n d a r d s
When the sequence of the insert was confirmed, standards were created for 
each gene. The GeneQuant measurement of the eluted DNA (Section 
4.3.1.4) was used to calculate the dilution factor necessary to obtain a 
concentration of 1ng/pl. Serial dilutions were then carried out to obtain a 
series of standards ranging from 10fg/pl to 100pg/pl.
4 .3 .9 .7  Q -P C R  o f  E x p e r im e n t a l  G e n e s
RNA was isolated from experimental lung as described in Section 4.3.1.2, and 
cDNA was synthesised from this, by a reverse transcription reaction (Section 
4.3.9.1). Samples and standards were prepared for Q-PCR using the 
QuantiTect SYBR Green PCR Kit. The PCR reactions were set up as shown 
in Table 4.6. Each sample and standard was loaded in triplicate (20pl per 
well) into a Thermofast 96 well PCR detection plate. The plate was analysed 
on an Applied Biosystems ABI PRISM 7700 Sequence Detection System.
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4 .4  R e s u l t s
4 .4 .1  ISOLA TION AND PREPARA TION OF RNA
RNA preparations from Tri-reagent™ (Sigma-Aldrich) and the RNeasy Mini kit 
(Qiagen) were compared (n=3) using the GeneQuant (Pharmacia) (Table 4.8).
Isolation Technique Absorbance
(260nm)
RNA concentration 
(MQ/ml)
Ratio
A260/A280
T ri-reagent™ 1.020 771.9 1.87
Tri-reagent™ 1.787 1421.9 1.51
T ri-reagent™ 1.105 950.7 1.39
Mean 1.304 1048.2 1.59
RNeasy Mini kit 1.021 996.6 2.04
RNeasy Mini kit 0.479 383.3 1.99
RNeasy Mini kit 0.647 532.4 2.03
Mean 0.716 637.4 2.02
Table 4.8 Comparative data from the two RNA isolation techniques generated by the 
GeneQuant RNA/DNA Calculator. RNA was isolated from the same section of lung tissue 
each time.
The isolated RNA was run on an agarose gel and viewed under UV 
(Syngene™ gel doc System) to check the integrity and highlight any genomic 
contamination. The presence of DNA was detected as a third band (Figure 
4.8). Smeared bands would indicate RNA degradation.
 <------- gDNA contamination
 <------- 28S band
m   18Sband
Figure 4.8 Agarose gel of total RNA isolated from lung tissue. A: Isolated using the RNeasy 
Mini kit, followed by DNase treatment; B: Isolated using Tri-reagent™.
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Preparation with Tri-reagent™ resulted in almost double the RNA yield, 
however, the RNeasy isolation contained fewer contaminants. This can be 
seen from the gel pictures (Figure 4.8) and the high absorbance ratios 
calculated by the GeneQuant (Table 4.8). RNA preparations of greater purity 
were isolated following DNase treatment (Section 4.3.1.3).
Before using the isolated RNA in the array procedure, the GeneQuant 
(Pharmacia) was used to confirm the purity and yield of the samples. Sham- 
control samples and bleomycin-treated samples were used as outlined in 
Chapter 2. Samples with a ratio of over 1.8 were chosen, as this value 
indicated that there was little or no DNA contamination. The RNA purity was 
confirmed by checking against the agarose gel images.
4.4.2 M a c r o a r r a y
4.4 .2 .1  M a c r o a r r a  y O p t im is a  tio n
Initial array studies were ineffective due in part to poor RNA isolations.
However, even after optimisation of RNA isolation procedures (Section 4.3.1), 
some arrays were still not providing adequate gene expression images 
(Figure 4.9).
Figure 4.9 Scanned phosphorimage of Clontech Rat 1.2 Macroarray showing poor 
hybridisation and high background.
The lack of hybridisation and relatively high background resulted in indistinct 
separation on the arrays. The two possible causes of this were problems with 
the hybridisation solution, or inadequate separation of the labelled probe. The
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hybridisation solution was probably ineffective due to repeated heating to 
60°C. To remedy these problems, a new batch of hybridisation solution, 
designed specifically for use on the Atlas Rat 1.2 macroarrays (7854-1) was 
purchased. The solution was separated into aliquots to avoid repeated 
heating. The technique used to purify the labelled probe was updated from a 
large scale gravity-fed column purification method (procedure not shown), to 
the method described in Section 4.3.2.2 (spin-column chromatography). 
Subsequent arrays showed clear hybridisation, and a relatively low 
background (Figure 4.10).
4.4.2.2 M a c r o a r r a y  A n a ly s e s
The array procedure was designed to find genes that were consistently 
significantly up or down-regulated by 1.5-fold or greater in the oedematous 
lung. The first stages of oedema in the rat lung occurred three days post­
bleomycin instillation, as confirmed by the biochemical analysis detailed in 
Chapters 2 and 3. Consequently, lung tissue from this time point was taken 
for genetic analysis. Saline-treated and bleomycin-treated samples were 
used in conjunction with the Atlas™ Rat 1.2 Macroarray (7854-1) and the 
resultant array images analysed with the Atlaslmage 2.0 (Clontech) computer 
software. Visual examination of the array images showed a great deal of 
change in the expression of many of the genes (Figure 4.10).
The images were imported into the Atlaslmage 2.0 (Clontech) computer 
program. This software was used to carry out a comparative quantitative 
analysis of the arrays and an Atlaslmage report (a text file) was generated for 
each of the arrays.
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Figure 4.10 Scanned phosphorimage of Clontech Rat 1.2 Macroarrays, three days after 
treatment. A: Saline; B: Bleomycin. Examples of two genes altered by bleomycin treatment 
are indicated: O , Down-regulated; O. Up-regulated; □ , Cluster/family of genes.
4.4.3 Ex c e l  A n a l y s is
4.4.3.1 S tan d ar d  D e v ia t io n  M e th o d
The quantitative data generated for each of the arrays by Atlaslmage 2.0 were 
exported to an Excel file. The genes with a consistent change in expression 
were identified (as described in Section 4.3.5.2) and limited to genes with a 
ratio change of over 1.5. A total of 23 genes were identified (Figure 4.11 and 
Table 4.9).
1.40 -r 
1.30
1.20 -  
1.10 
1.00
0.70
0.60
0.50
0.40
-
1
*
i ► <► < . i ► . < ► < ► < ► 4 ► < ► 4 ► 4 • <► <
4 ► < * i ► 4► '
-  ■1
■  ■
r  ■ -  "  ■ .  ■  ■
■  ■  ■ ■ ■ ■  ■
■  ■
' ' I ' ' 1 ’ 1 “  1 i i ’ ■ 1 “ 1 "  ! —  i
S S cooO
O) c
o  o  Q D
in in
S
Ein
■o
CDOO
S  (O’ ^  N  o  o  <£ o  Q Q g Q
G e n e  co d e
oo a? o> gS S S S
05 55
c d  c n  go  o  xa  a  Q
Figure 4.11 Analysis of saline (n=9) and bleomycin (n=9) arrays by the standard deviation 
method in Excel. Mean saline intensity mean bleomycin intensity ( M ), ± 2sd (X).
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Genbank ID Ratio Gene/Protein Name
X62314 -1.65 somatostatin receptor 1
M 31838 -1.71 substance K receptor (SKR)
X56661 -1.51 gastrin-releasing peptide receptor (GRP-R)
M 34842 -1.55 thyroid stimulating hormone receptor
L02842 -1.80 follicle stimulating hormone receptor
D32045 -1.76 alpha 1B adrenergic receptor
L05596 -1.81 Serotonin receptor 1F
L10072 -1.74 serotonin receptor 5A
M 88096 -1.53 cholecystokinin receptor
M 93273 -1.70 somatostatin receptor 2
U37058 -1.70 neuromedin B receptor
U40395 -1.70 cannabinoid receptor 1
L10073 -1.74 serotonin receptor 5B
X63574 -1.55 somatostatin receptor 3
J03933 -1.69 thyroid hormone beta receptor
M 14053 -1.84 glucocorticoid receptor
X95579 -1.51 GABA-A receptor rho-1 subunit precursor
L31622 -1.99 neuronal ACh receptor beta 2 subunit
M 85035 -1.53 glutamate receptor 2 precursor
X 15467 -2.08 GABA-A receptor beta-2 subunit precursor
L08497 -1.72 GABA-A receptor gam ma-2 subunit
L08493 -1.54 GABA receptor alpha 4 subunit
U37101 -1.51 granulocyte colony stimulating factor (GCS-F)
Table 4.9 Relevant genes detected by the 2sd analysis in Excel. Ratio calculated using 
mean intensity values. Genes all have a ratio of greater than 1.5.
4 .4 .3 .2  T-T e s t  m ethod
The same data generated by the Atlaslmage 2.0 program were analysed 
using a two-tailed t-test (described in Section 4.3.5.3). These genes were 
also limited only to genes with a ratio change of over 1.5. The resulting data 
are shown in Table 4.10.
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Genbank ID Ratio p-value Gene/Protein Name
D50497 2.12 0.038 chloride channel protein
U 15098 1.66 0.032 glutamate transporter
U28927 1.69 0.032 Na+/C I- betaine/GABA transporter
U 10096 2.15 0.021 sod i u m - potass i u m -ch loride cotra ns po rter
L10362 1.83 0.018 synaptic vesicle protein 2B
L02842 -1.80 0.037 follicle stimulating hormone receptor
D32045 -1.76 0.045 alpha 1B adrenergic receptor
L05596 -1.81 0.034 Serotonin receptor 1F
L10072 -1.74 0.049 serotonin receptor 5A
Z11690 -2.10 0.038 vasopressin/arginine receptor
L10073 -1.74 0.049 serotonin receptor 5B
J03933 -1.69 0.028 thyroid hormone beta receptor
M 36074 -2.14 0.034 mineralocorticoid receptor (MR)
M 14053 -1.84 0.029 glucocorticoid receptor
Z11716 -2.16 0.031 glutamate receptor 7 (GLUR7)
L31622 -1.99 0.015 neuronal ACh receptor p 2 subunit
X 15467 -2.08 0.016 GABA-A receptor beta-2 subunit precursor
Table 4.10 Relevant genes detected by the t-test analysis in Excel. Ratio calculated using 
mean intensity values. Genes have a p-value < 0.05 and a ratio difference greater than 1.5.
4 .4 .3 .3  S ta n d a r d  D e v i a tio n  /  T -t e s t  C o m p a r is o n
The gene lists generated in Sections 4.4.3.1 and 4.4.3.2 were compared for 
consistencies. These genes were considered particularly relevant. A list 
combining genes from both analysis techniques was compiled, as shown in 
Table 4.11.
As well as considering the statistical relevance as determined above, it is 
important to take into account the biological significance and clustering of the 
genes. Of the five up-regulated genes, four are involved in active transport of 
molecules across membranes and the fifth is a chloride channel. Many of the 
remaining significantly altered genes belonged to two functional groups, the 
neurotransmitter receptors (seven genes) and hormone receptors (fifteen 
genes).
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Genbank ID Ratio Gene/Protein Name Classification
D50497 2.12 chloride channel protein Ion channels & trafficking proteins
U15098 1.66 glutamate transporter Ion channels & trafficking proteins
U28927 1.69 Na+/CI- betaine/GABA transporter Ion channels & trafficking proteins
U10096 2.15 Na-K-CI cotransporter Ion channels & trafficking proteins
L10362 -1.83 synaptic vesicle protein 2B Ion channels & trafficking proteins
X62314 -1.65 somatostatin receptor 1 Hormone receptors
M31838 -1.71 substance K receptor (SKR) Hormone receptors
X56661 -1.51 gastrin-releasing peptide receptor Hormone receptors
M34842 -1.55 thyroid stimulating hormone receptor Hormone receptors
L02842 -1.80 follicle stimulating hormone receptor Hormone receptors
D32045 -1.76 alpha 1B adrenergic receptor Hormone receptors
L05596 -1.81 Serotonin receptor 1F Hormone receptors
L10072 -1.74 serotonin receptor 5A Hormone receptors
M88096 -1.53 cholecystokinin receptor Hormone receptors
M93273 -1.70 somatostatin receptor 2 Hormone receptors
U37058 -1.70 neuromedin B receptor Hormone receptors
U40395 -1.70 cannabinoid receptor 1 Hormone receptors
Z11690 -2.10 vasopressin/arginine receptor Hormone receptors
L10073 -1.74 serotonin receptor 5B Hormone receptors
X63574 -1.55 somatostatin receptor 3 Hormone receptors
J03933 -1.69 thyroid hormone beta receptor Nuclear receptors
M36074 -2.14 mineralocorticoid receptor (MR) Nuclear receptors
M 14053 -1.84 glucocorticoid receptor Nuclear receptors
X95579 -1.51 GABA-A receptor rho-1 subunit Neurotransmitter receptors
Z11716 -2.16 glutamate receptor 7 (GLUR7) Neurotransmitter receptors
L31622 -1.99 neuronal ACh receptor (3-2 subunit Neurotransm itter receptors
M85035 -1.53 glutamate receptor 2 precursor Neurotransmitter receptors
X15467 -2.08 GABA-A receptor (3-2 subunit Neurotransm itter receptors
L08497 -1.72 GABA-A receptor gamma-2 subunit Neurotransmitter receptors
L08493 -1.54 GABA receptor a -4  subunit Neurotransmitter receptors
U37101 -1.51 granulocyte colony stimulating factor GFs, Cytokines & Chemokines
Table 4.11 Relevant genes detected by the 2sd analysis combined with the t-test analysis. 
Ratio calculated using mean intensity values. Genes all have a ratio change greater than 1.5. 
Genes in blue were identified only by the t-test. Genes in black were identified only by the 
2sd method. Genes in bold were identified by both techniques
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4.4.3.4 R a n g e  /S t a n d a r d  D e v i a t io n  C om parison
A comparison was carried out between the range method developed initially, 
and the statistical method derived from it. From the 18 arrays carried out, 
three saline and three bleomycin arrays were chosen randomly. These six 
arrays were then analysed by the ‘range’ method as described in Section 
4.3.5.1. The resulting data were compared to the data generated by the 
analysis of all 18 arrays by the 2sd method described in Section 4.3.5.2.
The range method highlighted 56 genes that were altered by greater than 1.5- 
fold. Of these genes, 23 were up-regulated, eight of which were altered by 
greater than two-fold. The remaining 33 genes were down-regulated, 20 of 
which had greater than two-fold changes. The standard deviation method 
selected 23 genes, all of which were down-regulated by greater than 1.5-fold, 
as shown in Table 4.9. The genes which were consistent throughout both 
these analysis methods are shown in Table 4.12.
Genbank ID Ratio(range)
Ratio
(sd) Gene/Protein Name Classification
X62314 -2.56 -1.65 somatostatin receptor 1 Hormone receptors
M 31838 -2.78 -1.71 substance K receptor (SKR) Hormone receptors
M 34842 -1.96 -1.55 thyroid stimulating hormone receptor Hormone receptors
D32045 -2.72 -1.76 alpha 1B adrenergic receptor Hormone receptors
M 93273 -2.80 -1.70 somatostatin receptor 2 Hormone receptors
U37058 -2.61 -1.70 neuromedin B receptor Hormone receptors
U40395 -2.85 -1.70 cannabinoid receptor 1 Hormone receptors
L10073 -3.00 -1.74 serotonin receptor 5B Hormone receptors
X63574 -1.76 -1.55 somatostatin receptor 3 Hormone receptors
J03933 -3.21 -1.69 thyroid hormone beta receptor Nuclear receptors
M 14053 -3.00 -1.84 glucocorticoid receptor Nuclear receptors
X95579 -2.83 -1.51 GABA-A receptor rho-1 subunit Neurotransmitter receptors
L31622 -3.03 -1.99 neuronal ACh receptor (3-2 subunit Neurotransmitter receptors
X 15467 -1.81 -2.08 GABA-A receptor (3-2 subunit Neurotransmitter receptors
U37101 -2.09 -1.51 granulocyte colony stimulating factor GFs, Cytokines & Chemokines
Table 4.12 Genes common in both the 2sd analysis and the range analysis. Ratio change 
calculated using mean intensity values. Genes all have a ratio of greater than 1.5.
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There was a relatively high level of correlation between the two methods, with 
15 of the 23 genes identified by the standard deviation method also being 
picked up by the range method. Although a larger number of genes were 
highlighted using the range method, this may be indicative of more false 
positives.
4 .4 .4  Na v ig a t o r  A n a ly s is
The data generated by Atlaslmage were imported into Navigator as described 
in Section 4.3.6. This produced a graphical representation of the global gene 
expression patterns generated by the Atlas 1.2 Rat macroarray (Figure 4.12).
Bleomycin Dose (units 0 S ml saline)
Figure 4.12 The altered expression of all the genes on the Atlas Rat 1.2 macroarray.
The entire array illustrated on one graph was not particularly beneficial (Figure 
4.12). The large number of genes masked any extreme effects that may have
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been visible with fewer genes present on the graph. Examination of functional 
groups individually, or genes that were previously determined as relevant, 
was found to be much more effective (Figure 4.13).
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Figure 4.13 The expression of the genes identified by a combination of the standard deviation 
and t-test methods (Section 4.4.3.3).
Visualisation of the relevant data previously displayed in tabular format (Table
4.11) is shown in Figure 4.13. The effect of bleomycin was clearly seen on 
the 31 identified genes. A general trend towards down-regulation was much 
more noticeable and identification of those genes that were most affected by 
the treatment was made easier.
The differential expression of these genes was studied next, according to the 
level of oedema (Figure 4.14). The difference in pathology was determined
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Relative 
Intensity (ratio)
0.0039 0 0047 0.0055 0.0063' 0.0091 0.0118Lung: body weight ratio
Figure 4.14 The expression pattern o f genes at different levels of oedema as determined by 
the L:B ratio. The genes shown are only those previously determined as relevant.
This gives a more detailed picture of the expression patterns at progressing 
levels of oedema. The lowest L:B ratios were generated from the saline- 
instilled animals (e.g. L:B= 0.0039-0.0053). In undamaged tissue, normal 
gene expression fluctuations were occurring that resulted in large variations 
between samples. The greater the level of oedema (i.e. the greater the 
change from normal) the more the behaviour of the genes appeared to 
synchronise (e.g. L:B= 0.0063-0.0116).
One of the restrictions of this method of analysis is the lack of exact 
duplicates of the data. This means the level of confidence in these data is 
limited.
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4 .4 .5  S p o t f ir e  A n a ly s is
Spotfire was another technique used for visualising the expression data. It 
could potentially reveal different expression patterns overlooked by the 
previous methods. The data were plotted on a graph with the gene names 
along the x-axis and the ratio change as calculated in Excel on the y-axis. 
Genes were coloured according to their main functional group (Figure 4.15).
■ i ATPase Transporters
■  Extracellular Matrix Proteins 
d  Growth Factors, Cytokines, Chemokines 
■ i Hormone Receptors 
*  Hormones
m  Intracellular Kinase Network Members
■  Intracellular Protein Phosphatases 
m  Neuropeptides 
d  Neurotransmitter Receptors 
51 Nuclear Receptors 
EH Other Extracellular Communication Proteins 
51 Other Receptors
d  Other Trafficking and Targeting Proteins 
S i Phospholipases and Phosphoinositol Kinases 
d  Ion Channels and Trafficking Proteins 
m  Voltage-Gated Ion Channels
Figure 4.15 Legend for the Spotfire analysis, showing the colour coding of the functional 
classification of the genes on the Atlas Rat 1.2 macroarray.
The data for all the genes are shown in Figure 4.16. The information 
presented in this graph was unclear as a result of the clustering of data 
around the horizontal axis.
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Figure 4.16 All the array data. Gene codes listed along x-axis and ratio on the y-axis. Genes 
are coloured according to their main functional classification (Figure 4.15).
To clarify this, the crowded genes were removed, and a graph was generated 
showing only those genes that had a ratio change of over 1.5 (Figure 4.17).
« # »  4 k
No
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B04a b07c 012k po5i D07m po9l D"l4f E08n
Gene co-ordinate
Figure 4.17 Macroarray data excluding genes which have a ratio of less than 1.5. Gene 
codes listed along x-axis and the ratio on the y-axis. Genes are coloured according to their 
main functional classification (Figure 4.15).
The grouping of families of genes on the array could clearly be seen. The 
genes with extreme responses to bleomycin in terms of ratio change were 
also easily identified.
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Consequently, the next stage was to look at the relevant genes previously 
identified by the Excel techniques (Figure 4,18). From this graph it was easy 
to identify the clusters of genes most affected by the bleomycin treatment. 
The group of five up-regulated genes encoding for ion channels and trafficking 
proteins are shown in yellow. Whilst the down-regulated genes encoding for 
hormone receptors (purple), nuclear receptors (brown), neurotransmitter 
receptors (blue/grey) and growth factors, chemokines and cytokines (pale 
blue) were also clearly indicated.
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Figure 4.18 Genes determined as relevant in Section 4.4.3.3. Gene codes listed along x-axis 
and ratio on the y-axis. Genes are coloured according to their main functional classification 
(Figure 4.15).
4 .4 .6  P h y l o g e n ic  Tr e e  -  Clu s te r in g
Tree top was used to cluster the genes previously identified as relevant (Table
4.11). The sequence homology between the protein products of the 
significant genes was used as the basis for clustering. The more related the 
protein sequences were to each other, the shorter the ‘branches’ were. The 
resultant dendogram is depicted in Figure 4.19. The relationship between the 
genes was clearly represented. For example, each cluster of either green, 
blue or purple coloured gene codes were loosely related to each other. 
However, the shorter branches on the tree (indicated by three different 
shades of blue) were more closely associated. By the same standard, longer
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branches signified genes that showed no structural similarities, indicated by 
the brown colour.
D50497
U15098
U28927
U10096
L10362
X62314
X56661
L10072
Z11690
L05596
M93273
U37058
L10073
M31838
X63574
M88096
U40395
X05579
X15467
L08497
L31622
M34842
L02842
D32045
J03933
M36074
M14053
Z11716
M85035
L08493
U37101
Figure 4.19 Phylogenic tree showing the relationship between genes. The shorter branches 
indicate close similarity, whilst the longer branches (brown genes) indicate less similarity.
4.4.7 Q u a n t ita  t iv e  PCR
Quantitative PCR was carried out to achieve two separate aims. The first and 
most important reason was to determine whether the changes in gene 
expression predicted by the array were accurate. Secondly, this technique 
was used to determine whether the 2sd method or the t-test method of 
analysis (Sections 4.3.5.2 and 4.3.5.3) was better at highlighting relevant 
gene changes.
Q-PCR was carried out on five of the relevant genes shown in Table 4.11, and 
one housekeeping gene. The genes were chosen according to their potential 
biological significance, as well as the method by which they were highlighted.
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The genes were: a chloride channel protein (D50497), substance K receptor 
(M31838), vasopressin receptor (Z11690), neuronal acetylcholine receptor 
beta-2 subunit (L31622), granulocyte colony stimulating factor (U37101) and 
cytoplasmic p-actin (V01217). The chloride channel protein and the 
vasopressin receptor may both be involved in water transport and 
reabsorption, and both were highlighted by the t-test method. Substance K 
receptors have been implicated in bronchoconstriction of large airways and 
enhancement of vascular permeability. Granulocyte colony stimulating factor 
(GCS-F) has been shown to significantly increase alveolar cell recruitment 
and pulmonary oedema (Azoulay et a/., 2003). Both the substance K receptor 
and GCS-F were selected using the standard deviation (sd) method. The 
acetylcholine receptor was selected because it was identified by both 
methods. The housekeeping gene p-actin (V01217) was utilised because 
there appeared to be no change between saline and oedema samples.
After optimisation, the initial RT-PCR was partially successful, as illustrated in 
Figure 4.20.
LADDER V01217 D50497 L31622 M31838 Z11690 U37101
Figure 4.20 Agarose gel containing all the PCR product (50pl) of the six genes named above. 
Ladder: 1 kb made up of 100 bp graduations.
Of the six genes, five were entirely successful and were immediately 
processed to generate standards for Q-PCR. The faint band visible for GCS- 
F was eluted using Sigma GenElute agarose spin columns, and re-run 
through the PCR reaction. This resulted in a clear band, and was used to 
produce standards for Q-PCR.
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DNA sequencing confirmed that the recombinant clones contained the correct 
insert. These were then used to make up a series of standards for each 
gene. The standards were made to concentrations of 10fg, 100fg, 1 pg, 10pg, 
and 100pg. The standards and unknown samples for each gene were 
analysed on an Applied Biosystems ABI PRISM 7700 Sequence Detection 
System.
The PCR reactions for all genes were successful. The standard curves were 
of a high calibre (e.g. Figure 4.21), with the lowest R2 value equal to 0.92.
35  ----------- ----------------------------------------------------------------------------------
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Figure 4.21 Standard curve for the vasopressin receptor (Z11690). Standards for other 
genes are not shown.
The concentration of each gene in the samples was determined from the 
standard curves. The average concentration of the saline controls and the 
average concentration of the bleomycin treated samples were used to 
calculate a ratio change for each gene. The results are shown in Table 4.13 
and Figure 4.22.
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The correlation between the macroarray and Q-PCR predicted ratio change 
was generally very high. This was especially true for genes M31838 and 
U37101, both of which were highlighted by the standard deviation method.
Genbank ID Gene Array ratio Q-PCR ratio
D50497 Chloride channel protein 2.12 1.56
M31838 Substance K receptor -1 .71 -1 .64
Z11690 Vasopressin receptor -2 .1 0 -1 .13
L31622 Acetylcholine receptor -1 .9 9 -1 .87
U37101 GCS-F -1.51 -1.51
V01217 |3-actin 1.01 1.20
Table 4.13 Comparison between ratio predicted by the macroarray, and the ratio calculated 
from the Q-PCR data.
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Figure 4.22 Comparison between ratio change predicted by the macroarray (M ) and ratio 
change determined by the Q-PCR (A).
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4 .5  D is c u s s io n
4.5.1 M a c r o a r r a y  O p t im is a t io n
Optimisation of the macroarray procedure was successfully achieved by 
paying particular attention to the hybridisation solution and probe purification, 
but primarily by ensuring high quality RNA.
An essential requirement for any gene expression study is the production of 
good RNA samples. The ability to obtain conclusive and reproducible results 
from an array is limited by the purity of the starting material. This chapter has 
reviewed the development of the most suitable method for isolation of RNA 
from lung tissue, and the optimisation of the macroarray procedure.
Two RNA isolation procedures were investigated and the most suitable 
adopted for subsequent work. Both methods generated a relatively high, yet 
variable yield of RNA. This variability is due, in part, to the heterogeneity of 
the lung tissue. There are over 40 cell types within the lung and 
consequently, depending on the success of the lysis and homogenisation 
process, different levels of RNA will be released from each cell type. The 
phenol chloroform extraction resulted in a comparatively high concentration of 
RNA, but samples consistently contained genomic DNA contamination. 
Column purification resulted in a similar yield of RNA but with less 
contamination. Following the DNase treatment step, also on column, the 
purity of the sample was increased. These conclusions were supported by 
both agarose gel electrophoresis and GeneQuant analysis. These findings 
dictate that column purification of RNA, with additional DNase treatment, 
should be implemented in all subsequent research.
After the macroarray procedure was optimised, the consistency and quality of 
the array images was greatly improved.
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4.5.2 D a t a  N o r m a l is a t io n  a n d  A n a l y s is
To gain a more comprehensive understanding of the oedematous reaction in 
the lung, 18 rats were used for genetic analysis. This approach was chosen 
in preference to using replicate samples from one tissue source. Obtaining 
replicates from different biological samples results in increased random error, 
but the findings have better external validity and broader applicability (Nadon 
and Shoemaker, 2002). The variation in genetic expression may be due to 
inherent differences in animal response to treatment and day-to-day 
experimental variations. Initial normalisation of the data was performed to 
overcome these experimental differences. Biological variation was addressed 
by the number of sample replicates and the design of the normalisation and 
data analysis methods.
The range method of analysis was a good technique for determining 
significant genes from a limited number of samples. A small modification of 
this method may improve the robustness of the analysis. The mean of the 
three data points may not be the best value for calculating the ratios since one 
extreme value could skew the data. For further experimental analysis using a 
small number of replicates, the median or mid-range value should be used.
The range method was developed to include a statistical element, in the form 
of the standard deviation method. However, this was only appropriate with a 
larger number of replicates. The standard deviation method was a very 
stringent analysis method, where any gene that fell outside the two standard 
deviation limit was considered to be altered by the treatment to the 0.05 
significance level. Therefore, when the mean of all nine genes fell outside this 
control range, the gene was considered to be a reliable marker for oedema. 
Once the control data set had been established, individual samples could 
easily be assessed against it. As such, this approach had a good potential for 
clinical use, for example, screening of patients receiving bleomycin treatment.
The t-test was used to generate more statistical evidence of altered gene 
expression. This technique is appropriate for use on both small and large
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sample sets, but cannot be used to compare one individual sample against a 
control data set.
Navigator was a useful tool for visualising the global expression patterns by 
displaying the information in a graphical form. The data was shown according 
to the relative intensity ratio which resulted in all down-regulated genes being 
compressed to a region between one and zero (whereas up-regulated genes 
ranged from one to infinity). However, different representations can be 
utilised. A logarithmic scale could be used to plot the ratios and remove this 
imbalance. Navigator is most useful when studying the gene expression 
separated according to pathology. The biological effect of the oedema 
becomes more noticeable. The problem with this method was the limited 
number of exact duplicates these data produce, which reduces confidence in 
the data.
Spotfire provided a good visual interpretation of the array data, but no 
additional information was supplied. Some of the genes identified by a 
combination of these analysis methods are discussed below.
4.5.3 G e n e  C h a n g e s  O c c u r r in g  in  M il d  O e d e m a
A group of five up-regulated ion channels and trafficking proteins were 
identified as significant following bleomycin-treatment. Of these genes, three 
were chloride channels. These genes may be involved in movement of water 
molecules by active transport. Up-regulation could result in increased 
movement of water, an event which is likely to occur during oedema. In 
contrast, a vasopressin receptor (Z11690), which is involved in water 
reabsorption, was down-regulated by over two-fold. Vasopressin controls the 
resorption of water and regulates the osmotic content of blood. In the kidney 
it acts on the renal collecting ducts, increasing the permeability to water 
(Nielsen et a!., 1995). Therefore, in the lung, down-regulation of this gene 
may reduce cellular permeability. This could lead to increased water on the 
alveolar surface, which is known to occur during oedema. Mineralocorticoid 
receptors (M36074) are also involved in regulation of water balance via an
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effect on ion transport in the epithelium of the renal tubules. If a similar 
response occurs in the lung, down-regulation of this gene may lead to 
reduced movement of water away from the lung surface. This could again 
result in water accumulation in the alveolar spaces.
All of the remaining genes were down-regulated. Several of the hormone 
receptors appeared to be involved in the physiological response to oedema. 
The substance K receptor (M31838) and gastrin-releasing peptide receptor 
(X56661) affect smooth muscle constriction (Haley et at, 2001; Lach et a!., 
1993). Down-regulation could affect dilation of the conducting airways of the 
lung, which should increase the flow of air to the lungs. This would seem 
appropriate as the air spaces are covered by the oedematous fluid reducing 
the level of oxygen exchange. More direct links to oedema were unclear. 
Granulocyte colony stimulating factor (U37101) mediates the inflammatory 
response and is involved in the enhancement of vascular permeability 
(Sedgwick et a i,  2002). Gastrin-releasing peptide receptor (X56661) is 
implicated in vasodilation (Clive et a i,  2001). Conversely, the serotonin 
receptors (L05596, L10072, L10073), are involved in pulmonary vascular and 
airway constriction (Selig et a i,  1988); effects often observed during the 
inflammatory process. Alpha 1B adrenergic receptor (D32045) is also 
implicated in venule constriction (Leech and Faber, 1996). Glucocorticoid 
receptors (M 14053) are thought to be involved with anti-inflammatory 
responses (Walsh et al., 2003). Down-regulation could result in increased 
inflammatory responses, indicated by the elevated number of free cells in 
BAL.
4.5.4 Gen e  Clustering
Clusters of genes are more reliable as markers for a pathological reaction, as 
a single anomaly should not effect the successful identification of oedema. Of 
the 31 significant genes identified, five belonged to the ion channels and 
trafficking proteins family, all of which are up-regulated. The 25 genes 
classified as receptors included three genes encoding nuclear receptors 
(J03933, M36074, M14053) which were closely associated. Although it is not
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clear how these genes are related to oedema, as a cluster they were worth 
considering further.
The Phylogenic tree predictor (Tree Top) was used to determine the 
relationship between the genes. The genes were clustered in functionally- 
related families. A large group containing a number of hormone receptors 
and neurotransmitter receptors was identified. This contained several more 
tightly clustered groups. A number of specific hormone receptors were 
grouped into two clusters containing four genes each. A group of six genes 
encoding for four GABA-A receptors and two other hormone receptors was 
also identified. The substance K receptor and serotonin receptor were also 
clustered together, indicating a similar structure and function. However, the 
separation between these clusters was small and all these genes act in a 
similar manner to each other. The largest separation identified by Tree top 
was the group of genes encoding for the ion channels and trafficking proteins. 
As these genes behave in a different way to the majority of the altered genes 
(all up-regulated by approximately two-fold), this cluster of genes have 
potential as markers for early oedema.
4.5.5 Q-PCR
The changes in gene expression predicted by the macroarray were confirmed 
by Q-PCR. All of the genes tested showed an extremely high level of 
correlation, with the exception of the vasopressin receptor (Z11690). 
However, even in this case, the genetic response was shown to be down- 
regulated, which was in agreement with the change predicted by the array. 
The closest correlation was for the substance K receptor (M31838) and GCS- 
F (U37101) both of which were identified using the 2sd method. The gene 
encoding for the acetylcholine receptor (L31622) which was identified using 
both methods was also accurately predicted. This indicated that the 2sd 
method may be the best technique for identifying significant changes in 
genetic expression. Nevertheless, the t-test was also appropriate for 
selecting relevant genes, and may pick up some genes falsely discarded by
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the very stringent 2sd method. The most effective approach may be to 
combine these two techniques (Balharry et al., 2005).
4 .6  C o n c lu s io n s
In conclusion, the preliminary macroarray analysis has provided new 
transcriptional data on the mechanisms of the early events leading to 
pulmonary oedema following bleomycin treatment. High numbers of 
replicates (n=9) implies a good level of trust in the resulting data, and has 
been confirmed by Q-PCR. New methods have been developed for 
successful analysis of macroarray data. The t-test is a well established 
conventional method with recognised statistical significance. The standard 
deviation method is good for analysing groups of data. It can also be used to 
compare individual unknown samples against an established control range, 
which may be more practical in industrial/medical scenarios. The range 
method is a suitable alternative to the 2sd method for studies where obtaining 
a large number of replicates is not practicable.
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C h a pter  5:
A n a lysis  of T r a n sc r iptio n a l  C hanges
in
P er sisten t  a n d  S evere  O edem a
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5.1 I n t r o d u c t io n
The toxicological effect of bleomycin instillation into the rat lung has been 
studied using biochemical analysis of BAL fluid (Chapter 2) and histology 
(Chapter 3). These investigations showed that bleomycin produced different 
biological endpoints relating to both dose (single or double) and time post­
instillation.
A transient model of mild oedema resulted from a single bleomycin 
instillation. Utilising this model, the changes in mRNA expression during the 
onset of mild oedema (three days post-single instillation) have been identified 
(Chapter 4). The oedema persisted until seven days after instillation, 
whereupon the lung repair mechanisms began. After this time, the lung 
tissue rapidly returned to its normal state. In order to study this more 
persistent form of oedema, and some repair mechanisms, gene expression 
analysis was carried out on tissue seven days after a single bleomycin 
instillation.
Following a double bleomycin instillation, a model of severe oedema 
developed (Chapter 3). By using both toxicology and histology as tools for 
identifying oedema, the most significantly damaged tissue was identified at 
day three after the second instillation. As such, this time point was selected 
to profile gene expression changes during severe oedema.
Successful optimisation of the macroarray procedure and subsequent 
analysis (Chapter 4) resulted in clearly defined procedures which generate 
high levels of confidence in the gene expression data (Balharry et a i, 2005). 
This facilitated the objective of this study, which was to investigate altered 
gene expression in oedematous tissue in order to gain a better understanding 
of the genetic mechanisms underlying the disease state.
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5.2 M a t e r ia l s  a n d  M e t h o d s
5.2.1 M a t e r ia l s  a n d  S u p p l ie r s
All materials and suppliers are detailed in Section 4.2.1. A brief summary of 
the materials needed for RNA extraction and the array procedure are outlined 
below.
Supplier:
Qiagen, West Sussex
Materials:
RNeasy Mini kit (74104), QIAshredders 
(79654), RNase-Free DNase Set (79254)
Clontech, Oxford Atlas™ Rat 1.2 Macroarray (7854-1)
Amersham, Buckinghamshire [a-32P]dATP (10 pCi/mmol) (PB 10204)
Sigma-Aldrich, Dorset Salmon Testes DNA (9.5 mg/ml) (D7656)
Amersham, Buckinghamshire Storage Phosphor Screen (63-0034-89)
Clontech, Oxford Atlaslmage 2.0
The stock solutions required to carry out the array procedure are detailed in 
Section 4.2.2.1.
5.2.2 M e t h o d s
RNA was isolated (Sections 4.3.1.2 and 4.3.1.3) from lung tissue collected 
seven days after a single bleomycin instillation, and three days after a double 
bleomycin instillation. The array procedure was carried out as described in 
Section 4.3.2. The resulting data was normalised (Section 4.3.4), and 
analysed utilising the standard deviation method (Section 4.3.5.2) and a 
Student’s t-test (Section 4.3.5.3). Further analysis was carried out using 
phylogenic tree clustering (Section 4.3.8).
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5 .3  R e s u l t s
5.3.1 Relevant  Genes  Identified  D uring  Progressive  Oedema
5.3.1.1 S ta n d a rd  D e v ia tio n  a n d  T - t e s t  A n a ly s is
The quantitative data generated for each of the arrays by Atlaslmage 2.0 was 
analysed using the standard deviation method and a two-tailed t-test 
(Sections 4.3.5.2 and 4.3.5.3). Genes with a consistent change in expression 
were identified and limited to genes with a ratio change of over 1.5. The 
resulting list of relevant genes for persistent oedema (day seven, single 
instillation) is shown in Table 5.1.
Progressive oedema was studied using lung tissue taken seven days after a 
single intratracheal bleomycin instillation. In comparison to saline-treated 
tissue, 53 genes were identified as significantly altered in bleomycin-treated 
lung. With the exception of one gene, all genes were down-regulated. The 
candidate genes were assigned into five major functional groups (Figure 5.1), 
which included ion channel and trafficking proteins, kinases, metabolism 
proteins, hormones and growth factors, cytokines and chemokines. The main 
significant gene changes are outlined below:
• A group of ten genes encoding for ion channels and trafficking proteins 
(J03145, X74834, L77929, L39018, AF013598, M26643, M86621, 
X83580, X83583, L25264) were down-regulated by 1.6-fold on 
average. Ion channels have been shown to modulate the transport of 
fluid to and from the lung.
• A synapsin (M27925) and syntaxin (L20823) were both down-regulated 
by 1.6-fold. Synapsins encode for proteins involved in trafficking of 
molecules.
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Genbank ID Gene/Protein Name Ratio Genbank ID Gene/Protein Name Ratio
J03145 Glucose transporter protein ■ -1.51 M17523 Peptide YY precursor (PYY) □  -1.77
X74834 Serotonin receptor 3 □ -1.53 AFO10466 Interferon gamma precursor (IFN-gamma) -1.65
L77929 G-protein activated K+ inward rectifier ■ -1.52 U69272 Interleukin 15 (IL-15) -1.53
L39018 Sodium channel protein 6 □ -1.66 M64711 Endothelial 1 precursor □  -1.52
AF013598 Proton gated cation channel drasic □ -1.66 M69055 Insulin-like growth factor-binding protein -1.67
M26643 Skeletal muscle Na+ channel protein a subunit El -1.54 M88469 F-spondin precursor -1.51
M86621 Calcium channel, -type, a 2 subunit ■ -1.57 U03628 Arrestin C -3.63
X83580 K+ channel, inward rectifier 11 m -2.11 X58631 Tyrosine-protein kinase A -158
X83583 K+ channel-like protein, (3 cell m -1.59 U13396 Jak 2 tyrosine-protein kinase A -169
L25264 G-protein activated inward rectifier K+ channel 1 0 -1.51 L27112 c-jun N-terminal kinase 2 (JNK2) A -1.55
M27925 Synapsin 2A -1.60 L27128 c-jun N-terminal kinase 3 (JNK3) A -163
L20823 Syntaxin 2 (STX2) -1.60 M90661 Insulin receptor-related receptor-a A -1.64
J03577 Intrinsic factor precursor (INF) -1.50 U22296 Casein kinase 1 A -1.74
X54080 Cytochrome c oxidase, subunit Vila o -1.56 M16112 Calcium/calmodulin-dependent protein kinase A -1.60
L09216 Secretory glycoprotein-3 (GP-3) o -1.53 D26178 Serine/threonine kinase A -156
M33986 Cytochrome P-450 19 o -1.53 U23443 PAK-a serine/threonine kinase A -1.99
U60063 Aldehyde dehydrogenase 2 o -1.56 X60767 Cell division control protein 2 homolog (CDC2) A -2.26
M14053 Glucocorticoid receptor -1.95 D31838 Wee1 tyrosine kinase A -1.67
M96377 Non-processed neurexin ll-beta major -1.51 D89863 Ras-related protein m-ras -1.54
L35767 Very low-density lipoprotein receptor precursor -1.71 U12187 Ras associated with diabetes (RAD1) -1.53
X13722 Low-density lipoprotein receptor precursor -1.90 M17527 Adenylate cyclase-inhibiting G a protein -1.54
X66539 Tumour necrosis factor a precursor (TNF-a) • -1.57 Y14019 Rab-3b ras-related protein E3 -151
M36589 p-nerve growth factor precursor (p-NGF) • -1.55 M75153 Rab-11A □  -1.69
D64085 Fibroblast growth factor 5 (FGF5) • -1.66 M95780 G protein, gamma 5 subunit ■  -1.74
Z25868 Bone morphogenic protein 2 • -1.51 U18771 Rab26, ras reated GTPase □  -2.22
U25651 Phosphofructokinase 1 □ -1.63 X78605 Rab4B, ras related GTPase □  -1-55
U25684 Thymosin p-like protein □ 6.31
CJ
Table 5.1 Relevant genes (seven days, post single dose) highlighted using a combination of the 2sd method and a t-test. The major functional groupings are 
indicated: H! Ion channels and trafficking proteins, A  Kinases, O  Metabolism proteins, ^G rowth factors, cytokines and chemokines, [JHormones
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•  A group of four genes encoding for metabolism proteins (X54080, 
L09216, M33986, U60063) were altered by ratios of between -1.53 and 
-1.56.
• The only gene to be significantly altered at both three and seven days 
after a singe bleomycin instillation was encoding for a glucocorticoid 
receptor (M 14053). Glucocorticoids have been shown to modulate 
anti-inflammatory responses. At both time points this gene was down- 
regulated by approximately two-fold.
• Four genes classified as growth factors, cytokines and chemokines 
(X66539, M36589, D64085, Z25868) were down-regulated by 
approximately 1.6-fold. These genes have potential roles in the 
regulation of epithelial and endothelial cell proliferation.
• Peptide YY (M17523) plays an important role in regulating the 
secretion of fluids. This gene was down-regulated by 1.8-fold.
• Interferon gamma (AF010466) is a pro-inflammatory, pro-apoptotic 
protein, which was down-regulated by 1.7-fold.
• Interleukin 15 (U69272) was down-regulated by approximately 1.5-fold 
and is one of a large number of cytokines involved in the innate 
immune response.
• Endothelial 1 (M64711) is involved in vasoconstriction and was altered 
by -1.5-fold.
• The most down-regulated gene was encoding for arrestin C (U03628), 
which was altered by approximately four-fold. Arrestins mediate signal 
transduction.
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• The largest group of genes at this time point consisted of 11 genes 
encoding for kinases (X58631, U13396, L27112, L27128, M90661, 
U22296, M16112, D26178, U23443, X60767, D31838). These genes 
are involved in a number of signalling pathways including intracellular 
signalling, immune responses and cell cycle. On average, the kinases 
were down-regulated by approximately 1.7-fold.
• Six genes were identified that encode for ras-related proteins (D89863, 
U12187, Y14019, M75153, U18771, X78605). Ras proteins are 
involved in intracellular signal transduction and were down-regulated 
by approximately 1.6-fold.
• Only one gene was up-regulated in bleomycin-treated tissue. This 
gene was encoding for thymosin p-like protein (U25684) and was 
altered by 6.3-fold; the largest change observed at this time point. 
Thymosin proteins have been shown to have a stimulatory effect on 
immune responses.
5 .3 .1 .2  P h y l o g e n ic  Tr e e  C l u s t e r in g
Tree Top was used to cluster genes according to the homology between the 
gene sequences. This identified clusters of related genes which have similar 
sequence and function. The information was represented as a dendogram. 
The data for persistent oedema (day seven, single instillation) are shown in 
Figure 5.1.
There were several genes which were associated in pairs (Figure 5.1, clusters 
4, 6 and 7), but there were three large groups. The first cluster of eight genes 
(Figure 5.1, cluster 1) were encoding for six trafficking genes and two genes 
involved in metabolism. The second group of eight genes (Figure 5.1, cluster 
2) consisted of three potassium channels, four kinases and the intrinsic factor 
gene. The third main cluster (Figure 5.1, cluster 7) was made up of two
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growth factors and all five of the ras-related proteins. All the groups behaved 
in a similar manner, being down-regulated by approximately 1.6-fold.
J03145 1  
AFO13598  
X 74834  
M 16112  
U 23443  
M 33986  
U 60063  
M 27925 _ 
L77929 " 
U22296  
X 83580  
X58631  
X 83583  
L27112  
L27128  
J03577 -  
L39018  
M 26643  
M86621  
L25264 _
L20823  
X 60767  
D64085  
U12187 . 
X 54080  
L09216  
M 14053  
M 96377  
L35767 
X13722 
X 66539  
M 75153  
D 89863  
Y 14019  
X 78605  
M 69055  
U 18771 _ 
M 36589  
Z 25868  
U25651 
U 25684  
M 17523  
U 03628 _ 
AFO10466 
U 69272 _ 
M64711 
M 88469  
U 13396  
M 90661 
D 26178  
D 31838  
M 17527 
M 95780
Figure 5.1 Phylogenic tree clustering of relevant genes from seven days after a single 
bleomycin instillation.
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5.3.2 R e le v a n t  G en es Id e n tif ie d  D u r in g  S e v e re  Oedem a
5 .3 .2 .1  S ta n d a r d  D e v ia t io n  a n d  T -t e s t  A n a ly s is
Genes with a consistent change in expression were identified using the 
standard deviation method and a two-tailed t-test (Sections 4.3.5.2 and 
4.3.5.3). This list was then limited to genes with a ratio change of over 1.5. 
The resulting list of relevant genes for severe oedema (day three, double 
instillation) is shown in Table 5.2.
To study severe oedema, lung tissue was taken three days after a double 
intratracheal bleomycin instillation. In comparison to saline-treated tissue, 72 
genes were identified as significantly altered in bleomycin-treated lung. In 
contrast to the other time points studied, all genes were up-regulated. The 
candidate genes were assigned into six major functional groups (Figure 5.2) 
which included ion channel and trafficking proteins, kinases, metabolism 
proteins, hormones, exocytosis proteins and growth factors, cytokines, 
chemokines, as outlined below:
• A large number of ion channels and trafficking proteins were altered in 
the bleomycin-treated tissue. There were five potassium channels 
(M59980, X16476, X62841, U10096, J04629) and nine sodium 
channels (M22253, L19102, U28927, L13257, M85300, M85301, 
U10096, U10097, J04629). On average these genes were up- 
regulated by approximately two-fold.
• The exocytosis proteins included a synapsin (M27925) and syntaxin 
(L20823) which were altered by two-fold.
• Also included in this group of genes were two synaptotagmins 
(AF000423, L38247). Two similarly related genes were the genes 
encoding for the secretogranins (M93669, U02983) which were up-
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regulated by over 2.5-fold. These four genes are involved in the 
formation and release of synaptic vesicles.
• Included in the receptor family were two P2Y purinoceptors (U22830, 
D63665) which were up-regulated by approximately two-fold. These 
proteins may modulate the function of ion channels.
• This group of receptor genes also includes a heat-stable enterotoxin 
receptor (M55636). This gene is thought to regulate salt and water 
transport and was altered by approximately two-fold.
• A group of ten growth factors, cytokines and chemokines (M32748, 
L15305, M60525, U00620, D32207, AF014827, D10763, D64085, 
M22427, X55183) were all significantly altered in bleomycin-treated 
tissue. These genes are thought to affect a number of epithelial and 
endothelial alterations. On average, the growth factors, cytokines and 
chemokines were up-regulated by approximately three-fold.
• The group of five genes encoding for hormones included peptide YY 
(M17523) and preprolactin (AF022935). These genes were up- 
regulated by approximately 2.5-fold and are thought to have an effect 
on osmoregulation.
• Also in the group of hormones was the gene encoding for vasoactive 
intestinal peptide (X02341). The receptor for this hormone (U09631) 
was also up-regulated. These genes are thought to have an effect on 
immune responses.
• Interleukin 1 (M98820) affects a pro-inflammatory response and was 
altered by 2.5-fold.
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Genbank ID Gene/Protein Name Ratio
M34097 natural killer (NK) cell protease 1 1.84
M22253 sodium channel I □ 1.56
M59980 voltage-gated K+ channel protein □ 2.03
X16476 potassium channel drk1, delayed rectifier □ 2.23
X62841 potassium channel □ 1.96
X61394 calcium channel, beta subunit, brain □ 2.31
D63834 monocarboxylate transporter M C T1 □ 2.45
L19102 sodium dependent sulfate transporter □ 2.86
U28927 Na+/CI- betaine/GABA transporter □ 1.58
L13257 sodium/phosphate cotransporter 2 □ 2.24
M85300 sodium/hydrogen exchange protein 3 □ 1.66
M85301 sodium/hydrogen exchange protein 4 □ 2.19
M95762 gamma-aminobutyric acid (GABA) transporter 2 m 3.13
U 10096 sodium-potassium-chloride cotransporter □ 2.24
U 10097 sodium/chloride cotransporter m 2.43
J04629 sodium/potassium-transporting ATPase beta 2 subunit □ 1.57
U08344 ATPase, copper-transporting, Menkes protein □ 1.94
L05435 synaptic vesicle protein 2 (SV2) □ 1.93
M97381 synaptic vesicle amine transporter (SVAT) □ 2.07
AF007775 aquaporin (AQP 8) m 1.61
U77971 urea transporter □ 1.61
U89529 fatty acid transport protein □ 2.36
L19031 organic anion transporter □ 2.07
U67958 urate transporter/channel □ 2.29
M27925 synapsin 2A o 1.92
L20823 syntaxin 2 (STX2) o 2.79
AF000423 synaptotagmin XI; membrane trafficking protein o 1.53
AF007836 Rab3 effector in synaptic-vesicle fusion o 1.57
L38247 synaptotagmin IV (SYT4) □ 1.86
M93669 secretogranin II precursor (Sg2) □ 2.60
M35991 fatty acid-bindinq protein 1.96
U09631 vasoactive intestinal polypeptide receptor 2 precursor (VIP-R-2) ▲ 1.93
X57514 GABA-A receptor, gamma 1 subunit □ 2.88
L08491 GABA receptor alpha 2 subunit precursor □ 2.50
M61099 metabotropic glutamate receptor 1 precursor A 3.24
M92076 glutamate receptor, metabotropic 3 A 1.88
U22830 P2Y purinoceptor A 1.91
Table 5.2 Relevant genes (three days post double dose) highlighted using a combination of the 
2sd method and a t-test. The major functional groupings are indicated:
B Ion channels and trafficking proteins, A Kinases, OExocytosis proteins,
•  Growth factors, cytokines and chemokines, Q  Hormones, AReceptors
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Genbank ID Gene/Protein Name Ratio
D63665 P2Y purinoceptor 6 ▲ 2.19
M55636 heat-stable enterotoxin receptor precursor A 2.29
M94555 neuromedin U-23 precursor (NMU-23) 2.26
M32748 leukemia inhibitory/cholinergic neuronal differentiation factor • 2.36
L15305 glial cell line-derived neurotrophic factor precursor • 2.99
M60525 VGF8A protein precursor • 2.64
U00620 granulocyte-macrophage colony-stimulating factor (GM-CSF) • 3.08
D32207 trombopoietin • 3.22
AF014827 vascular endothelial growth factor D (VEGF-D) • 2.34
D10763 erythropoietin precursor (EPO) • 2.19
D64085 fibroblast growth factor 5 (FGF5) • 2.22
M22427 basic fibroblast growth factor (bFGF) • 4.06
X55183 growth factor, schwannoma-derived • 3.16
M 36804 follicle stimulating hormone beta-subunit □ 2.54
M 17523 peptide YY precursor (PYY) □ 2.35
X02341 vasoactive intestinal peptide □ 2.72
AF022935 preprolactin (Prl) □ 2.80
M54987 corticotropin-releasing hormone □ 3.16
M98820 interleukin 1, beta 2.52
U10071 cocaine/amphetamine-induced rat transcript (CART) 2.39
X58023 corticotropin-releasing factor binding protein 1.71
U02983 secretogranin 3 (Sg3) □ 2.91
X57986 cAMP-dependent protein kinase catalytic subunit A 2.01
L29281 Initiation factor-2 kinase A 3.36
L27128 c-Jun N-terminal kinase 3 (JNK3) A 1.84
X07286 protein kinase C alpha type (PKC-alpha) A 1.87
X07287 protein kinase C gamma type (PKC-gamma) A 1.99
X07320 phosphorylase kinase, gamma subunit A 2.07
U63971 rhodopsin kinase A 2.31
AB005541 serine/threonine kinase PCTAIRE3 A 2.43
U28356 protein-tyrosine phosphatase A 1.91
X06889 Rab-3a ras-related protein □ 1.67
X06890 Rab-4a ras-related protein □ 8.20
X67241 guanine nucleotide release/exchange factor (GNRP) 2.27
U07798 14-kDa phospholipase A2 precursor (PLA2) A 2.21
Table 5.2 continued:
H  Ion channels and trafficking proteins, A  Kinases, OExocytosis proteins,
•  Growth factors, cytokines and chemokines, \Z\ Hormones, AReceptors
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• Kinases were altered in the bleomycin-treated tissue by approximately 
two-fold. These genes have been implicated in the control of cell-cycle 
and apoptosis.
• Two ras-related genes (X06889, X06890) were up-regulated at this 
time point. Rab3a (X06889) had an over eight-fold increase in 
expression, making it the most altered gene at all of the time points. 
These genes have an effect on endocytosis and exocytosis.
• Phospholipase A2 (U07798) precursor was shown to be altered in 
bleomycin-treated tissue by two-fold. This protein is involved in 
regulating inflammatory reactions.
5.3.2.2 P h y l o g e n ic  Tr e e  C l u s t e r in g
The Phylogenic tree predictor (Tree Top) was used to determine the 
relationship between the genes. The genes were clustered in functionally 
related groups. The information for severe oedema (day three, double 
instillation) is represented as a dendogram shown in Figure 5.2. There were a 
large number of genes which were associated in small groups (Figure 5.2, 
clusters 3, 4, 5, 6, 7, 8, 10, 11 and 12), but there were four main groups 
(Figure 5.2, clusters 1, 2, 9 and 13). Of these groups, two appeared to be 
more significant. The first cluster consisted of eight genes (Figure 5.2, cluster 
1), six of which were encoding for ion channels and trafficking proteins. The 
second group of six genes (Figure 5.2, cluster 2) was made up of a growth 
factor and five ion channels and trafficking proteins. These groups were 
considered to be potentially more significant than the other clusters because 
they could be related to changes occurring in the early oedema model (three 
days after a single bleomycin instillation).
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Figure 5.2 Phylogenic tree clustering of relevant genes from three days after a double 
bleomycin instillation.
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5.3.3 Comparison o f  Gene Changes in P rog ress ive  versus Severe
Oedema
During both progressive (seven days after a single dose) and severe (three 
days after a double dose) oedema the expression of a large number of genes 
was significantly altered in bleomycin-treated tissue. Some of the similarities 
and differences between these genes are highlighted below.
• Large groups of genes encoding for ion channels and trafficking 
proteins were significantly altered in bleomycin-treated tissue of both 
progressive and severe oedema. These genes may be linked to the 
maintenance of fluid balance in the lung. During progressive oedema 
these genes were all down-regulated, whilst in severe oedema they 
were all up-regulated.
• The two exocytosis genes synapsin (M27925) and syntaxin (L20823) 
were significantly altered in both progressive and severe oedema. 
These genes are believed to be involved in signal transduction. Again, 
during progressive oedema these genes were down-regulated by 1.6- 
fold, whilst in severe oedema they were up-regulated by two- to three­
fold.
• Genes encoding for growth factors, cytokines and chemokines were 
present at both time points. These genes have been indicated in the 
regulation of epithelial and endothelial cell cycle. During progressive 
oedema these genes were all down-regulated, whilst in severe oedema 
they were all up-regulated.
• The gene encoding for fibroblast growth factor 5 (D64085) was 
detected at both time points. FGF has been shown to affect 
proliferation of epithelial and endothelial cells. As seen with the other 
growth factors, this gene was down-regulated by 1.7-fold during
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persistent oedema, but was up-regulated by four-fold in severe 
oedema.
• Peptide YY (M 17523) was found to be down-regulated in bleomycin- 
treated tissue taken seven days after a single instillation. In contrast, it 
was up-regulated in bleomycin-treated tissue from three days after a 
double dose. Peptide YY may be involved in osmoregulation.
• During progressive oedema, interleukin-15 (U69272), which is a pro- 
inflammatory cytokine, was down-regulated by 1.5-fold. Conversely, in 
severe oedema, interleukin-1, which is also pro-inflammatory, was 
found to be up-regulated by 2.5-fold.
• At both time points, ten genes encoding for various kinases were 
significantly altered. Kinases are involved in a large number of 
signalling mechanisms. Unlike the kinases which were down-regulated 
seven days after a single instillation, the kinases at three days after a 
double dose were all up-regulated.
• The gene encoding for C-jun N-terminal kinase 3 (L27128) was 
detected at both time points. This kinase is involved in pro-apoptotic 
responses. This gene was down-regulated seven days after a single 
bleomycin dose, but up-regulated three days after a double dose.
• During progressive oedema, six ras-related genes (D89863, U12187, 
Y14019, M75153, U18771, X78605) were down-regulated by roughly 
1.5-fold. However, in severe oedema two different ras-related genes 
(X06889, X06890) were up-regulated by 1.7-fold and over eight-fold. 
These proteins have been implicated in trafficking of small molecules.
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5.3.4 Comparison of Gene  Changes in M ild versus Progressive
and  Severe Oedema
There were few similarities between the families of genes that were altered 
during all three stages of oedema. However, there appeared to be several 
specific genes which were consistent:
• At all three time points a number of ion channels and trafficking 
proteins were altered. In both mild and severe oedema (three days 
after a single or double dose of bleomycin) these genes were 
consistently up-regulated by approximately two-fold.
• The gene encoding for a Na+/CI- betaine/GABA transporter (U28927) 
was up-regulated by approximately 1.6-fold in both mild and severe 
oedema.
• The gene encoding for a glucocorticoid receptor (M 14053) was 
consistently down-regulated by approximately 1.9-fold in both mild and 
progressive oedema.
143
Analysis of Transcriptional Changes in Persistent and Severe Oedema
5 .4  D is c u s s io n
Following successful optimisation of the macroarray procedure, protocols for a 
simplistic analysis of the arrays were established (Chapter 4). These
techniques were applied to two sample groups from the model of bleomycin-
induced pulmonary oedema: seven days after the single instillation, which 
represented progressive injury, and three days after the double instillation 
which represented severe injury.
5.4.1 P ro g re ss ive  Oedema
The large group of genes encoding for ion channels and trafficking proteins 
contained a number of potassium channels (L77929, X83580, X83583, 
L25264). Potassium channels in the epithelium play an essential role in 
electrolyte and fluid transport by regulating fluid clearance from the lung 
(O’Grady and Lee, 2003). Similarly, the two sodium channels (L39018, 
M26643) are involved in movement of sodium ions across the alveolar 
epithelium. This creates an osmotic force leading to re-absorption of alveolar 
fluid (Matalon et a/., 2002). Down-regulation of these six genes could result in 
increased fluid in the alveolar space, an event which is likely to occur during 
oedema. However, a previous study has shown that fluid clearance was 
increased despite down-regulation of alveolar sodium channels (Folkesson et 
a/., 1998).
Closely related to the trafficking proteins are a synapsin (M27925) and 
syntaxin (L20823). Synapsins encode for proteins involved in the regulation 
of neurotransmitter release. These phosphoproteins are widely distributed in 
nerve terminals and coat synaptic vesicles which can then bind to the 
cytoskeleton (Sudhof et al., 1989). Similarly, the syntaxins affect the docking 
of synaptic vesicles with the presynaptic membrane by acting as receptors 
(Bennett et al., 1993). The alteration in expression of these genes may affect 
signal transduction.
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The group of four genes encoding for metabolism proteins included 
Cytochrome c oxidase, which is one of the key functional and regulatory sites 
of energy metabolism. Subunit Vila (X54080) is nuclearly encoded and 
involved in the assembly and regulation of this enzyme (Kadenbach et al., 
1991). This implies that reduced expression of the Vila gene could result in 
reduced cytochrome c oxidase activity. In a previous in vitro study, partial 
inactivation of cytochrome c oxidase has been implicated in increased 
apoptosis (Das et al., 2001). This may be occurring in the damaged lung 
tissue; as evidenced by the destruction of alveolar architecture revealed by 
the TEM images (Chapter 3). The cytochrome P450 (M33986) family are 
involved in metabolism of a large number of compounds, including foreign 
compounds, xenobiotics and other toxicants. Cytochrome P450 oxidises the 
xenobiotic, converting it into a more water-soluble derivative that is easier to 
excrete (Gonzalez, 2005). Down-regulation of this gene could potentiate the 
effect of the damage being caused by the bleomycin. Not only would 
bleomycin remain active, but any toxicants entering the alveoli due to the 
damage at the lung surface may not be effectively excreted.
The small family of growth factors, cytokines and chemokines included a gene 
encoding for tumour necrosis factor alpha (TNF-a). TNF-a (X66539) is a 
cytokine which plays a significant role in inflammation and the immune 
response (Grunfeld and Palladino, 1990). It is also involved in a number of 
cellular activities including differentiation and apoptosis (Leong and Karsan, 
2000). The influence of TNF-a can be either pro- or anti-apoptotic, dependant 
on the nature of the stimulus (Sanlioglu et al., 2004). Therefore, it is not 
possible to establish the effects of this gene in the bleomycin-treated tissue 
without further study.
TNF -a has also been linked to increased vascular permeability by either 
altering endothelial cell morphology, or by enhancing neutrophil-mediated 
cytotoxicity (Turnage et al., 2002). Down-regulation of this gene may result in 
decreased vascular permeability, which is a potential candidate for a repair 
mechanism. Two growth factors, beta-nerve growth factor (p-NGF) and
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fibroblast growth factor (FGF) were within this group of four genes. NGF 
(M36589) has been shown to promote epithelial cell proliferation in the eye 
(You et al., 2000). Similarly, FGF (D64085) affects proliferation and 
differentiation of epithelial and endothelial cells (Warburton and Bellusci, 
2004). The fourth gene in this group encodes for bone morphogenic protein 
(Z25868). This protein has been shown to induce the formation of epithelial 
cells (Zeisberg et al., 2005). It was considered that if the effects of growth 
factors and bone morphogenic protein were consistent in lung tissue, then 
perhaps this would decrease levels of lung epithelial proliferation.
The hormone peptide YY (M17523) plays an important role in regulating 
gastrointestinal secretion of fluids (El-Salhy et al., 2002). This protein inhibits 
the secretion of fluid and electrolytes, whist stimulating their absorption in the 
intestine (Mannon and Taylor, 1994). If a similar effect occurs within the lung, 
inhibited expression may result in increased secretion of fluids and reduced 
absorption. This in turn could increase the levels of fluid in the lung, as 
observed during oedema.
Interferon gamma (AF010466) has an inhibitory effect on cellular proliferation, 
and has been shown to induce apoptosis (Dai et al., 1998). The effect of 
down-regulation of this gene may be to increase cellular proliferation and 
reduce apoptosis; mechanisms that could be linked to repair of the lung 
tissue. Interleukin 15 (U69272) is one of a large number of cytokines involved 
in the innate immune response. It stimulates natural killer (NK) cells, T- and 
B-cell proliferation and cytokine secretion (Yoshikai and Nishimura, 2000). 
Down-regulation of this gene could result in reduced inflammatory responses; 
although throughout the progressive oedema model, inflammatory responses 
appeared to be increased. Endothelial 1 (M64711) is secreted by endothelial 
cells and is involved in vasoconstriction (Yanagisawa et al., 1988). 
Constriction of pulmonary vasculature is often observed during the 
inflammatory process. Down-regulation of Endothelial 1 could potentially 
combat this effect.
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Arrestin C (U03628) was the second most highly altered gene at this time 
point. Arrestins mediate signal transduction by regulating G-protein-coupled 
receptor (GPCR) signalling. These proteins bind with most activated GPCRs, 
and prevent G-protein/receptor interaction, resulting in uncoupling of the 
receptor. One of the strongest associations is between arrestin and 
vasopressin receptors (Stalheim et al., 2005). Reduction in the levels of 
arrestin may increase vasopressin activity, leading to reabsorption of water 
(Nielsen et al., 1995). This would represent another step towards reinstating 
normal lung function.
The large group of kinases included two tyrosine-protein kinases (X58631, 
U13396), which are involved in a number of pathways including intracellular 
signalling (Foster, 1993), immune responses (Mustelin and Burn, 1993) and 
cell cycle. These kinases are involved in pathways which promote
progression through the cell cycle and inhibit apoptosis (Tallett et al., 1996). 
Down-regulation of these genes may cause damage to the epithelium, as 
observed at this time point, by reducing cell proliferation and inducing
apoptosis. C-jun N-terminal kinases 2 and 3 (JNK2, JNK3) are involved in the 
transcription of pro-apoptotic genes (Gelderblom et al., 2004) and induction of 
programmed cell death (Kanda and Miura, 2004). Down-regulation of JNK2 
and JNK3 (L27112, L27128) could result in reduced cell death. This may be a 
defence mechanism in response to the destruction of the lung tissue due to 
bleomycin treatment. Casein kinases (U22296) are involved in many cellular 
processes. These include membrane transport and DNA repair pathways, 
induction of cell division and delaying apoptosis (Knippschild et al., 2005). 
Cell proliferation is mediated by a number of proteins, including 
calcium/calmodulin-dependant kinases (CaMK) and cell division control 
protein 2 (CDC2). Progression through Gi and from G2 to M phase of the cell 
cycle is dependant on CaMK (M16112) (Kahl and Means, 2003). The
transition from the G2 to M phase can also be activated by a CDC2
(X60767)/cyclin complex (Black, 2000). Reduced expression of the casein 
kinase, CaMK and CDC2 genes might result in reduced cellular proliferation 
and increased apoptosis. There is a possibility that these mechanisms were 
occurring in the bleomycin-treated tissue, as indicated by the destruction of
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the normal lung architecture. Conversely, Wee1 kinase (D31838) delays 
entry into mitosis (Kellogg, 2003); therefore down-regulation of this gene may 
promote cellular proliferation. This could be yet another feature of the repair 
mechanisms.
A small group of ras-related proteins (D89863, U12187, Y14019, M75153, 
U18771, X78605) was also identified. Ras proteins are small regulatory GTP- 
binding molecules involved in intracellular signal transduction (Hall, 1990). 
The ras-related proteins (D89863, U12187) play an essential role in regulating 
some of the physical exchanges between a cell and its environment, including 
endocytosis and exocytosis (Chardin, 1988). In particular, ras-related rab 
proteins (Y14019, M75153, U18771, X78605) have been implicated in 
intracellular trafficking of vesicles (Rosenfeld e ta l., 2002).
The most altered gene expression during progressive oedema was encoding 
for thymosin p-like protein (U25684). Thymosin proteins have a stimulatory 
effect on immune responses by modulating the activity of cytokines and 
chemokines (Goldstein and Badamchian, 2004). In this instance, up- 
regulation could result in increased immune responses; an event which 
appeared to be confirmed by the influx of inflammatory cells to the lung 
(Section 2.4.1). There was also evidence that cells showing increased 
expression of thymosin p4 have a greater resistance to apoptosis (Iguchi et 
al., 1999). This may be a response to the injury and represent another 
possible step toward repair.
The glucocorticoid receptor (M14053) was the only gene to be significantly 
altered during both mild (Chapter 4) and progressive oedema. Down- 
regulation of this gene may result in increased inflammatory responses similar 
to those observed in this study (Section 2.4.1).
Using the phylogenic tree predictor (Tree Top), three large groups of genes 
were detected. All the groups behaved in a similar manner, and as such, any 
one of these gene clusters could act as potential markers for progressive
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pulmonary oedema. Unfortunately, at this stage, none of the clusters 
appeared to correlate with the clusters found at the early stages of oedema, 
i.e. three days after a single dose. This might be due to the increased level of 
repair-related gene changes. The only consistent gene was encoding for a 
glucocorticoid receptor which was down-regulated by about 1.9-fold at both 
three and seven days after a single bleomycin dose.
5.4.2 Severe Oedema
Similar to both mild and progressive oedema, a large number of ion channels 
and trafficking proteins were altered in the bleomycin-treated tissue. As 
previously discussed, these ion channels play a role in fluid reabsorption, 
therefore their up-regulation may result in increased fluid clearance from the 
lung; an event which is likely to occur in response to oedema. One of these 
genes encoded for a Na+/CI- betaine/GABA transporter (U28927), which was 
also up-regulated three days after a single bleomycin dose (mild oedema). 
Betaine is an osmolyte used by plants, invertebrates and vertebrates to 
compensate for hypertonic stress (Petty and Lucero, 1999). The up- 
regulation of this gene could possibly be a response to the increased fluid on 
the lung, as observed during oedema. An aquaporin was also altered in 
bleomycin-treated tissue. In a similar manner to the other ion channels, the 
up-regulation of this gene might result in increased movement of water, in an 
attempt to equilibrate the osmotic pressure (Verkman and Mitra, 2000).
Closely related to the ion channel and trafficking proteins are the exocytosis 
proteins. These include a synapsin (M27925) and syntaxin (L20823) which 
were also significantly altered in the progressive oedema model (seven days 
after a singe dose). The effects of changes in expression of these genes 
have been discussed in Section 5.4.1. Also included in this group of genes 
are two synaptotagmins (AF000423, L38247). These proteins are involved in 
signal transduction by stimulating the release of synaptic vesicles (Sudhof, 
2004). Two similarly related genes are those encoding for the secretogranins 
(M93669, U02983). Secretogranins contribute to the formation of secretory 
vesicles and also have the ability to form ion channels (Taupenot etal., 2003).
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In a similar fashion to the synapsin and syntaxin, alteration in expression of 
synaptotagmins and secretogranins could effect signal transduction.
A number of receptors showed increased gene expression in bleomycin- 
treated tissue. These included two P2Y purinoceptors which belong to a 
family of G-protein-coupled receptors. These proteins may modulate the 
function of ion channels (Lee and O’Grady, 2003). P2Y purinoceptors have 
been shown to affect an increase in epithelial fluid (Leipziger, 2003), as 
observed during oedema. The heat-stable enterotoxin receptor (M55636) is 
believed to regulate salt and water transport in the intestine (Vaandranger, 
2002). Should the same effect occur in the lung, up-regulation may lead to an 
increase in fluid on the alveolar surface.
A large group of genes encoding for growth factors, cytokines and 
chemokines were all significantly altered in bleomycin-treated tissue. Glial 
cell line-derived neurotrophic factor (GDNF) has been shown to promote 
epithelial cell proliferation in the eye (You et al., 2000). Up-regulation of the 
GDNF (L15305) gene may stimulate epithelial repair. Granulocyte- 
macrophage colony-stimulating factor (GM-CSF) was another of the genes 
classed with this group. Excess phospholipid and protein on the lung can be 
ablated by increased GM-CSF (U00620), owing to its effect on alveolar 
macrophages (Trapnell and Whitsett, 2002). It has also been shown to 
modulate proliferation of the lung epithelium (Huffman Reed et al., 1997). 
Both these effects of GM-CSF could be related to potential repair 
mechanisms. Vascular endothelial growth factor (VEGF) plays an important 
role in regulating vascular permeability in a number of organs (Mura et al., 
2004). Elevated levels of VEGF (AF014827) are strongly related to increases 
in capillary leak (Thickett et al., 2002). In the lung tissue samples, VEGF was 
over two-fold higher in the damaged tissue, which may have led to increased 
breakdown of the endothelial/epithelial barriers and increased fluid on the lung 
surface. Erythropoietin (EPO) is a multifunctional cytokine that has potent 
tissue-protective activity. These effects are governed in part by the inhibition 
of apoptosis and restoration of vascular auto-regulation (Brines et al., 2004). 
Up-regulation of EPO may result in reduced apoptosis and restoration of the
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damaged vasculature observed during oedema. FGF was up-regulated at 
this time point, compared to down-regulation at seven days post-instillation of 
a single bleomycin dose. The effects of FGF (D64085) have been described 
previously. The up-regulation of this gene could result in increased 
proliferation of epithelial and endothelial cells. The most effected of the 
growth factors was basic FGF (bFGF), with a four-fold up-regulation in gene 
expression. Increases in bFGF (M22427) could lead to increased endothelial 
proliferation and differentiation (Yayon and Klagsbrun, 1990). Thus, the 
effects of FGF and bFGF may also be involved in the potential repair 
mechanisms.
Within the group of hormones, peptide YY (M 17523) was found to be down- 
regulated in bleomycin-treated tissue taken seven days after a single 
instillation. In contrast, it was up-regulated in bleomycin-treated tissue from 
three days after a double dose. Increased levels of peptide YY could lead to 
increased reabsorption of fluid from the lung, acting as a potential repair 
mechanism. The hormone vasoactive intestinal peptide (VIP) and its receptor 
(U09631) are thought to have an influence on a variety of immune responses 
(Bellinger et al., 1996). The increased inflammatory response is evidenced by 
the large influx of free cells to the lung. VIP (X02341) is also implicated in 
liquid secretion (Ballard and Inglis, 2004). Again, the up-regulation of this 
gene may result in increased liquid on the lung. Preprolactin (AF022935) is a 
precursor to prolactin, which has been shown to have osmoregulatory effects 
(Robertson, 1989) and elevated levels may result in increased fluid on the 
lung surface. However, prolactin has also been implicated in epithelial cell 
differentiation in the skin (Paus, 1991), which is more likely to form part of the 
repair mechanisms.
Interleukin 1 (IL-1) mediates a potent pro-inflammatory response, including 
the activation of neutrophils (Tanabe et al., 2005). The up-regulation of IL-1 
(M98820) causes an increase in inflammation, which coincides with the 
increased number of inflammatory cells in BAL at this time point.
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Similar to progressive oedema, a large number of kinases were altered in the 
bleomycin-treated tissue. Modulation of pro-inflammatory responses is known 
to be one of the effects of the cAMP-dependant protein kinase (X57986) 
(Panettieri, 2002). Up-regulation of this gene might cause an increased 
inflammatory response. Initiation factor-2 Kinase plays an important role in 
the control of cell growth and survival (Kaempfer, 2003). Activation of this 
kinase can induce apoptotic cell death (Clemens, 2004). JNK3 (L27128) was 
altered during both progressive and severe oedema; the effects of JNK 3 
were previously described in Section 5.4.1. The two isoforms of protein 
kinase C (PKC) have a distinct role in the regulation of cell cycle. Over­
expression of these genes can attenuate cellular proliferation (Zhou and 
Hershenson, 2003). Up-regulation of initiation factor-2 kinase, JNK3 and the 
PKC (X07286, X07287) isoforms could lead to impaired cell growth and 
increased apoptosis; events which appear to have taken place as evidenced 
by the large scale destruction of the alveolar architecture.
A number of ras-related genes were differentially expressed in the model for 
progressive oedema (seven days, single instillation). During this model for 
severe injury, two different ras-related genes (X06889, X06890) were altered. 
Changes in expression of these genes may have an effect on endocytosis 
and exocytosis.
A 14-kDa phospholipase A2 (PLA2) precursor was shown to be significantly 
altered in bleomycin-treated tissue. This 14-kDa isoform of PLA2 (U07798) is 
a secretory protein which is involved in signalling pathways involving 
inflammatory reactions (Niessen et al., 2003). The up-regulation of this gene 
could result in increased inflammatory responses, which were observed 
during this study.
The phylogenic tree predictor (Tree Top) was used to identify clusters of 
genes. There were four large groups, of which two were of particular interest 
because they were similar to a cluster occurring in the early oedema model 
(three days after a single bleomycin instillation). Although the specific genes 
in these clusters varied between the two time points, the behaviour of the
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genes as a group was very similar. As such, these clusters, both consisting 
mainly of ion channels and trafficking proteins, could act as potential markers 
for mild and severe pulmonary oedema.
5 .5  C o n c l u s io n s
During progressive oedema (seven days after a single bleomycin dose), a 
number of changes in gene expression were observed. Whilst a large 
proportion of these were related to cellular signalling, a number of the 
changes could be linked to oedema and inflammation. There was also 
evidence pointing to some potential repair mechanisms, such as reduced 
apoptosis and increased cellular proliferation.
In the severe oedema model (three days after a double bleomycin dose), a 
greater number of changes in gene expression were observed. Similar to 
progressive oedema, a large proportion of these were related to cellular 
signalling and a number of the changes could also be linked to oedema and 
inflammatory responses. Contrary to the thymidine uptake assay, which 
indicated that there was no significant increase in cellular turnover at this time 
point, some potential repair mechanisms were noted. A number of gene 
products could be related to reduced apoptosis and/or increased cellular 
proliferation. These repair mechanisms may be a continuation of processes 
that were induced earlier during the time course of the bleomycin treatment.
Five genes were consistent across progressive and severe oedema. 
However, in every case the genes were down-regulated during progressive 
oedema and up-regulated during severe oedema. Consequently, these 
genes were not useful as markers for pulmonary oedema.
There was more consistency when comparing the mild oedema model to the 
severe model. The cluster of ion channels and trafficking proteins were 
consistently up-regulated during both mild and severe oedema. The 
relationship between these two stages of injury could be linked to the early
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phase of oedema, as both the mild and severe models are three days post 
dosing (either single or double instillation). Although there were no genes 
which were considered relevant during all three stages of injury, there were 
two genes which appeared over two time points. The gene encoding for a 
Na+/CI- betaine/GABA transporter appeared during mild and severe oedema. 
The glucocorticoid receptor gene was consistently altered during both mild 
and progressive injury. Therefore, these single genes may be the best 
potential biomarkers of oedematous injury.
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6.1 In t r o d u c tio n
The discovery of novel proteins provides new opportunities for development of 
drug therapies. In particular, secreted and transmembrane proteins have 
properties that lend themselves to being used as therapeutic agents or targets 
(Clark et a/., 2003). The cysteine-rich secreted protein (CRISP) family is a 
large group of secreted proteins that function in some invertebrates, insects 
and plants as venoms and toxins. Several non-venomous family members 
have previously been described, although the function of these proteins is 
largely unknown (Smith et al., 2001). One of these proteins is known as 
cocoacrisp (CC). The function of CC is still under investigation, however the 
sequence and structure is well defined (Figure 6.1).
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Figure 6.1 Sequence homology map for cocoacrisp (NCBI) showing SCP module and two 
LCCL domains.
Cocoacrisp contains an SCP module which is found in many species of 
secretory proteins, including the CRISP family (Ookuma et al., 2003). The 
main characteristic of this protein is the presence of two LCCL domains. The 
LCCL domain was first identified in Limulus factor C from the horse-shoe 
crab. The key functional aspect of this protein is its sensitivity to 
lipopolysaccharide (LPS) endotoxin. Binding of LPS to factor C initiates a 
host defence mechanism, protecting the organism from infection. It is thought 
that the LCCL domain may be involved in the binding of LPS (Trexler et al., 
2000). Another protein known to contain the LCCL domain is the late 
gestation lung protein, Lgl1. Lgl1 is involved in lung maturation, and like CC it 
contains two LCCL domains. Increased expression of Lgl1 has been shown 
to coincide with the production of surfactant (Kaplan et al., 1999). Similarly to 
factor C, surfactant proteins SP-A and SP-D bind LPS and therefore play an 
important role in the innate immune response. The increase in Lgl1 could
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induce a similar effect as the surfactant components, resulting in protection of 
the lung from pathogens (Trexler eta l., 2000).
Investigations into the function of CC were carried out by Dr. Ilyas Kahn in the 
laboratory of Prof. Charlie Archer at the Cardiff School of Biosciences. During 
Dr Kahn’s investigations, immunohistochemical analysis of bovine embryos 
revealed a CC signal in the developing lung. Consequently, it was decided to 
carry out the same procedures on mature lung. Tissue sections were taken 
from the rat lung used in the preliminary bleomycin studies. CC was detected 
in bleomycin tissue both three and seven days after bleomycin dosing, 
however, no signal was observed after saline instillation. These initial studies 
indicated that CC may act as a potential marker for early bleomycin-induced 
pulmonary injury. Further studies were carried out using lung tissue from the 
double dose experiment.
The following chapter details the procedures and findings from the 
immunohistochemical detection of cocoacrisp in bleomycin-treated lung tissue 
sections.
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6.2 M a t e r ia l s
6.2.1 M aterials  and  S uppliers
Supplier:
Vector Laboratories, 
Peterborough
In-house antibody production
BDH, Dorset 
Sigma-Aldrich, Dorset
Leica Microsystems (UK) Ltd, 
Buckinghamshire
Material:
Antigen Unmasking Solution (H-3300)
RTU Vectastain Universal Quick Kit (PK-7800) 
Vector NovaRed Substrate Kit for Peroxidase 
(SK-4800)
Cocoacrisp Primary Antibody (rabbit)
Control Serum Pre-Bleed (rabbit)
DPX Mountant (36029)
Tris Buffered Saline (T6664)
Tween 20 (P7949)
Leica Q550 IW Workstation 
Leica QWin Image Analysis Software
6.2.2 S tock  solutions
Hydrogen Peroxide Solution
TBS/Tween
Primary Antibody/Serum Control
0.3% Hydrogen Peroxide 
Methanol
0.1% Tween 20
Tris Buffered Saline (TBS)
0.05% Primary Antibody (1°)/Serum Control
1.5% Blocking Serum
TBS
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6 .3  M e t h o d s
6.3.1 Preparation of Tissue  for  Immunohistochemistry
Animals were treated with a single or double dose of bleomycin or saline and 
then sacrificed three, seven and twenty-eight days after dosing, as described 
in Sections 2.3.1-2.3.4. The lungs were inflated and stored in 10% neutral 
buffered formalin at 4°C for a minimum of 24 hours (Section 3.3.3.1). After 
this time the lungs were processed for paraffin embedding and sectioning 
(Section 3.3.3.2-3.3.3.4).
6.3.2 A ntigen  Unmasking
Sectioned tissue samples were prepared for the immunoassay by dewaxing 
as described in Section 3.3.3.4. After dewaxing, antigen unmasking was 
carried out on the fixed lung tissue sections. The fixation process led to 
cross-linking within the tissue to such an extent that the specific antigen 
binding sites were masked. This was due to the length of time the tissue was 
stored in 10% neutral buffered formalin. Antigen unmasking breaks down 
some of this cross-linking to expose the antigen for further immunoassay 
techniques.
Antigen unmasking solution (Vector) was diluted 1 in 100 with distilled water 
in glass coplin jars. The solution was then heated to boiling point in a 
microwave. The lung tissue sections were immersed in the boiling solution for 
two minutes prior to washing in tap water for five minutes.
6.3.3 Blocking  Endogenous  Peroxidase  A ctivity
In order to quench peroxidase activity endogenous to the tissue, all the lung 
tissue sections were immersed in 0.3% hydrogen peroxide solution (section 
6.2.2) for 30 minutes, followed by a wash in tap water (two minutes).
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6.3.4 IMMUNOHISTOCHEMISTRY
The immunoassay was carried out using a RTU Vectastain Universal Quick kit 
(Vector) containing prediluted blocking serum (normal horse serum), 
prediluted biotinylated pan-specific secondary antibody and ready-to-use 
streptavidin/peroxidase preformed complex. Tissue sections were washed 
with TBS/tween solution (section 6.2.2) prior to incubating the sections with 
blocking serum for 10 minutes. The sections were then incubated with the 
cocoacrisp primary antibody or serum control (section 6.2.2) at 4°C overnight. 
The following morning the sections were given two five-minute TBS washes 
before the secondary antibody was added. The secondary antibody was 
incubated for 10 minutes before being washed for another five minutes with 
TBS. The streptavidin/peroxidase complex was added to the sections for five 
minutes. Another five-minute wash with TBS was carried out prior to addition 
of the peroxidase substrate, NovaRed (Vector). NovaRed solution was made 
up according to the kit instructions and incubated on the sections for 15 
minutes. Sections were washed in tap water then counter-stained for five 
minutes with light green stain. Following a 30 second wash in tap water, 
slides were dehydrated and fixed using DPX mounting medium, described in 
Section 3.3.4.
6.3.5 Image Analysis
Image analysis (IA) was used to capture digitised LM images of saline and 
bleomycin-treated tissue sections. LM images (x100 magnification) were 
saved as TIFF files and imported into the Leica Q550IW Image Analysis 
System (Leica Microsystems, UK), for image processing.
Image processing involved adjustment of the background white levels to 
ensure all the lung tissue and staining were detected in the TIFF images 
(Figure 6.2A). Once this parameter was established, IA involved the detection 
of lung tissue that contained the CC label (shaded blue, Figure 6.2B). The 
total area (mm2) of CC label in control versus bleomycin-treated samples was 
calculated.
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Figure 6.2 Digitised images of cocoacrisp labelled tissue. A: Raw image showing cocoacrisp 
labelling as a red/brown colour, indicated by arrows; B: Image converted by image analysis 
system for colour detection, cocoacrisp label coloured blue.
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6. 3.6 S tatistical A nalysis
At each time point, 10 TIFF images were captured of random areas over three 
lung tissue sections. These images were then quantified using the Qwin 
analysis software (Leica Microsystems). The resulting data was imported into 
Excel. A two-tailed Student’s t-test was then applied to determine any 
statistical differences in the expression of cocoacrisp across the various time 
points.
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6.4 R e s u lts
6.4.1 L M  o f  L u n g  Tis s u e  S e c t io n s
Microscopic analysis of sections treated with serum control rather than 
primary antibody was carried out at all time points for both saline and 
bleomycin-instilled lung tissue. These samples showed no evidence of 
labelling (Figure 6.3).
Figure 6.3 Lung sections three days post-single bleomycin-treatment. Sections incubated 
with serum control rather than primary antibody. A: Alveolar spaces (x100 magnification), B: 
Blood vessel (x200 magnification).
Equivalent analysis was carried out to determine the expression of CC in 
bleomycin and saline-instilled lung. A very low level of the protein could be 
detected in all the saline-treated samples, although it was very difficult to 
determine visually (data not shown). At three and seven days after a single 
bleomycin dose an increase in CC expression was observed. Examples of 
these observations are shown in Figure 6.4. Cocoacrisp could be seen 
mainly lining the surface of the tissue (Figure 6.4A). This occurred primarily in 
areas of the tissue which appeared more severely effected by the treatment. 
There was also consistent appearance of CC detected in the blood vessels 
(Figure 6.4B). The other significant area of CC expression was in regions of 
the tissue where the lung architecture was largely disorganised (Figure 6.4C).
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Figure 6.4 Cocoacrisp expression in lung tissue three days after bleomycin treatment. Cocoacrisp labelling: red/brown colour, indicated by arrows; 
A: Alveoli, B: Blood vessel, C: Region of disorganised tissue structure. All images shown at x200 magnification.
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6.4.2 Im a g e  A n a l y s is  o f  L u n g  T is s u e  S e c t io n s
Quantification of the images shown in Section 6.4.1 allowed further analysis of 
cocoacrisp expression in the tissue. The area (mm2) of cocoacrisp label 
detected in the tissue was used as the value for CC expression. The resulting 
data is shown in Figure 6.5.
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Figure 6.5 Cocoacrisp expression in lung sections after saline ( ♦ )  or bleomycin ( ■  ) 
treatment. Error bars indicate one standard deviation. ** Significant (p< 0.001)
After a single bleomycin instillation the amount of cocoacrisp expression was 
more than doubled in comparison to saline instillation. At both three and 
seven days post-instillation the difference in CC expression in lung tissue was 
statistically significant with a t-test result of p<0.0003. After the second 
instillation, there was no significant difference between saline and bleomycin- 
instilled tissue.
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6.5 D is c u s s io n
The cocoacrisp study was carried out to investigate the possibility that this 
novel secreted protein might act as a marker for early bleomycin-induced 
injury. During the preliminary investigations Dr. Kahn only found CC 
expression in bleomycin-treated tissue. No signal was observed in saline- 
instilled lung. However, during this study, in all saline samples there 
appeared to be a low level of CC expression. This baseline signal appeared 
to be matched by the samples treated with a double bleomycin instillation. It 
was thought that some non-specific hybridisation may have been occurring. 
However, the lack of signal in the serum control samples confirmed that the 
cocoacrisp expression observed in the experimental samples was genuine. 
Cocoacrisp expression appeared to be significantly elevated three and seven 
days after a single bleomycin instillation; as the injury progressed the amount 
of CC dropped back down to control levels.
The homology of CC to Lgl1 and other CRISP proteins suggested that it was 
a secreted extracellular protein. This appeared to be confirmed by the 
location of CC on the surface of the lung and in the blood vessels. If the 
similarity in structure between CC and Lgl1 persists to the function of the 
protein, CC could be involved in the defence of the lung to insult (Trexler et 
a i,  2000). The appearance of CC on the lung surface would seem to support 
this theory, if this is the case, it is purely an immediate response, as the 
levels rapidly return to baseline levels.
The Lgl1 protein has also been implicated in the regulation of extracellular 
matrix (ECM) degradation by modulation of trypsin activity (Kaplan et a/., 
1999). The breakdown of the ECM, particularly proteoglycans, leads to 
increased vascular permeability (Miserocchi et a i, 2001). This is one of the 
critical events in the development of pulmonary oedema. Lgl1 causes trypsin 
inhibition which could result in reduced ECM degradation, and hence, reduced 
oedema. Again, assuming a similar role for CC as Lgl1, this could mean CC 
was involved in the protection of the ECM. This theory was supported by the
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significant levels of CC in areas of disorganised lung architecture. Similarly, 
some mammalian CRISP proteins are found loosely associated to sperm and 
have been indicated in sperm-oocyte fusion (Evans, 2002). As oocytes are 
surrounded by a matrix containing hyaluronan (a proteoglycan) (Richards, 
2005), there is potential that these interactions could be linked to CRISP- 
related ECM remodelling.
Some CRISPs isolated from snake venom have been shown to function by 
blocking voltage-gated calcium and/or potassium channels (Yamazaki and 
Morita, 2004; Guo et a i , 2004). This implies yet another potential role for CC 
in the resistance to developing pulmonary oedema.
An important feature of this secreted protein was its regular appearance in the 
blood vessels and in the lung lining. If cocoacrisp can be detected in blood or 
BAL, it has good potential as a biological marker for early bleomycin-induced 
oedema. The ability to screen blood or lavage samples (rather than tissue 
samples, requiring a biopsy for gene analysis) increases the possibility of 
creating screening or diagnostics tools for clinical applications.
6 .6  C o n c l u s io n s
To summarise, cocoacrisp has many potential mechanisms involving 
resistance to the development of pulmonary oedema, and the defence of the 
lung to pathogens. The appearance of elevated levels of CC in the blood and 
possibly BAL gives it great potential as a clinical marker for early bleomycin- 
induced lung injury.
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7.1 O v e r v ie w
The primary aim of this study was to identify biomarkers for pulmonary 
oedema, inflammation and epithelial repair. This would be achieved by using 
an animal model of lung injury to develop a better understanding of the 
genetic mechanisms underlying the disease state.
Bleomycins are a family of antibiotic compounds used extensively in cancer 
chemotherapy. Unfortunately, the repeated use of bleomycin in the treatment 
of these diseases is known to cause pulmonary toxicity. The lung injury 
induced by bleomycin ranges from pulmonary oedema, inflammation (cellular 
infiltration) and type II hyperplasia, to interstitial fibrosis. This progression of 
injury is reproducibly generated in a variety of experimental animal models. In 
this study, a single intratracheal instillation of bleomycin was employed. This 
was expected to induce a model of lung inflammation, oedema and the 
progressive destruction of normal lung architecture.
An important objective was to use conventional toxicological and histological 
approaches to characterise the model and to determine the severity of lung 
injury. Once this had been accomplished, the principal aim was achieved by 
applying genomics to evaluate the genetic responses of the tissue to various 
levels of injury.
The purpose of genomics is to gain a better understanding of biochemical 
mechanisms and cellular pathways at the genetic level. An important element 
of this is to define global gene expression profiles. Gene arrays have been 
developed which can simultaneously determine the expression of numerous 
genes by measuring mRNA abundance. Using these arrays, and by 
assessing gene expression patterns, it was possible to identify genetic 
markers of various stages of pulmonary damage and repair.
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7 .2  C h a r a c t e r is a t io n  o f  B l e o m y c in  M o d e l
Prior to gene profiling, this model of bleomycin-induced lung injury was 
characterised. By investigating the biochemical (conventional toxicology) and 
morphological (histology and TEM) changes in the lung, clear differentiation 
between models of injury and cellular repair was successfully achieved.
Three days after a single bleomycin dose evidence of focal lung damage and 
mild oedema could be measured. This progressed into focal areas of intra- 
alveolar oedema by seven days post-instillation. The most severe oedema 
was observed three days after the second bleomycin instillation, with large 
areas of the lung showing complete destruction of the normal architecture. 
The injury had lessened after seven days but severe interstitial and intra- 
alveolar oedema remained. Three weeks after the second dose, the levels of 
lung injury had significantly reduced but remained noticeable. The endpoints 
of pulmonary injury are outlined below:
Day 3 (single dose) I  Mild/early oedema
Day 21 (double dose) I
Day 7 (single dose) I  Progressive oedema
Day 7 (double dose) I
Day 3 (double dose) ¥  Severe oedema
Measurement of DNA synthesis and the progressive alteration in the structure 
of type II cells indicated that that cellular proliferation was induced seven days 
after bleomycin dosing (acute repair). These repair processes were still 
functioning three weeks (chronic) after a double bleomycin dose.
Models for mild, progressive and severe oedema were successfully 
characterised, providing the opportunity to study both the onset and 
progression of the injury whilst allowing some investigation into epithelial 
repair mechanisms.
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7 .3  Id e n t if ic a  t io n  o f  B io l o g ic a l  M a r k e r s
Optimisation of the macroarray procedure was successfully achieved, 
primarily by increasing the purity of the starting material. By improving the 
RNA isolation techniques the capacity to obtain reproducible results from the 
macroarray was increased.
To gain a wider understanding of the oedematous reactions, a number of 
replicates were used at each stage of the injury. The inherent variations in 
genetic expression were overcome by the design of the normalisation and 
data analysis methods. A number of different analytical tools were applied to 
the data, however most proved to be redundant. Two analytical methods 
were developed to enable analysis of a small number of replicates (range 
method) and a larger number of replicates (2sd method). These methods 
were combined with a Student’s t-test to give a more statistical element to the 
analysis. Changes in gene expression predicted by the macroarray were 
compared to changes quantified by Q-PCR. The data correlated very 
strongly, indicating that the optimisation of the array procedure and the newly 
developed analysis methods were successful. These techniques were then 
applied to the oedema model.
During mild oedema (three days after a single dose) a cluster of five up- 
regulated ion channels and transporter proteins was identified. All these 
genes could be linked to the movement of water, which coincided with the 
progression of oedema. Of the remaining genes a large number appear to be 
involved in osmoregulation, whilst several more may be involved in 
inflammation. The majority of the genes altered at this time point appeared to 
be involved in the control of water balance in the lung and the progression of 
inflammatory responses.
Almost twice the number of genes were altered during progressive oedema 
(seven days after a single bleomycin dose). Once more, a large number of 
ion channels and transporter proteins were identified, many of which could be
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linked to water transport. The second largest cluster was made up of kinases, 
several of which were involved in cell cycle and apoptosis signalling. A 
number of the remaining genes had potential links to metabolism, cell cycle 
control and maintenance of water levels. So while a large proportion of these 
genes were related to cellular signalling, a number of the changes could be 
linked to oedema and inflammation. There was also evidence pointing to 
some potential repair mechanisms, such as reduced apoptosis and increased 
cellular proliferation.
During severe oedema (three days after a double bleomycin dose) an even 
greater number of changes in gene expression were observed. The majority 
of differentially expressed genes were encoding for ion channels and 
transporter genes. Of the remaining genes, a large number could be 
associated with epithelial and endothelial cell cycle, immune responses and 
osmoregulation. Thus, during the severe oedema model, whilst some of the 
genes appeared to be involved in the continuation of repair mechanisms, the 
majority of genes were involved in regulating lung water content and 
modulating immune responses.
There were a few consistencies between the different models of oedema. 
One consistency was denoted by the up-regulation of the cluster of ion 
channels and trafficking proteins during both mild and severe oedema. This 
similarity in gene behaviour could be related to the development (onset) of 
oedema, as in both of these models onset occurs only three days after 
dosing. This family of genes could potentially act as a marker for the onset of 
oedema. Two individual genes appeared consistently across two time points. 
The Na+/CI- betaine/GABA transporter gene was consistently up-regulated 
during mild and severe oedema, and the gene encoding for a glucocorticoid 
receptor gene was similarly altered during both mild and progressive injury. 
As such, these single genes may be potential markers
The serendipitous discovery of cocoacrisp expression in oedematous tissue 
could represent the best marker uncovered by this study. This protein may be 
linked to surfactant production, extracellular matrix remodelling and the
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blocking of ion channels. One of the most significant elements of this 
discovery was that CC was detected on the surface of the lung and in blood 
vessels. This affords the opportunity to develop clinical screening or 
diagnostic tools utilising blood or BAL samples.
7 .4  C o n c lu s io n s
In conclusion, the macroarray analysis of the bleomycin oedema model has 
provided new transcriptional data on the mechanisms of the events leading to 
pulmonary oedema. Some potential repair mechanisms have also been 
highlighted. The main findings from this study are outlined below:
• The use of toxicology and histology was demonstrated as an 
appropriate technique for quantifying and characterising a model of 
pulmonary injury.
• A simple and effective method was created for analysing the large 
amounts of data generated by these high throughput array systems. 
This form of analysis has been corroborated by the use of the well 
established molecular biology technique Q-PCR. This method can be 
used for comparison of groups of data, as in this study. A more clinical 
application of this technique may be achieved by using it to compare a 
single patient or unknown sample to an established ‘normal’ or control 
data set.
• Implementation of the macroarrays combined with suitable analysis 
methods successfully provided screening of large numbers of genes to 
aid in the search for biomarkers.
• A group of genes encoding for ion channels and transporter proteins 
were found to be consistently altered in the early stages after 
bleomycin treatment. This family of genes shows good potential to act 
as markers for early pulmonary oedema.
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• Potential genetic markers were identified in the specific genes 
encoding for the Na+/CI- betaine/GABA transporter and the 
glucocorticoid receptor. As well as acting as markers, these genes are 
prospective targets for treatment.
• Cocoacrisp protein was also identified as a possible biomarker for early 
bleomycin-induced pulmonary injury. The presence of this protein in 
BAL and blood render it a potential clinical tool.
7.5 F u t u r e  W o r k
The Clontech macroarray was not the most robust of techniques, and better 
technologies have recently come on the market which may be preferable. For 
example, the GEArray (Bioscience Corporation, USA) utilises cDNA oligos on 
a small nylon membrane, and chemiluminescence or fluorescence rather than 
radiolabelling can be used for detection. As such, the results can be achieved 
within hours rather than days. These arrays can be used to study a wide 
range of genes as done in this study, or to study specific pathways (e.g. 
apoptosis, signal transduction). Application of these new ‘pathway’ arrays has 
the potential to generate a more specific understanding of the mechanisms 
underlying oedema. Or conversely, microarrays could be tailored to specific 
families of genes and used to broaden the search for markers. The findings 
of the current study could be used to direct the type of genes on either 
pathway or microarrays, i.e. ion channels and trafficking proteins, growth 
factors, chemokines and cytokines, kinases.
The RNA used in this study was extracted from tissue and therefore contains 
a large number of different cell types. Using laser capture methods it may be 
possible to select individual cells (e.g. type II cells, macrophages), and carry 
out gene array analysis on RNA extracted from a single cell type. This could 
further clarify the specific mechanisms of the progression of oedema, and 
particularly the repair processes.
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It is certainly worth considering further investigations into the function of the 
ion channels and trafficking proteins with regard to oedema. Perhaps 
research into the effects of channel blockers might be considered, to prevent 
the progression of oedema. In addition, more in-depth studies of the specific 
marker genes Na+/CI- betaine/GABA transporter and the glucocorticoid 
receptor should be carried out. This would help to clarify their specific 
involvement in the onset of oedema and perhaps identify their role as 
therapeutic targets.
Changes in gene expression are good early indicators of injury, as the first 
biological responses to insult are at the genetic level. However, a major 
setback with regard to using these results at the clinical level is the necessity 
for tissue samples to obtain RNA. In order to obtain a patient sample, a lung 
biopsy would need to be carried out. This causes particular difficulty in 
obtaining normal control samples. As such, it would be preferable to identify 
changes in specific proteins which may be present in blood or even in BAL to 
act as clinical markers. A major problem with using changes in mRNA level is 
that it does not necessarily correlate to changes in protein expression and 
function. Accordingly, it would seem important that the changes in protein 
expression between normal and oedematous samples are studied. This could 
involve either specifically targeting gene products identified by this study 
(Western blotting), or by carrying out further proteomic studies (2D-SDS 
PAGE) to identify proteins of interest.
Further investigations into the function of cocoacrisp, whether it is present in 
BAL, and whether it can be detected in blood are important. CC is potentially 
a very good marker for early oedema and research into its role in the 
development or resistance to oedema could prove enlightening.
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Abstract
This study was undertaken primarily to identify genetic markers of oedema and inflammation. Mild pulmonary injury was induced 
following the instillation of the oedema-producing agent, bleomycin (0.5 units). Oedema was then confirmed by conventional toxicology 
(lavage protein levels, free cell counts and lung/body weight ratios) and histology 3 days post-bleomycin instillation.
The expression profile of 1176 mRNA species was determined for bleomycin-exposed lung (Clontech Atlas macroarray, n = 9). To obtain 
pertinent results from these data, it was necessary to develop a simple, effective method for bioinformatic analysis of altered gene expression. 
Data were logio transformed followed by global normalisation. Differential gene expression was accepted if: (a) genes were statistically 
significant (P  < 0.05) from a two-tailed t test; (b) genes were consistently outside a two standard deviation (SD) range from control levels. A 
combination of these techniques identified 31 mRNA transcripts (approximately 3%) which were significantly altered in bleomycin treated 
tissue. O f these genes. 26 were down-regulated whilst only five were up-regulated. Two distinct clusters were identified, with 17 genes 
classified as encoding hormone receptors, and nine as encoding ion channels. Both these clusters were consistently down-regulated.
The magnitude of the changes in gene expression were quantified and confirmed by Q-PCR (n = 6), validating the macroarray data and 
the bioinformatic analysis employed.
In conclusion, this study has developed a suitable macroarray analysis procedure and provides the basis for a better understanding of the 
gene expression changes occurring during the early phase of drug-induced pulmonary oedema.1 
€ 2004 Elsevier Inc. All rights reserved.
Keywords: Pulmonary oedema: Macroarray; Bleomycin: Inflammation
Introduction
The development of pulmonary oedema is caused by a 
number of factors, including: capillary damage, oxygen 
and ozone toxicity, clinical intravenous administration o f 
fluids, drug/chemical action and high altitude (Spencer,
* Corresponding author. Cardiff School o f Biosciences, Cardiff 
University. Museum Avenue, Cardiff. CF10 3US, United Kingdom. Fax: 
+44 029 20874116.
E-mail address: balharry@cf.ac.uk (D. Balharry).
1 This work has been presented orally, in part at the British Association 
for Lung Research Summer Meeting, University o f  Brighton, 3-5  
September, 2003 and in full at the British Toxicology Society Annual 
Congress, Heriot Watt University, Edinburgh, 21-24 April 2004.
0041-008X/S - see front matter © 2004 Elsevier Inc. All rights reserved, 
doi: 10.1016/j.taap.2004.08.022
1985). It is also a life-threatening complication of a variety 
of heart and lung diseases (Roguin et al., 2000). As such, 
it is important that we understand more about the 
mechanisms o f oedema and are able to identify this 
disease as early as possible.
The primary objective o f this study was to investigate 
differential gene expression at the transcriptional level 
during the development o f pulmonary oedema and 
inflammation. Comparing compromised and non-compro- 
mised samples provided a list o f candidate genes involved 
in the early phase response to pulmonary injury. These 
genes could provide potential biomarkers for pulmonary 
oedema.
Bleomycin has been used in a variety of animal models 
to induce pulmonary injury and ultimately fibrosis (rabbit;
102 D. Balharrx et al. Toxicology and Applied Pharmacology 204 t2005) 101-10,\
Catravas et al., 1983; mouse: Aso et al., 1976; hamster: 
Starcher et al., 1978; Snider et al., 1978; rat: Thrall et al.. 
1979; and pig: Balazs et al., 1994). In this study, a single 
intratracheal instillation was used to investigate the earlier 
stages o f pulmonary injury in rats.
Bleomycin initially induces oedema and inflamma­
tion. followed by progressive destruction of the normal 
lung architecture (Shen et al.. 1988). The pathological 
changes in the lung parenchyma following intratracheal 
instillation of bleomycin are cellular infiltration, pulmo­
nary oedema, changes to type II pneumocytes. changes 
to alveolar architecture, and following multiple instilla­
tion. pulmonary fibrosis (Brown et al., 1988). The lung 
injury that develops in the initial 48 h following a 
single intratracheal bleomycin dose (1.5 units) is charac­
terised histologically by perivascular oedema, capillary 
congestion and alveolar wall thickening (Thrall et al.. 
1979). The oedema is predominantly interstitial, with 
minimal intra-alveolar oedema. The inflammatory cell 
infiltrate in the alveolar walls and spaces has been 
quantified in hamsters treated with a single intratracheal 
dose (1 unit). Chandler et al. (1983) found an eight-fold 
increase in the number o f macrophages, monocytes, 
lymphocytes, and neutrophils 4 days after bleomycin 
instillation.
The maximum level o f cellular infiltrate has been 
shown to occur 3 days post-bleomycin instillation 
(Adamson and Bakowska, 1999). Another study used 
the accumulation of albumin in the interstitial tissues as a 
measure o f vascular permeability. This resulted in an 
increase in the albumin space, which peaked at 3 days 
(Hay et al.. 1987). These experiments both indicated that 
oedema consistently occurred 3 days after pulmonary 
injury.
In the present study, conventional toxicological techni­
ques (lung w eight lavage protein free cell numbers) w ere 
used to monitor the extent o f pulmonary oedema and 
inflammation (Lee and Richards, 2004).
Experiments were designed to identify early molecular 
markers for events in pulmonary injury. Recent advances in 
gene array technology mean it is possible to compare 
patterns of mRNA expression o f many thousands o f genes 
simultaneously. For the majority o f genes, changes in 
m RNA abundance are related to changes in protein 
concentration (Lockhart and Winzeler, 2000). The degree 
of mRNA expression is very informative about the state of a 
cell and the activity o f genes.
In order to examine global gene expression in lung 
tissue, macroarray technology was applied. The Clontech 
Atlas™ rat cDNA expression macroarray system was used 
for this study. This was chosen because it is readily available 
and offers reproducibility to a greater range o f laboratories 
than the more expensive microarray systems. This method­
ology has been used successfully in previous studies to 
investigate toxicant effects in the lung (Reynolds and 
Richards, 2001).
Materials and methods
Experimental model o f  pulmonary oedema and 
inflammation
Experiments were performed in accordance with the 
codes o f practice specified by the Home Office (UK), and 
follow ing approval from the local ethical committee.
Pathogen-free, male Sprague-Daw ley rats (Charles River 
Ltd.. U K ) weighing 200 250 g were lightly anaesthetised 
with halothane (Rhone Merieux. UK) and dosed with a 
single intratracheal (IT ) instillation (Reynolds and Richards. 
2001). Animals w ere treated w ith 0.5 units of bleomycin 
sulphate (Kyowa Hakko. UK) suspended in 0.5 ml0.15 M 
NaCl (n = 9). Sham controls received only 0.5 ml 0.15 M 
NaCl (n = 9). Animals were closely monitored over the 
three day period, using a post procedure pain and distress 
score sheet (Wolfensohn and Lloyd. 1998). Recovery was 
rapid with no signs o f adverse health effects.
Bronchoalveolar lavage (BAL) fluid analysis
Three days post-IT instillation o f bleomycin, the animals 
were anaesthetised with halothane and sacrificed by a lethal 
intraperitoneal injection (1 -2  ml) o f Euthatal (Rhone 
Merieux. UK). The rats were subsequently weighed and 
cardio-respiratory death confirmed prior to dissection. Lung 
wet weight (including trachea and bronchi) was measured. 
Bronchoalveolar lav age (B A L ) was performed by cannula- 
tion o f the trachea followed by four washes with 6-8 ml 
sterile saline (0 .9°o). The recovered aliquots were pooled 
and centrifuged for 20 min (300 x g). The trachea and 
bronchi were removed and the weight of the lung 
parenchyma (LP) was calculated. The lobes of the lung 
were separated, flash frozen in liquid nitrogen and stored at 
- 8 0  C for use in gene-profiling studies.
The LP weight measured previously was used to 
calculate the LP to body mass ratio. During infection, 
injury or inflammation, an influx o f cells and protein will 
cause an increase in the lung weight, reflected in an elevated 
LPbody mass ratio (Richards and Curtis, 1984).
The increase in concentration of acellular protein in 
BAL was used as a sensitive marker of oedema resulting 
from damage to epithelial or endothelial cells (Richards 
and Curtis. 1984). The total protein concentration of BAL 
(300 x g ) was determined by the Bradford assay 
(Bradford, 1976). Assays for each animal w ere  performed 
in triplicate.
Increased cellular infiltrate was used to monitor the level 
o f inflammation. The number o f large free cells (LFC) within 
the BAL fluid was measured using a haemocytometer.
Histology o f  lungs
In separate experiments, histological specimens were 
prepared for light microscopy. Lungs were excised 3 days 
post-IT instillation o f saline (n = 3) or bleomycin (n = 3) 
and inflated with 10% neutral-buffered formalin. The 
inflated lungs were tied o ff and immediately immersed in
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10% neutral buffered formalin to be processed for paraffin 
embedding and sectioning. The upper right lobe was 
embedded in paraffin wax and 5 pm sections were cut on 
a microtome. Sections were stained with haematoxylin and 
eosin and analysed by light microscopy.
Macroarray o f  lung tissue
The Atlas cDNA Rat 1.2 array system (BD Biosciences) 
was used to assess gene expression. These macroarrays 
consist of 1185 cDNA sequences (200-600 bp) spotted onto 
a nylon membrane. These include plasmid and bacterio­
phage DNAs as negative controls to confirm hybridisation 
specificity, as well as several housekeeping cDNAs as 
positive controls.
The macroarray procedure was carried out on saline- (n = 
9) and bleomycin- (n =  9) treated tissue in accordance with 
the BD Atlas cDNA Expression Arrays User Manual. In 
brief, probe mixtures were synthesised by reverse tran­
scription of each RNA population (isolated using RNeasy 
mini kit. Qiagen). The resultant 32P-labeled cDNA was then 
purified and hybridised to separate array membranes over­
night. The following day. the membranes were washed with 
a high stringency solution. The hybridisation pattern was 
ascertained by phosphorimaging.
Macroarray data analysis
Initial processing of the array data was carried out using 
Atlas Image 2.0. The ratio and difference thresholds were 
set to 1 and 1000. respectively to ensure all genes were 
included in further analysis. The signal-to-background ratio 
for all arrays was set low at 50%. The resultant report was 
comprised o f all genes on the array and their corresponding 
adjusted intensity value (total signal minus background).
Normalisation. The raw array data resulting from process­
ing by Atlas Image is not normally distributed. Therefore, 
prior to further analysis, the raw expression data was logio 
transformed. This served to reduce skewness, kurtosis and 
outliers. Subsequently, each array was normalised by 
dividing the spot intensity o f each gene by the median spot 
intensity of the w hole array. The median value was chosen 
as the preferred method o f normalisation, as the mean value 
is highly influenced by the extreme behaviour of relatively 
few genes. This removed the effects o f experimental 
differences and enabled direct comparison between arrays.
Analysis. Post normalisation, a quantitative analysis was 
carried out. The ratio o f adjusted intensities was calculated 
as a measure o f altered gene expression. Ratio was 
calculated for up-regulated genes by dividing bleomycin 
gene intensity by sham gene intensity. For down-regulated 
genes, sham was divided by bleomycin intensity, and a 
minus sign was placed in front o f the resulting ratio. This 
generated a figure that was representative of fold change in 
expression. The positive or negative sign indicated up- or 
down-regulation of the gene. Previous experiments have
shown that 75% of genes with a ratio change of 1.5 or more 
can be confirmed by RT PCR (deVos et al., 2003; Treadwell 
and Singh, 2004). The lower cut off point for identifying 
relevant genes was therefore set at a ratio of 1.5.
Numerous statistical techniques are available to make 
comparisons between groups of data. However, with a 
relatively low number o f experimental replicates, an 
alternative method of determining significant differences 
in gene expression, which took into account the intra 
group variability, was required. The method developed 
accommodated the limited sample size and included a 
statistical element to generate a greater level o f confidence 
in the data. This simple analysis technique was developed 
using the sham-control data to set parameters against 
which the bleomycin samples were compared. For each 
gene, the mean adjusted intensity value from each o f the 
nine sham arrays was plotted on a graph ±  two standard 
deviations (SD). The interval was set at two standard 
deviations because for any given gene, if  the data are 
normally distributed, 95% of the population will fall 
within ±  2SD from the mean. The mean ±  2SD 
established the range of normal gene expression against 
which the oedema samples could be compared. I f  the 
mean of all nine o f the oedema samples fell outside the 
two standard deviation limits, the gene was considered 
relevant for further study (Fig. 1).
This method was compared and contrasted with a two- 
tailed unpaired Student’s t test.
Quantitative PCR (Q-PCR) o f selected genes
The macroarray procedure is considered semi-quanti- 
tative due to the inherent variations in hybridisation 
reactions. Therefore, confirmation of the gene expression 
changes calculated from the macroarray and subsequent 
analysis was required. To accurately quantify these alter­
ations in genetic expression and to confirm the reproduci­
bility of the data, quantitative PCR (Q-PCR) was used. A
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Fig. 1. Gene 1: not significantly different from controls; genes 2 and 3: 
relevant for further study. Sample o f experimental data.
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Table 1
Primer sequences for PCR
Primer name Primer sequence Primer length Fragment size
B04d Forward TGGCAGACGCTCTTGGGCGAGAG 23 227
B04d Reverse CACCACCGGAAAGCCGCTGTACG 23
D03j Forward GGG AC CCGTGCC ATT GTTT CT G AC 24 279
D03j Reverse GGCGTAGATGAAGTTGAAGGTCGCG 25
DO 7c Forward CGCCGCTCGCGCCTCATGATC 21 190
D07c Reverse CGAAGACACCGCTGGTCATCCAG 23
D09f Forward GAAGTTTCGCTCATGGACCTACGAC 25 192
D09f Reverse AGTGGTTTGCGACGAATGATGAAGTC 26
D14i Forward AGCT GCT GCT GT GGC AC AGT GC AC 24 297
D14i Reverse GC AGTT GGCT C AGGC ACTTT GTCTG 25
G43 Forward CCCT CTG A AC C CTA AGGC C A ACCG 24 285
G43 Reverse GTGGTGGTGAAGCTGTAGCCACGC 24
small sample of genes (n = 6) highlighted by the previously 
described methods was chosen (Table 1). The genes were 
selected primarily by their biological function, but also 
according to the analytical method by which they were 
detected (2SD method, or t test).
The purified PCR product of the gene of interest was 
ligated into a pGEM-T plasmid vector (Promega). This was 
than transformed into competent Escherichia coli cells 
(JM109, Promega). Successful transformation was detected 
by the differing ability of the clones to metabolise X-Gal/ 
IPTG. The plasmids and inserts were isolated from liquid 
culture using Wizard Plus SV Miniprep DNA Purification 
Systems (Promega). The inserts were sequenced to confirm 
that the correct product had been achieved.
Real-time PCR was carried out on an Applied Biosystems 
AB I PRISM 7700 Sequence Detection System. SYBR green 
(Qiagen) incorporation was used to quantify relative gene 
expression. A  standard curve (10 fg-100 pg) was constructed 
for each gene from RNA extracted from untreated lung 
tissue. This was then used as a reference for calculating the 
RNA expression within the experimental samples.
Results
Bronchoalveolar lavage (BAL) flu id  analysis
The following parameters were recorded for each rat: 
body weight, the lung parenchymal (LP)/body weight 
ratio, the total surface protein concentration and the large 
free cell (LFC) count from the lavage sample. The saline- 
treated (n -  9) and bleomycin-treated (n =  9) groups were 
compared for each of the toxicological effects. A two- 
tailed Student’s t test was used to determine the statistical 
relationship between the two groups, shown in Fig. 2.
The weight gain of the bleomycin treated rats was 
carefully monitored from the time of the dose to the time of 
sacrifice. The final difference in weight between the sham 
group and the bleomycin treated group was only 5%. This 
indicated that the animals had not reacted adversely to the 
bleomycin treatment.
An increase in the lung/body weight ratio, protein 
concentration and the number of large free cells indicates 
oedema and mild inflammation of the lung. In all these 
categories, data are significantly different between saline- 
and bleomycin-treated groups. This clearly indicates that 
oedema and mild inflammation was occurring in the lungs 
of the bleomycin treated rats after 3 days.
Histology’ o f lungs
Haematoxylin and eosin staining was carried out on 
separate tissue sections. This was done as visual confirma­
tion to the basic toxicology described above. The results 
from 3 days after bleomycin instillation are shown in Fig. 3.
Sham-treated tissue has normal alveolar architecture, 
with no evidence o f swollen septa. In the bleomycin-treated 
samples, there was evidence of an influx of macrophages 
after 3 days and widespread thickening of the alveolar 
interstitium (indicated by arrows).
Macroarray analysis
Following histological and biochemical confirmation of 
pulmonary oedema, the lung tissue was processed through 
the macroarray system. The information generated from the 
macroarray was analysed as described previously. Genes 
with a consistent difference in expression between saline- 
and bleomycin-treated tissue were identified by the standard 
deviation method (Fig. 4). The same data were analysed by 
a two-tailed t test. The resulting gene lists were limited to 
genes with a ratio change of over 1.5. The gene lists 
generated using the two methods of analysis were compared 
for consistencies. Genes present on the lists from both 
techniques were considered particularly relevant. A list 
combining genes from both analysis techniques was 
compiled and is shown in Table 2.
As well as considering the statistical relevance as 
determined above, it was important to take into account 
the biological significance and clustering o f the genes.
O f the five up-regulated genes, four are involved in active 
transport of molecules across membranes and the fifth was a
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Saline Bleomycin Saline Bleomycin
Fig. 2. Graphs showing a comparison between the saline-treated and bleomycin-treated groups. Error bars show standard deviation (n = 9).
Fig. 3. Photomicrographs o f lung sections stained with haematoxylin and 
eosin (x  16 magnification). (A) sham-treated; (B) bleomycin treated. Black 
arrow: interstitial thickening.
chloride channel. The remaining significantly altered genes 
belonged to two functional groups, the neurotransmitter 
receptors/ion transport proteins (seven genes) and hormone 
receptors/G protein-coupled receptors (18 genes).
Quantitative PCR
Quantitative PCR was carried out to achieve two separate 
aims. The first was to validate the accuracy of gene 
expression changes predicted by the array. Secondly, this 
technique was used to determine the suitability of the mean ±  
2SD and t test methods of analysis for highlighting relevant 
gene changes.
Q-PCR was carried out on five of the genes selected by 
the two analysis methods, and one housekeeping gene. The 
genes were chosen according to their potential biological 
significance, as well as the method by which they were 
highlighted. The genes were; a chloride channel protein 
(B04d), substance K receptor (D03j), vasopressin receptor 
(D07c), neuronal acetylcholine receptor beta-2 subunit 
(D09f), granulocyte colony stimulating factor (D14i) and 
cytoplasmic (3-actin (G43). Genes B04d and D07c may both 
be involved in water transport and reabsorption, and both 
were highlighted using the t test. Gene D03j has been 
implicated in bronchoconstriction of large airways and 
enhancement of vascular permeability. Gene D14i has been 
shown to significantly increase alveolar cell recruitment and 
pulmonary oedema (Azoulay et al., 2003). Both D03j and 
D14i were selected using the standard deviation (SD) 
method. Gene D09f was chosen because it was one of 
several genes in a tight cluster, and was the only gene 
identified by both methods to undergo Q-PCR. The house-
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Fig. 4. Shows a sample of experimental data that has undergone the 
standard deviation analysis method. Three genes are considered relevant 
(down-regulated), two are not deemed significant.
keeping gene, P-actin (G43), was selected because there 
appeared to be no change between sham and oedema 
samples.
The concentration of each gene in the samples was 
determined, and used to calculate a ratio change for each
2.5
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No
Change
-1.5
o
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- 2.0
-2.5
B04d D03j D07c D09f D14i G43 
Transcript 
■  Array A  Q-PCR
Fig. 5. Shows comparison between ratio change predicted by the macro­
array and ratio change predicted by the Q-PCR.
gene. The ratio calculated from Q-PCR was compared 
with the ratio predicted by the macroarray (Fig. 5). The 
correlation between the ratios calculated by both techni­
ques was very high. Gene D07c showed a lower level 
agreement, but both methods consistently indicated 
down-regulation.
Table 2
Shows all genes identified by the standard deviation and or t test methods
Code Accession # Gene Ratio t  test,
P  value
Code Accession # Gene Ratio /test,
P value
B04d D50497 chloride channel protein ♦ 2.12 0.038 D06k U40395 cannabinoid receptor 1, 
neuronal ■
-1 .7 0 0.064
B071 U 15098 glutamate transporter A 1.66 0.032 D07c Z11690 vasopressin/arginine 
receptor ■
-2 .10 0.038
B07m U28927 Na+/Cl- betaine/GABA 
transporter A
1.69 0.032 D07f L10073 serotonin receptor SB ■ -1 .74 0.049
B08m U 10096 Na-K-Cl cotransporter A 2.15 0.018 D07m X63574 somatostatin receptor 3 ■ -1 .55 0.064
B09h L I0362 Synaptic vesicle 
protein 2B A
1.83 0.018 D08e J03933 thyroid hormone beta 
receptor ■
-1 .69 0.028
D02j X62314 somatostatin receptor
i  m
-1 .65 0.079 D08f M36074 mineralocorticoid receptor 
(MR) ■
-2 .14 0.034
D03j M31838 substance K  receptor 
(SKR) m
-1 .71 0.058 D08g M l4053 glucocorticoid receptor ■ -1.84 0.029
D03k X56661 gastrin-releasing peptide 
receptor ■
-1.51 0.085 D09b X95579 GABA-A receptor rho-1 
subunit A
-1.51 0.086
D04g M34842 thyroid stimulating hormone 
receptor ■
-1 .55 0.062 D09e Z11716 glutamate receptor 7 
(GLUR7) A
-2 .16 0.031
D04n L02842 follicle stimulating hormone 
receptor ■
-1.80 0.037 D09f L31622 neuronal ACh receptor 
p2 subunit A
-1.99 0.015
D05i D32045 alpha IB  adrenergic 
receptor ■
-1 .76 0.045 D09g M85035 glutamate receptor 2 
precursor A
-1.53 0.077
D051 L05596 Serotonin receptor IF  ■ -1.81 0.034 D09k X15467 GABA-A receptor fl-2 
subunit A
-2.08 0.016
D05m L10072 serotonin receptor 5A ■ -1 .74 0.049 D091 L08497 GABA-A receptor 
gamma-2 subunit A
-1.72 0.059
D06d M88096 Cholecystokinin receptor ■ -1 .53 0.072 DIOg L08493 GAB A receptor x—4 
subunit A
-1 .54 0.079
D06f M93273 Somatostatin receptor 2 ■ -1 .70 0.060 D14i U37101 granulocyte colony 
stimulating factor A
-1.51 0.084
D06j U37058 Neuromedin B receptor ■ -1 .70 0.060
Genes in italics were identified as significant by the 2SD method.
Genes in bold italics were identified by both techniques. A Transporter proteins, Hormone receptors, A Ion channels.
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Discussion
The objectives of this study were to develop suitable 
methods for analysis of macroarray data, and to use these 
methods to identify potential markers of pulmonary oedema. 
Conventional toxicology was used to determine the level of 
oedema and inflammation in the lung. The tissue was then 
processed for genetic analysis. To gain a more comprehen­
sive understanding of the oedematous reaction, 18 individual 
rats were used for genetic analysis. This approach was 
chosen in preference to using replicate samples from one 
tissue source. Obtaining replicates from different biological 
samples results in increased random error but the findings 
have better external validity and broader applicability 
(Nadon and Shoemaker, 2002). Conventional toxicology 
methods were successfully used to determine the level of 
lung injury. The increased lung/body weight ratio and 
protein levels in bleomycin-treated rats all pointed to 
oedema. The increase in macrophages indicated a slight 
inflammation of the lung tissue. As these changes were 
statistically significant, it suggested that the alterations were 
caused by the bleomycin dose. These results were supported 
by the histological data. After 3 days, the damaged 
interstitium was clearly visible, as was an apparent accumu­
lation of macrophages at focal regions of the lung surface.
After these techniques were used to identify the extent of 
damage to the lung at 3 days, the tissue was then processed 
for genetic analysis. The variation in genetic expression was 
due to inherent differences in animal response to treatment, 
and day-to-day experimental variations. Initial normalisa­
tion of the data was performed to overcome experimental 
differences. Biological variation was addressed by the 
number of sample replicates, and the design of the normal­
isation and data analysis methods.
The standard deviation method is a very stringent analysis 
technique for determining significant genes from a limited 
number of sample replicates. Any gene that falls outside the 
two standard deviation limit is considered to be altered by the 
treatment to the 0.05 significance level. Therefore, when the 
mean of all nine genes fell outside this control range (Fig. 1), 
the gene was considered to be a reliable marker for oedema. 
Once the control data set has been established, individual 
samples can easily be assessed against it. As such, this 
approach has good potential for clinical use.
The t test was used to generate more statistical evidence 
of altered gene expression. This technique is appropriate for 
use on both small and large sample sets, but cannot be used 
to compare one individual sample against a control data set.
Some of the genes identified by a combination o f these 
analysis methods are discussed below.
A group of five transporter proteins (symporters and 
antiporters) were identified as significant. O f these genes, 
three were chloride channels. These were up-regulated and 
may be involved in increased movement of water molecules 
by active transport, an event which would certainly occur in 
oedema. However, a vasopressin receptor (D07c), which is
involved in water reabsorption was down-regulated by over 
two-fold. Vasopressin controls the resorption of water and 
regulates the osmotic content of blood. In the kidney, it acts 
on the renal collecting ducts, increasing the permeability to 
water (Nielsen et al., 1995). Therefore, in the lung, down- 
regulation of this gene may reduce cellular permeability. This 
would lead to increased water on the alveolar surface, which 
is known to occur during oedema. Mineralocorticoid 
receptors (D08f) are also involved in regulation of water 
balance via an effect on ion transport in the epithelium of the 
renal tubules. A  similar response may be observed in the lung. 
This gene is down-regulated, which could lead to reduced 
movement of water away from the lung surface. This could 
again result in water accumulation in the alveolar spaces.
All o f the remaining genes were down-regulated. Several 
of the hormone receptors appear to be involved in the 
physiological response to oedema. The substance K  receptor 
(D03j) and gastrin-releasing peptide receptor (D03k) affect 
smooth muscle constriction (Haley et al., 2001, Lach et al., 
1993). Down-regulation could affect dilation of the conduct­
ing airways of the lung, which should increase the flow of air 
to the lungs. This would seem appropriate as the air spaces are 
covered by the oedematous fluid reducing the level of oxygen 
exchange. More direct links to oedema are unclear. Gran­
ulocyte colony-stimulating factor (D14i) mediates the 
inflammatory response, and is involved in the enhancement 
of vascular permeability (Sedgwick et al., 2002). Gastrin- 
releasing peptide receptor (D03k) is implicated in vaso­
dilation (Clive et al., 2001). Conversely, the serotonin 
receptors (D051, D05m, D07f) are involved in pulmonary 
vascular and airway constriction (Selig et al., 1988), effects 
often observed during the inflammatory process. Alpha IB  
adrenergic receptor (D05i) is also implicated in venule 
constriction (Leech and Faber, 1996). Glucocorticoid recep­
tors (D08g) are thought to be involved with anti-inflamma­
tory responses (Walsh et al., 2003). Down-regulation would 
result in increased inflammatory responses, as evidenced by 
the elevated number of free cells in BAL.
Clusters of genes are more reliable as markers for a 
pathological reaction, as a single anomaly should not affect 
the successful identification of oedema. O f the 31 significant 
genes selected by the methods described in this study, five 
belong to the symporters and antiporters family, all of which 
were up-regulated. The 18 genes classified as hormone 
receptors included a cluster of three genes encoding nuclear 
receptors (D08e, D08f, D08g). These genes are not necessa­
rily directly related to oedema, however, as a cluster they are 
worth considering further. Similarly, within the group of 
seven ion channels, three were more tightly clustered (D09e, 
D09f, D09g).
The changes in gene expression predicted by the macro­
array were confirmed by Q-PCR. All of the genes tested 
showed an extremely high level of correlation, with the 
exception of D07c. However, even in this case, the genetic 
response was shown to be down-regulated, which was in 
agreement with the change predicted by the array. This
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indicated that both analysis methods are appropriate for 
selecting relevant genes.
In conclusion, the preliminary macroarray analysis has 
provided new transcriptional data on the mechanisms of 
pulmonary oedema following bleomycin treatment. High 
numbers of replicates (n = 9) imply a good level of trust in the 
resulting data, and have been confirmed by Q-PCR. New 
methods have been developed for successful analysis of 
macroarray data. The t test is a well-established, conventional 
method with recognised statistical significance. The standard 
deviation method is good for analysing groups of data. It can 
also be used to compare individual unknown samples against 
an established control range, which may be more practical in 
industrial/medical scenarios.
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